Systemic Lupus Erythematosus
Conditions
Keywords
SLE, Lupus
Brief summary
This is a continuation study to evaluate the long-term safety and efficacy of LymphoStat-B™ in subjects with SLE disease, that completed study LBSL02 and benefitted from treatment.
Detailed description
The purpose of this continuation study to evaluate the long-term safety and efficacy of LymphoStat-B™ in subjects with Systemic Lupus Erythematosus (SLE), that completed study LBSL02 and benefitted from treatment.
Interventions
BIOLOGICALBelimumab
Belimumab 10mg/kg IV over one hour every 28 days
Sponsors
GlaxoSmithKline
Human Genome Sciences Inc., a GSK Company
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Primary Inclusion Criteria 1\. Have completed the LBSL02 trial and achieved a satisfactory response. Primary
Exclusion criteria
1. Required more than 2 courses of corticosteroids for treatment of severe SLE flares in the last 5 months of LBSL02. 2. Had an SLE flare during the last 30 days of LBSL02 and through the 1st dose in LBSL99. 3. Used any of the following prohibited medications during their participation in LBSL02: * Other investigational agents. * Biologic therapeutic agents: adalimumab (Humira™), etanercept (Enbrel™), infliximab (Remicade™), and rituximab (Rituxan™). * Intravenous cyclophosphamide. * Corticosteroids \>100 mg/day prednisone equivalent for reasons other than severe SLE flare.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | Baseline and approximately up to 13 years | Clinical chemistry parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in ALT, AP, AST, GGT and LD are summarized. Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. |
| Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Baseline and approximately up to 13 years | Hematology parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in basophils, eosinophils, lymphocytes, monocytes, neutrophils segmented and platelets is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. |
| Change From Baseline in Erythrocytes at the Indicated Time Points | Baseline and approximately up to 13 years | Hematology parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in erythrocytes is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. |
| Change From Baseline in Hematocrit at the Indicated Time Points | Baseline and approximately up to 13 years | Hematology parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in hematocrit is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. |
| Change From Baseline in Hemoglobin at the Indicated Time Points | Baseline and approximately up to 13 years | Hematology parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in hemoglobin is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. |
| Change From Baseline in Albumin and Protein at the Indicated Time Points | Baseline and approximately up to 13 years | Clinical chemistry parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in albumin and protein is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. |
| Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Baseline and approximately up to 13 years | Clinical chemistry parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in BUN, glucose, calcium, carbon dioxide, chloride, magnesium, phosphate, potassium and sodium is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. |
| Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Baseline and approximately up to 13 years | Clinical chemistry parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in creatinine, urate, and bilirubin is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. |
| Change From Baseline in BUN/Creatinine at the Indicated Time Points | Baseline and approximately up to 13 years | Clinical chemistry parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in BUN/creatinine is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. |
| Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) | Approximately up to 13 years | An AE is defined as any unfavorable or unintended sign, symptom, or disease that is temporally associated with the use of a study agent but is not necessarily caused by the study agent. This includes worsening (example \[eg\], increase in frequency or severity) of pre-existing conditions. An SAE is defined as an AE resulting in any of the following outcomes: death, is life threatening (that is, an immediate threat to life), inpatient hospitalization, prolongation of an existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, and is medically important. |
| Adverse Event (AE) Rates by System Organ Class (SOC) During the Study | Approximately up to 13 years | AE rates by SOC adjusting for participant-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatmentemergent AEs are summarized. The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. The event rate of an AE was calculated as the number of events per 100 participant years: Event Rate=100\* number of events divided by participant years. Participant years were calculated as sum across all participants (\[last visit of interval day minus first visit of interval day plus 1\] divided by 365). |
| SAE Rates by System Organ Class (SOC) During the Study | Approximately up to 13 years | SAE rates by SOC adjusting for participant-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatmentemergent SAEs are summarized. The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pretreatment value in the parent study for participants treated with belimumab in the parent study. The event rate of an SAE was calculated as the number of events per 100 participant years: Event Rate=100\* number of events divided by participant years. Participant years were calculated as sum across all participants (\[last visit of interval day minus first visit of interval day plus 1\] divided by 365). |
| Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | Baseline and approximately up to 13 years | Hematology parameters were assessed at Baseline, Week 8, 16, 24, 40, and 48 during Year 1 to 8; Week 8, 16, 24, and 40 during Year 9; Week 24 and 40 during Year 10; Week 48 during Year 11; Week 32 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in APTT and PT is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Approximately up to 13 years | Anti-double stranded DNA levels in participants positive at Baseline were assessed at Baseline, Week 16, 32, and 48 during Year 1 to 11, Week 16 and 32 during Year 13, Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study. |
| Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Baseline and approximately up to 13 years | Anti-double stranded DNA levels for participants positive at Baseline were assessed at Baseline, Week 16, 32, and 48 during Year 1 to 11, Week 16 and 32 during Year 13, Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study. Percent change from Baseline is defined as the percentage of the difference between the post-dose post-Baseline visit value and the Baseline value. |
| Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | Approximately up to 13 years | Complement C3 and C4 levels were assessed in participants low at Baseline at Baseline, Week 16, 32, and 48 during Year 1 to 12, Week 16 and 32 during Year 13, and Exit visit. The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study. |
| Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | Baseline and approximately up to 13 years | Complement C3 and C4 levels were assessed in participants low at Baseline at Baseline, Week 16, 32, and 48 during Year 1 to 12, Week 16 and 32 during Year 13, and Exit visit. The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study. Percent change from Baseline is defined as the percentage of the difference between the post-dose post-Baseline visit value and the Baseline value. |
| Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Approximately up to 13 years | Daily prednisone dose reduction was assessed at Baseline, Week 8, 16, 24, 32, 40, and 48 during Year 1 to 12 and Week 8, 16, 24, 32, and 40 during Year 13. Percentage of participants with daily prednisone dose reduced to \<=7.5 mg/day from \>7.5 mg/kg at the Baseline are summarized. Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. |
| Absolute Serum Immunoglobulin G Values at Indicated Time Points | Approximately up to 13 years | Serum immunoglobulin G values were assessed at Baseline, Week 8, 16, 24, 32, 40, and 48 during Year 1 to 12 and Week 8, 16, 24, 32, and 40 during Year 13, Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study. |
| Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Baseline and approximately up to 13 years | Serum immunoglobulin G values were assessed at Baseline, Week 8, 16, 24, 32, 40, and 48 during Year 1 to 12 and Week 8, 16, 24, 32, and 40 during Year 13, Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study. Percent change from Baseline is defined as the percentage of the difference between the post-dose post-Baseline visit value and the Baseline value. |
| Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Approximately up to 13 years | SRI response was assessed at Week 16, 32, and 48 during Year 1 to 12 and Week 16 and 32 during Year 13. Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. SRI response is defined as:\>=4 point reduction from the Baseline in safety of estrogen in lupus national assessment (SELENA) SLE disease activity index (SLEDAI) score and no worsening (increase of \<0.30 points from the Baseline) in Physician's Global Assessment (PGA), and no new British Isles Lupus Assessment Group (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with the Baseline at the time of assessment. |
Countries
Canada, United States
Participant flow
Recruitment details
Participants who completed the parent study LBSL02 (NCT00071487) through the 24-week extension period, who received belimumab 1 milligram (mg)/kilogram (kg), 4 mg/kg, 10 mg/kg or placebo in the parent study and achieved a satisfactory response were enrolled in the study.
Participants by arm
| Arm | Count |
|---|---|
| Belimumab 10 mg/kg IV Participants received 10 mg/kg of belimumab every 28 days as an intravenous (IV) infusion over a period of 1 to 2 hours. The first dose of belimumab was given 4 weeks after the last (Day 532) dose in LBSL02. Treatment continued for 10 years from the time the last participant was enrolled in the present study or until there were 100 or fewer participants continuing in the study, whichever came first. All participants received standard of care for systemic lupus erythematosus (SLE) during study participation. | 296 |
| Total | 296 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 44 |
| Overall Study | Behavioral problems and non-compliance | 1 |
| Overall Study | Current site closed | 7 |
| Overall Study | Lack of Efficacy | 22 |
| Overall Study | Lost to Follow-up | 4 |
| Overall Study | Miscommunication of visit window | 5 |
| Overall Study | Missed visits due to staff changes | 1 |
| Overall Study | Misunderstanding of protocol | 1 |
| Overall Study | Non-compliance with study drug | 28 |
| Overall Study | Physician Decision | 19 |
| Overall Study | Pregnancy | 7 |
| Overall Study | Protocol Violation | 2 |
| Overall Study | Sponsor request due to missed doses | 1 |
| Overall Study | Subject moved out of the country/state | 2 |
| Overall Study | Subject not dosed in LBSL99 | 1 |
| Overall Study | Withdrawal by Subject | 57 |
Baseline characteristics
| Characteristic | Belimumab 10 mg/kg IV |
|---|---|
| Age, Continuous | 43 Years STANDARD_DEVIATION 11.58 |
| Race/Ethnicity, Customized American Indian or Alaska Native | 6 Participants |
| Race/Ethnicity, Customized Asian | 6 Participants |
| Race/Ethnicity, Customized Black or African American | 68 Participants |
| Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander | 1 Participants |
| Race/Ethnicity, Customized White | 215 Participants |
| Sex: Female, Male Female | 276 Participants |
| Sex: Female, Male Male | 20 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 293 / 296 |
| serious Total, serious adverse events | 182 / 296 |
Outcome results
Primary
Adverse Event (AE) Rates by System Organ Class (SOC) During the Study
AE rates by SOC adjusting for participant-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatmentemergent AEs are summarized. The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. The event rate of an AE was calculated as the number of events per 100 participant years: Event Rate=100\* number of events divided by participant years. Participant years were calculated as sum across all participants (\[last visit of interval day minus first visit of interval day plus 1\] divided by 365).
Time frame: Approximately up to 13 years
Population: MITT Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Belimumab 10 mg/kg IV | Adverse Event (AE) Rates by System Organ Class (SOC) During the Study | Infections and infestations | 285 Events per 100 participant years |
| Belimumab 10 mg/kg IV | Adverse Event (AE) Rates by System Organ Class (SOC) During the Study | Musculoskeletal and connective tissue disorders | 276 Events per 100 participant years |
| Belimumab 10 mg/kg IV | Adverse Event (AE) Rates by System Organ Class (SOC) During the Study | Gastrointestinal disorders | 257 Events per 100 participant years |
| Belimumab 10 mg/kg IV | Adverse Event (AE) Rates by System Organ Class (SOC) During the Study | Skin and subcutaneous tissue disorders | 256 Events per 100 participant years |
| Belimumab 10 mg/kg IV | Adverse Event (AE) Rates by System Organ Class (SOC) During the Study | General disorders, administration site conditions | 247 Events per 100 participant years |
| Belimumab 10 mg/kg IV | Adverse Event (AE) Rates by System Organ Class (SOC) During the Study | Nervous system disorders | 244 Events per 100 participant years |
| Belimumab 10 mg/kg IV | Adverse Event (AE) Rates by System Organ Class (SOC) During the Study | Respiratory, thoracic and mediastinal disorders | 241 Events per 100 participant years |
| Belimumab 10 mg/kg IV | Adverse Event (AE) Rates by System Organ Class (SOC) During the Study | Investigations | 227 Events per 100 participant years |
| Belimumab 10 mg/kg IV | Adverse Event (AE) Rates by System Organ Class (SOC) During the Study | Injury, poisoning and procedural complications | 221 Events per 100 participant years |
| Belimumab 10 mg/kg IV | Adverse Event (AE) Rates by System Organ Class (SOC) During the Study | Psychiatric disorders | 180 Events per 100 participant years |
| Belimumab 10 mg/kg IV | Adverse Event (AE) Rates by System Organ Class (SOC) During the Study | Metabolism and nutrition disorders | 144 Events per 100 participant years |
| Belimumab 10 mg/kg IV | Adverse Event (AE) Rates by System Organ Class (SOC) During the Study | Vascular disorders | 134 Events per 100 participant years |
| Belimumab 10 mg/kg IV | Adverse Event (AE) Rates by System Organ Class (SOC) During the Study | Eye disorders | 133 Events per 100 participant years |
| Belimumab 10 mg/kg IV | Adverse Event (AE) Rates by System Organ Class (SOC) During the Study | Blood and lymphatic system disorders | 127 Events per 100 participant years |
| Belimumab 10 mg/kg IV | Adverse Event (AE) Rates by System Organ Class (SOC) During the Study | Reproductive system and breast disorders | 114 Events per 100 participant years |
| Belimumab 10 mg/kg IV | Adverse Event (AE) Rates by System Organ Class (SOC) During the Study | Renal and urinary disorders | 109 Events per 100 participant years |
| Belimumab 10 mg/kg IV | Adverse Event (AE) Rates by System Organ Class (SOC) During the Study | Immune system disorders | 101 Events per 100 participant years |
| Belimumab 10 mg/kg IV | Adverse Event (AE) Rates by System Organ Class (SOC) During the Study | Neoplasms benign, malignant and unspecified | 100 Events per 100 participant years |
| Belimumab 10 mg/kg IV | Adverse Event (AE) Rates by System Organ Class (SOC) During the Study | Cardiac disorders | 86 Events per 100 participant years |
| Belimumab 10 mg/kg IV | Adverse Event (AE) Rates by System Organ Class (SOC) During the Study | Ear and labyrinth disorders | 69 Events per 100 participant years |
| Belimumab 10 mg/kg IV | Adverse Event (AE) Rates by System Organ Class (SOC) During the Study | Endocrine disorders | 40 Events per 100 participant years |
| Belimumab 10 mg/kg IV | Adverse Event (AE) Rates by System Organ Class (SOC) During the Study | Hepatobiliary disorders | 27 Events per 100 participant years |
| Belimumab 10 mg/kg IV | Adverse Event (AE) Rates by System Organ Class (SOC) During the Study | Social circumstances | 15 Events per 100 participant years |
| Belimumab 10 mg/kg IV | Adverse Event (AE) Rates by System Organ Class (SOC) During the Study | Congenital, familial and genetic disorders | 7 Events per 100 participant years |
| Belimumab 10 mg/kg IV | Adverse Event (AE) Rates by System Organ Class (SOC) During the Study | Pregnancy, puerperium and perinatal conditions | 5 Events per 100 participant years |
Primary
Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points
Hematology parameters were assessed at Baseline, Week 8, 16, 24, 40, and 48 during Year 1 to 8; Week 8, 16, 24, and 40 during Year 9; Week 24 and 40 during Year 10; Week 48 during Year 11; Week 32 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in APTT and PT is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.
Time frame: Baseline and approximately up to 13 years
Population: MITT Population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, 24-Week Follow-up, n=3 | -10.23 Seconds | Standard Deviation 11.657 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 1, Week 8, n=274 | 0.3 Seconds | Standard Deviation 12.6 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 1, Week 16, n=276 | -1.3 Seconds | Standard Deviation 7.46 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 1, Week 24, n=222 | -1.6 Seconds | Standard Deviation 13.61 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 1, Week 32, n=221 | -1.9 Seconds | Standard Deviation 7.24 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 1, Week 40, n=219 | -1.6 Seconds | Standard Deviation 7 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 1, Week 48, n=218 | -1.0 Seconds | Standard Deviation 7.29 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 2, Week 8, n=220 | -0.3 Seconds | Standard Deviation 6.73 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 2, Week 16, n=214 | -0.2 Seconds | Standard Deviation 8.79 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 2, Week 24, n=212 | 0.6 Seconds | Standard Deviation 13.81 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 2, Week 32, n=35 | 1.5 Seconds | Standard Deviation 9.2 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 2, Week 40, n=28 | 2.6 Seconds | Standard Deviation 7.53 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 2, Week 48, n=21 | 3.0 Seconds | Standard Deviation 8.69 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 3, Week 8, n=25 | 2.4 Seconds | Standard Deviation 10.7 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 3, Week 16, n=23 | 2.3 Seconds | Standard Deviation 7.77 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 3, Week 24, n=23 | 1.7 Seconds | Standard Deviation 6.3 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 3, Week 32, n=22 | 5.4 Seconds | Standard Deviation 10.01 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 3, Week 40, n=18 | 2.1 Seconds | Standard Deviation 9.62 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 3, Week 48, n=18 | 3.9 Seconds | Standard Deviation 17.23 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 4, Week 8, n=14 | 2.9 Seconds | Standard Deviation 11.42 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 4, Week 16, n=16 | 3.1 Seconds | Standard Deviation 8.97 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 4, Week 24, n=10 | 1.1 Seconds | Standard Deviation 10.29 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 4, Week 32, n=18 | 2.1 Seconds | Standard Deviation 11.37 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 4, Week 40, n=13 | -2.1 Seconds | Standard Deviation 10.02 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 4, Week 48, n=11 | 2.2 Seconds | Standard Deviation 11.83 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 5, Week 8, n=4 | 3.0 Seconds | Standard Deviation 14.76 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 5, Week 16, n=11 | 1.3 Seconds | Standard Deviation 5.62 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 5, Week 24, n=3 | 13.0 Seconds | Standard Deviation 11.53 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 5, Week 32, n=12 | 3.1 Seconds | Standard Deviation 6.64 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 5, Week 40, n=10 | -0.5 Seconds | Standard Deviation 8.03 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 5, Week 48, n=3 | 12.3 Seconds | Standard Deviation 5.51 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 6, Week 8, n=3 | -2.3 Seconds | Standard Deviation 19.5 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 6, Week 16, n=3 | 9.0 Seconds | Standard Deviation 12.12 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 6, Week 24, n=3 | 14.0 Seconds | Standard Deviation 16.52 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 6, Week 32, n=2 | 6.5 Seconds | Standard Deviation 17.68 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 6, Week 40, n=8 | 9.9 Seconds | Standard Deviation 9.11 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 6, Week 48, n=4 | 18.3 Seconds | Standard Deviation 4.99 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 7, Week 8, n=1 | 27.0 Seconds | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 7, Week 16, n=2 | 24.5 Seconds | Standard Deviation 14.85 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 7, Week 24, n=2 | 19.5 Seconds | Standard Deviation 6.36 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 7, Week 32, n=1 | 7.0 Seconds | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 7, Week 40, n=2 | 16.5 Seconds | Standard Deviation 16.26 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 7, Week 48, n=2 | 18.5 Seconds | Standard Deviation 2.12 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 8, Week 8, n=3 | 11.7 Seconds | Standard Deviation 18.04 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 8, Week 16, n=3 | 15.7 Seconds | Standard Deviation 10.07 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 8, Week 24, n=3 | 21.3 Seconds | Standard Deviation 22.5 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 8, Week 32, n=3 | 8.7 Seconds | Standard Deviation 14.36 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 8, Week 40, n=2 | 25.0 Seconds | Standard Deviation 5.66 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 8, Week 48, n=3 | 13.3 Seconds | Standard Deviation 15.01 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 9, Week 8, n=3 | 10.3 Seconds | Standard Deviation 9.07 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 9, Week 16, n=3 | 11.0 Seconds | Standard Deviation 9.85 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 9, Week 24, n=2 | 24.0 Seconds | Standard Deviation 25.46 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 9, Week 32, n=4 | -11.0 Seconds | Standard Deviation 21.91 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 9, Week 40, n=1 | 20.0 Seconds | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 10, Week 24, n=1 | 10.0 Seconds | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 10, Week 40, n=1 | -9 Seconds | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 11, Week 48, n=1 | -27.0 Seconds | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Year 13, Week 32, n=1 | 26 Seconds | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, Exit, n=10 | 2.3 Seconds | Standard Deviation 9.66 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, 8-Week Follow-up, n=6 | 3.8 Seconds | Standard Deviation 6.24 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | APTT, 24-Week Follow-up, n=3 | -12.3 Seconds | Standard Deviation 16.56 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 1, Week 8, n=278 | -0.67 Seconds | Standard Deviation 12.222 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 1, Week 16, n=276 | -0.98 Seconds | Standard Deviation 12.134 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 1, Week 24, n=222 | -1.00 Seconds | Standard Deviation 13.859 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 1, Week 32, n=223 | -0.89 Seconds | Standard Deviation 13.887 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 1, Week 40, n=221 | -0.67 Seconds | Standard Deviation 14.262 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 1, Week 48, n=219 | -0.95 Seconds | Standard Deviation 13.496 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 2, Week 8, n=221 | -0.87 Seconds | Standard Deviation 13.364 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 2, Week 16, n=215 | -0.84 Seconds | Standard Deviation 13.682 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 2, Week 24, n=214 | -0.66 Seconds | Standard Deviation 14.156 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 2, Week 32, n=35 | 0.85 Seconds | Standard Deviation 6.887 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 2, Week 40, n=28 | 3.28 Seconds | Standard Deviation 11.046 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 2, Week 48, n=22 | 1.75 Seconds | Standard Deviation 8.747 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 3, Week 8, n=25 | 1.75 Seconds | Standard Deviation 12.409 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 3, Week 16, n=23 | 0.39 Seconds | Standard Deviation 5.469 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 3, Week 24, n=23 | 0.98 Seconds | Standard Deviation 3.12 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 3, Week 32, n=22 | 4.29 Seconds | Standard Deviation 10.64 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 3, Week 40, n=18 | 2.02 Seconds | Standard Deviation 8.833 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 3, Week 48, n=18 | 3.23 Seconds | Standard Deviation 15.863 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 4, Week 8, n=14 | 4.14 Seconds | Standard Deviation 9.948 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 4, Week 16, n=16 | 0.69 Seconds | Standard Deviation 8.188 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 4, Week 24, n=10 | 2.10 Seconds | Standard Deviation 8.506 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 4, Week 32, n=18 | 1.87 Seconds | Standard Deviation 11.251 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 4, Week 40, n=13 | -2.70 Seconds | Standard Deviation 6.698 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 4, Week 48, n=11 | 0.60 Seconds | Standard Deviation 9.651 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 5, Week 8, n=4 | -0.43 Seconds | Standard Deviation 12.189 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 5, Week 16, n=11 | 2.52 Seconds | Standard Deviation 6.118 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 5, Week 24, n=3 | 9.90 Seconds | Standard Deviation 8.347 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 5, Week 32, n=12 | 0.67 Seconds | Standard Deviation 3.731 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 5, Week 40, n=10 | -0.33 Seconds | Standard Deviation 5.443 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 5, Week 48, n=3 | 13.23 Seconds | Standard Deviation 9.064 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 6, Week 8, n=3 | -2.93 Seconds | Standard Deviation 7.859 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 6, Week 16, n=3 | 2.10 Seconds | Standard Deviation 5.336 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 6, Week 24, n=3 | 7.60 Seconds | Standard Deviation 11.623 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 6, Week 32, n=2 | 4.55 Seconds | Standard Deviation 21.425 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 6, Week 40, n=8 | 2.30 Seconds | Standard Deviation 5.865 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 6, Week 48, n=4 | 6.18 Seconds | Standard Deviation 10.637 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 7, Week 8, n=1 | 19.90 Seconds | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 7, Week 16, n=2 | 18.20 Seconds | Standard Deviation 14.425 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 7, Week 24, n=2 | 7.35 Seconds | Standard Deviation 0.636 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 7, Week 32, n=1 | 4.00 Seconds | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 7, Week 40, n=2 | 11.15 Seconds | Standard Deviation 19.587 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 7, Week 48, n=2 | 11.50 Seconds | Standard Deviation 4.808 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 8, Week 8, n=3 | 12.47 Seconds | Standard Deviation 15.546 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 8, Week 16, n=3 | 7.57 Seconds | Standard Deviation 6.799 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 8, Week 24, n=3 | 12.87 Seconds | Standard Deviation 13.787 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 8, Week 32, n=3 | 5.63 Seconds | Standard Deviation 9.85 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 8, Week 40, n=2 | 26.60 Seconds | Standard Deviation 13.435 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 8, Week 48, n=3 | 11.07 Seconds | Standard Deviation 9.845 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 9, Week 8, n=3 | 8.23 Seconds | Standard Deviation 7.976 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 9, Week 16, n=3 | 4.60 Seconds | Standard Deviation 6.773 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 9, Week 24, n=2 | 25.75 Seconds | Standard Deviation 36.416 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 9, Week 32, n=4 | -10.08 Seconds | Standard Deviation 8.139 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 9, Week 40, n=1 | 21.40 Seconds | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 10, Week 24, n=1 | 1.30 Seconds | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 10, Week 40, n=1 | -8.00 Seconds | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 11, Week 48, n=1 | -22.80 Seconds | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Year 13, Week 32, n=1 | 14.80 Seconds | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, Exit, n=10 | 0.64 Seconds | Standard Deviation 5.559 |
| Belimumab 10 mg/kg IV | Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points | PT, 8-Week Follow-up, n=6 | -0.95 Seconds | Standard Deviation 4.561 |
Primary
Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points
Clinical chemistry parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in ALT, AP, AST, GGT and LD are summarized. Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.
Time frame: Baseline and approximately up to 13 years
Population: MITT Population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 7, Week 8, n=179 | 9.0 International units per liter | Standard Deviation 24.52 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 8, Week 8, n=171 | 10.0 International units per liter | Standard Deviation 23.29 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 12, Week 24, n=87 | 11.5 International units per liter | Standard Deviation 20.69 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 2, Week 16, n=275 | -1.2 International units per liter | Standard Deviation 8.51 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 2, Week 32, n=284 | 0.2 International units per liter | Standard Deviation 13.8 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 2, Week 40, n=261 | -0.2 International units per liter | Standard Deviation 10.44 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 3, Week 16, n=258 | 1.0 International units per liter | Standard Deviation 11.84 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 5, Week 40, n=197 | 0.3 International units per liter | Standard Deviation 14.39 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 5, Week 48, n=207 | 0.0 International units per liter | Standard Deviation 11.58 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 6, Week 40, n=181 | -0.7 International units per liter | Standard Deviation 10.56 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 12, Week 24, n=85 | 1.0 International units per liter | Standard Deviation 13.58 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, 24-Week Follow-up , n=200 | 3.3 International units per liter | Standard Deviation 52.99 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 1, Week 8, n=284 | 0.6 International units per liter | Standard Deviation 23.57 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 1, Week 32, n=287 | 4.9 International units per liter | Standard Deviation 46.96 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 3, Week 24, n=244 | 4.0 International units per liter | Standard Deviation 51.58 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 4, Week 16, n=238 | 1.2 International units per liter | Standard Deviation 36.22 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 4, Week 32, n=233 | 3.4 International units per liter | Standard Deviation 47.24 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 4, Week 40, n=220 | 2.0 International units per liter | Standard Deviation 40.2 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 6, Week 24, n=190 | 1.6 International units per liter | Standard Deviation 43.58 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 6, Week 40, n=185 | 2.0 International units per liter | Standard Deviation 34.66 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 6, Week 48, n=186 | 2.2 International units per liter | Standard Deviation 38.05 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 7, Week 8, n=179 | 2.3 International units per liter | Standard Deviation 36.39 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 7, Week 24, n=173 | 4.5 International units per liter | Standard Deviation 33.15 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 7, Week 32, n=180 | 4.6 International units per liter | Standard Deviation 41.12 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 7, Week 40, n=175 | 4.9 International units per liter | Standard Deviation 36.94 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 7, Week 48, n=175 | 4.9 International units per liter | Standard Deviation 40.27 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 8, Week 24, n=168 | 8.5 International units per liter | Standard Deviation 48.16 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 8, Week 48, n=159 | 7.3 International units per liter | Standard Deviation 37.89 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 11, Week 24, n=130 | 3.4 International units per liter | Standard Deviation 26.42 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 11, Week 48, n=108 | 7.0 International units per liter | Standard Deviation 37.14 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 12, Week 8, n=110 | 7.9 International units per liter | Standard Deviation 37.22 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 12, Week 16, n=97 | 2.3 International units per liter | Standard Deviation 19.42 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 12, Week 48, n=72 | 1.6 International units per liter | Standard Deviation 18.01 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 13, Week 16, n=42 | 8.8 International units per liter | Standard Deviation 57.73 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 13, Week 24, n=20 | 10.5 International units per liter | Standard Deviation 40.97 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 13, Week 32, n=7 | 6.1 International units per liter | Standard Deviation 19.07 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 13, Week 40, n=1 | 3.0 International units per liter | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Exit, n=248 | 1.8 International units per liter | Standard Deviation 53.15 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 2, Week 16, n=275 | -0.3 International units per liter | Standard Deviation 30.16 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 3, Week 24, n=241 | 1.0 International units per liter | Standard Deviation 32.12 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 3, Week 32, n=245 | 0.9 International units per liter | Standard Deviation 36.26 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 4, Week 8, n=237 | 3.9 International units per liter | Standard Deviation 36.59 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 4, Week 16, n=235 | 4.2 International units per liter | Standard Deviation 38.16 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 4, Week 32, n=230 | 6.3 International units per liter | Standard Deviation 37.05 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 4, Week 48, n=214 | 8.5 International units per liter | Standard Deviation 39.8 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 6, Week 24, n=189 | 5.2 International units per liter | Standard Deviation 38.41 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 6, Week 32, n=192 | 6.1 International units per liter | Standard Deviation 34.07 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 7, Week 16, n=178 | 3.3 International units per liter | Standard Deviation 37.02 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 7, Week 32, n=179 | 4.7 International units per liter | Standard Deviation 40.87 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 8, Week 8, n=170 | 3.0 International units per liter | Standard Deviation 36.88 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 8, Week 16, n=169 | 2.4 International units per liter | Standard Deviation 36.06 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 8, Week 24, n=167 | 2.4 International units per liter | Standard Deviation 37.06 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 8, Week 32, n=166 | 7.4 International units per liter | Standard Deviation 36.86 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 9, Week 24, n=160 | 3.9 International units per liter | Standard Deviation 35.65 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 9, Week 32, n=162 | 3.8 International units per liter | Standard Deviation 37.69 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 9, Week 40, n=156 | 7.5 International units per liter | Standard Deviation 39.97 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 9, Week 48, n=150 | 5.8 International units per liter | Standard Deviation 39.05 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 10, Week 8, n=151 | 4.5 International units per liter | Standard Deviation 42.02 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 10, Week 16, n=143 | 2.5 International units per liter | Standard Deviation 34.44 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 10, Week 24, n=145 | 2.1 International units per liter | Standard Deviation 38.8 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 11, Week 8, n=138 | 6.1 International units per liter | Standard Deviation 45.9 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 11, Week 40, n=124 | 2.1 International units per liter | Standard Deviation 41.89 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 13, Week 32, n=7 | -27.3 International units per liter | Standard Deviation 63.45 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, 8-Week Follow-up, n=220 | 7.7 International units per liter | Standard Deviation 51.21 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 1, Week 8, n=284 | -0.7 International units per liter | Standard Deviation 12.05 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 1, Week 16, n=286 | 0.2 International units per liter | Standard Deviation 17.32 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 1, Week 24, n=292 | 0.9 International units per liter | Standard Deviation 17.04 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 1, Week 32, n=287 | -0.6 International units per liter | Standard Deviation 12.36 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 1, Week 40, n=284 | -0.6 International units per liter | Standard Deviation 14.15 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 1, Week 48, n=287 | -1.3 International units per liter | Standard Deviation 11.56 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 2, Week 8, n=288 | -0.7 International units per liter | Standard Deviation 13.36 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 2, Week 16, n=278 | -1.2 International units per liter | Standard Deviation 11.44 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 2, Week 24, n=273 | 0.3 International units per liter | Standard Deviation 13.35 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 2, Week 32, n=284 | 0.1 International units per liter | Standard Deviation 15.85 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 2, Week 40, n=264 | 0.0 International units per liter | Standard Deviation 14.02 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 2, Week 48, n=269 | 0.9 International units per liter | Standard Deviation 15.65 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 3, Week 8, n=265 | 0.5 International units per liter | Standard Deviation 14.46 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 3, Week 16, n=260 | 1.3 International units per liter | Standard Deviation 21.94 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 3, Week 24, n=244 | -0.1 International units per liter | Standard Deviation 13.95 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 3, Week 32, n=249 | 0.0 International units per liter | Standard Deviation 12.55 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 3, Week 40, n=245 | -0.3 International units per liter | Standard Deviation 13.08 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 3, Week 48, n=244 | -0.4 International units per liter | Standard Deviation 13.62 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 4, Week 8, n=239 | -0.5 International units per liter | Standard Deviation 10.97 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 4, Week 16, n=238 | -1.3 International units per liter | Standard Deviation 14.28 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 4, Week 24, n=227 | -1.3 International units per liter | Standard Deviation 13.29 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 4, Week 32, n=233 | -0.4 International units per liter | Standard Deviation 13.6 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 4, Week 40, n=220 | -1.6 International units per liter | Standard Deviation 12.83 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 4, Week 48, n=218 | -1.3 International units per liter | Standard Deviation 12.45 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 5, Week 8, n=218 | 0.1 International units per liter | Standard Deviation 12.76 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 5, Week 16, n=214 | -0.5 International units per liter | Standard Deviation 12.67 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 5, Week 24, n=211 | -0.9 International units per liter | Standard Deviation 14.68 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 5, Week 32, n=211 | -1.5 International units per liter | Standard Deviation 13.23 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 5, Week 40, n=198 | -1.3 International units per liter | Standard Deviation 13.9 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 5, Week 48, n=207 | -0.1 International units per liter | Standard Deviation 17.16 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 6, Week 8, n=206 | -1.4 International units per liter | Standard Deviation 12.09 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 6, Week 16, n=198 | -1.4 International units per liter | Standard Deviation 13.55 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 6, Week 24, n=190 | -1.6 International units per liter | Standard Deviation 13.87 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 6, Week 32, n=193 | -1.4 International units per liter | Standard Deviation 13.58 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 6, Week 40, n=185 | -1.4 International units per liter | Standard Deviation 14.78 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 6, Week 48, n=186 | -0.9 International units per liter | Standard Deviation 14.98 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 7, Week 8, n=179 | -0.4 International units per liter | Standard Deviation 14.5 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 7, Week 16, n=179 | 0.5 International units per liter | Standard Deviation 15.78 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 7, Week 24, n=173 | 0.1 International units per liter | Standard Deviation 16.09 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 7, Week 32, n=180 | -0.2 International units per liter | Standard Deviation 14.71 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 7, Week 40, n=175 | -0.1 International units per liter | Standard Deviation 16.43 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 7, Week 48, n=175 | -0.4 International units per liter | Standard Deviation 16.15 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 8, Week 8, n=171 | 0.9 International units per liter | Standard Deviation 16.58 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 8, Week 16, n=170 | -0.2 International units per liter | Standard Deviation 17.74 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 8, Week 24, n=168 | -0.2 International units per liter | Standard Deviation 15.62 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 8, Week 32, n=168 | -0.4 International units per liter | Standard Deviation 14.82 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 8, Week 40, n=162 | -0.7 International units per liter | Standard Deviation 14.79 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 8, Week 48, n=159 | -0.7 International units per liter | Standard Deviation 15.14 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 9, Week 8, n=164 | 1.5 International units per liter | Standard Deviation 21.38 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 9, Week 16, n=162 | -0.8 International units per liter | Standard Deviation 14.31 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 9, Week 24, n=161 | -1.5 International units per liter | Standard Deviation 14.35 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 9, Week 32, n=163 | 0.0 International units per liter | Standard Deviation 15.62 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 9, Week 40, n=156 | -0.5 International units per liter | Standard Deviation 14.61 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 9, Week 48, n=151 | -0.2 International units per liter | Standard Deviation 15.69 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 10, Week 8, n=152 | -0.6 International units per liter | Standard Deviation 14.25 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 10, Week 16, n=143 | -0.3 International units per liter | Standard Deviation 13.88 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 10, Week 24, n=145 | -1.1 International units per liter | Standard Deviation 15.71 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 10, Week 32, n=142 | -0.8 International units per liter | Standard Deviation 15.97 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 10, Week 40, n=138 | -1.9 International units per liter | Standard Deviation 15.56 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 10, Week 48, n=135 | -0.7 International units per liter | Standard Deviation 19.61 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 11, Week 8, n=138 | -1.9 International units per liter | Standard Deviation 15.75 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 11, Week 16, n=128 | -1.3 International units per liter | Standard Deviation 16.74 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 11, Week 24, n=130 | -2.5 International units per liter | Standard Deviation 15.11 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 11, Week 32, n=125 | -3.2 International units per liter | Standard Deviation 14.71 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 11, Week 40, n=124 | -2.8 International units per liter | Standard Deviation 15.31 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 11, Week 48, n=108 | -1.7 International units per liter | Standard Deviation 18.29 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 12, Week 8, n=110 | -1.9 International units per liter | Standard Deviation 16.3 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 12, Week 16, n=97 | -2.9 International units per liter | Standard Deviation 12.74 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 12, Week 24, n=87 | -2.0 International units per liter | Standard Deviation 13.47 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 12, Week 32, n=84 | -2.4 International units per liter | Standard Deviation 13.39 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 12, Week 40, n=82 | -2.3 International units per liter | Standard Deviation 14.74 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 12, Week 48, n=72 | -3.6 International units per liter | Standard Deviation 14.92 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 13, Week 8, n=53 | -5.3 International units per liter | Standard Deviation 16.58 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LT, Year 13, Week 16, n=42 | -5.7 International units per liter | Standard Deviation 20.42 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 13, Week 24, n=20 | -1.0 International units per liter | Standard Deviation 6.55 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 13, Week 32, n=7 | -0.6 International units per liter | Standard Deviation 9.14 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Year 13, Week 40, n=1 | 3.0 International units per liter | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, Exit, n=248 | -1.2 International units per liter | Standard Deviation 13.39 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, 8-Week Follow-up, n=220 | -0.6 International units per liter | Standard Deviation 15.74 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | ALT, 24-Week Follow-up , n=200 | 1.5 International units per liter | Standard Deviation 36.52 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 1, Week 8, n=284 | -0.1 International units per liter | Standard Deviation 11.43 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 1, Week 16, n=286 | 0.9 International units per liter | Standard Deviation 14.08 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 1, Week 24, n=292 | 0.7 International units per liter | Standard Deviation 13.87 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 1, Week 32, n=287 | 0.6 International units per liter | Standard Deviation 14.03 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 1, Week 40, n=284 | 1.1 International units per liter | Standard Deviation 14.61 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 1, Week 48, n=287 | 0.5 International units per liter | Standard Deviation 16.94 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 2, Week 8, n=288 | 1.2 International units per liter | Standard Deviation 17.67 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 2, Week 16, n=278 | 0.2 International units per liter | Standard Deviation 15.87 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 2, Week 24, n=273 | 1.3 International units per liter | Standard Deviation 16.91 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 2, Week 32, n=284 | 2.5 International units per liter | Standard Deviation 17.17 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 3, Week 16, n=260 | 5.3 International units per liter | Standard Deviation 44.46 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 3, Week 32, n=249 | 6.7 International units per liter | Standard Deviation 57.32 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 3, Week 40, n=245 | 3.7 International units per liter | Standard Deviation 29.97 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 3, Week 48, n=244 | 1.7 International units per liter | Standard Deviation 39.47 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 4, Week 8, n=239 | 3.1 International units per liter | Standard Deviation 53.57 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 4, Week 24, n=226 | 3.0 International units per liter | Standard Deviation 55.72 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 4, Week 48, n=218 | 2.6 International units per liter | Standard Deviation 39.26 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 5, Week 8, n=218 | 4.8 International units per liter | Standard Deviation 40.08 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 5, Week 16, n=214 | 1.6 International units per liter | Standard Deviation 41.04 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 5, Week 24, n=211 | 3.0 International units per liter | Standard Deviation 39.9 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 5, Week 32, n=211 | 1.7 International units per liter | Standard Deviation 36.58 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 5, Week 40, n=198 | 1.4 International units per liter | Standard Deviation 41.74 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 5, Week 48, n=207 | 3.6 International units per liter | Standard Deviation 46.1 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 6, Week 8, n=206 | 1.9 International units per liter | Standard Deviation 48.45 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 6, Week 16, n=198 | 1.8 International units per liter | Standard Deviation 37.61 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 6, Week 32, n=193 | 5.9 International units per liter | Standard Deviation 55.25 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 7, Week 16, n=179 | 3.8 International units per liter | Standard Deviation 43.49 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 8, Week 8, n=171 | 7.0 International units per liter | Standard Deviation 41.53 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 8, Week 16, n=170 | 6.8 International units per liter | Standard Deviation 41.7 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 8, Week 32, n=168 | 8.5 International units per liter | Standard Deviation 44.76 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 8, Week 40, n=162 | 3.5 International units per liter | Standard Deviation 38.79 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 9, Week 8, n=164 | 7.1 International units per liter | Standard Deviation 39.19 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 9, Week 16, n=162 | 5.0 International units per liter | Standard Deviation 37.32 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 9, Week 24, n=161 | 2.6 International units per liter | Standard Deviation 33.54 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 9, Week 32, n=163 | 2.4 International units per liter | Standard Deviation 29.43 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 9, Week 40, n=156 | 2.9 International units per liter | Standard Deviation 32.7 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 9, Week 48, n=151 | 4.5 International units per liter | Standard Deviation 33.25 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 10, Week 8, n=152 | 2.7 International units per liter | Standard Deviation 28.57 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 10, Week 16, n=143 | 4.5 International units per liter | Standard Deviation 33.5 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 10, Week 24, n=145 | 3.0 International units per liter | Standard Deviation 31.51 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 10, Week 32, n=142 | 4.2 International units per liter | Standard Deviation 31.74 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 10, Week 40, n=138 | 2.9 International units per liter | Standard Deviation 31.64 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 10, Week 48, n=135 | 5.9 International units per liter | Standard Deviation 29.18 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 11, Week 8, n=138 | 3.8 International units per liter | Standard Deviation 33.68 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 11, Week 16, n=128 | 4.8 International units per liter | Standard Deviation 32.72 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 11, Week 32, n=125 | 2.8 International units per liter | Standard Deviation 29.33 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 11, Week 40, n=124 | 2.5 International units per liter | Standard Deviation 28.02 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 2, Week 40, n=264 | 3.5 International units per liter | Standard Deviation 19.55 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 2, Week 48, n=269 | 5.6 International units per liter | Standard Deviation 23.81 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 3, Week 8, n=265 | 4.0 International units per liter | Standard Deviation 18.04 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 3, Week 16, n=260 | 3.2 International units per liter | Standard Deviation 19.53 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 3, Week 24, n=244 | 2.0 International units per liter | Standard Deviation 19.26 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 3, Week 32, n=249 | 3.7 International units per liter | Standard Deviation 21.48 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 3, Week 40, n=245 | 3.4 International units per liter | Standard Deviation 18.62 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 12, Week 24, n=87 | 5.2 International units per liter | Standard Deviation 32.26 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 12, Week 32, n=84 | 4.4 International units per liter | Standard Deviation 26.44 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 12, Week 40, n=82 | 2.0 International units per liter | Standard Deviation 27.54 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 13, Week 8, n=53 | 2.4 International units per liter | Standard Deviation 18.65 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, 8-Week Follow-up, n=220 | 3.3 International units per liter | Standard Deviation 24.91 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, 24-Week Follow-up , n=200 | 3.1 International units per liter | Standard Deviation 55.2 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 1, Week 8, n=281 | -0.4 International units per liter | Standard Deviation 23.41 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 1, Week 16, n=283 | -0.4 International units per liter | Standard Deviation 29.97 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 1, Week 24, n=287 | -0.8 International units per liter | Standard Deviation 31.43 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 1, Week 32, n=283 | -5.1 International units per liter | Standard Deviation 26.19 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 1, Week 40, n=282 | -3.6 International units per liter | Standard Deviation 27.97 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 1, Week 48, n=284 | -4.5 International units per liter | Standard Deviation 28.66 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 2, Week 8, n=288 | -1.7 International units per liter | Standard Deviation 28.26 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 2, Week 24, n=269 | -0.4 International units per liter | Standard Deviation 29.91 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 2, Week 32, n=284 | -2.1 International units per liter | Standard Deviation 34.05 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 2, Week 40, n=261 | -4.7 International units per liter | Standard Deviation 29.69 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 2, Week 48, n=267 | -1.9 International units per liter | Standard Deviation 29.81 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 3, Week 8, n=262 | -5.1 International units per liter | Standard Deviation 29.71 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 3, Week 16, n=258 | -2.9 International units per liter | Standard Deviation 31.27 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 3, Week 40, n=242 | 1.3 International units per liter | Standard Deviation 34 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 3, Week 48, n=239 | 4.5 International units per liter | Standard Deviation 35.46 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 4, Week 24, n=225 | 3.8 International units per liter | Standard Deviation 38.59 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 4, Week 40, n=218 | 2.0 International units per liter | Standard Deviation 37.75 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 5, Week 8, n=217 | 6.7 International units per liter | Standard Deviation 39.42 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 5, Week 16, n=213 | 7.9 International units per liter | Standard Deviation 42.94 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 5, Week 24, n=206 | 7.6 International units per liter | Standard Deviation 40.54 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 5, Week 32, n=211 | 7.0 International units per liter | Standard Deviation 36.84 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 5, Week 40, n=196 | 5.0 International units per liter | Standard Deviation 40.29 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 5, Week 48, n=207 | 6.1 International units per liter | Standard Deviation 37.15 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 6, Week 8, n=205 | 8.4 International units per liter | Standard Deviation 36.82 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 6, Week 16, n=198 | 6.4 International units per liter | Standard Deviation 36.98 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 6, Week 40, n=181 | 6.0 International units per liter | Standard Deviation 39.6 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 6, Week 48, n=186 | 2.9 International units per liter | Standard Deviation 39.2 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 7, Week 8, n=177 | 4.8 International units per liter | Standard Deviation 37.46 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 7, Week 24, n=171 | 8.9 International units per liter | Standard Deviation 39.81 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 7, Week 40, n=172 | 6.8 International units per liter | Standard Deviation 39.49 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 7, Week 48, n=175 | 3.5 International units per liter | Standard Deviation 37.36 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 8, Week 40, n=161 | 2.1 International units per liter | Standard Deviation 35.04 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 8, Week 48, n=159 | 6.6 International units per liter | Standard Deviation 39.01 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 9, Week 8, n=163 | 4.5 International units per liter | Standard Deviation 36.82 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 9, Week 16, n=160 | 1.8 International units per liter | Standard Deviation 36.46 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 10, Week 32, n=140 | 5.4 International units per liter | Standard Deviation 41.37 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 10, Week 40, n=137 | 7.6 International units per liter | Standard Deviation 37.07 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 10, Week 48, n=135 | 5.4 International units per liter | Standard Deviation 37.12 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 11, Week 16, n=128 | 2.4 International units per liter | Standard Deviation 38.69 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 11, Week 24, n=129 | 5.5 International units per liter | Standard Deviation 42.1 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 11, Week 32, n=124 | 0.8 International units per liter | Standard Deviation 44.21 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 11, Week 48, n=107 | 8.8 International units per liter | Standard Deviation 40.94 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 12, Week 8, n=109 | 5.9 International units per liter | Standard Deviation 51.46 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 12, Week 16, n=97 | 5.2 International units per liter | Standard Deviation 45.81 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 12, Week 24, n=85 | 6.6 International units per liter | Standard Deviation 47.18 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 12, Week 32, n=84 | 2.0 International units per liter | Standard Deviation 47.59 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 12, Week 40, n=82 | 2.2 International units per liter | Standard Deviation 47.71 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 12, Week 48, n=72 | 1.9 International units per liter | Standard Deviation 61.71 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 13, Week 8, n=53 | -0.3 International units per liter | Standard Deviation 31.81 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 13, Week 16, n=42 | -6.3 International units per liter | Standard Deviation 38.99 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 13, Week 24, n=20 | 0.3 International units per liter | Standard Deviation 51.57 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Year 13, Week 40, n=1 | 26.0 International units per liter | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, Exit, n=248 | 6.4 International units per liter | Standard Deviation 44.59 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | LD, 24-Week Follow-up , n=200 | 6.5 International units per liter | Standard Deviation 49.9 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 3, Week 48, n=244 | 3.4 International units per liter | Standard Deviation 19.32 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 4, Week 8, n=239 | 2.5 International units per liter | Standard Deviation 19.33 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 4, Week 16, n=238 | 2.8 International units per liter | Standard Deviation 17.37 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 4, Week 24, n=227 | 2.5 International units per liter | Standard Deviation 21.94 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 4, Week 32, n=233 | 3.7 International units per liter | Standard Deviation 21.17 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 4, Week 40, n=220 | 2.9 International units per liter | Standard Deviation 20.93 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 4, Week 48, n=218 | 3.7 International units per liter | Standard Deviation 22.97 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 5, Week 8, n=218 | 4.9 International units per liter | Standard Deviation 24.65 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 5, Week 16, n=214 | 4.1 International units per liter | Standard Deviation 23.87 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 5, Week 24, n=211 | 4.0 International units per liter | Standard Deviation 20.17 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 5, Week 32, n=211 | 5.7 International units per liter | Standard Deviation 20.68 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 5, Week 40, n=198 | 5.5 International units per liter | Standard Deviation 21.34 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 5, Week 48, n=207 | 6.6 International units per liter | Standard Deviation 21.74 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 6, Week 8, n=206 | 7.1 International units per liter | Standard Deviation 23.65 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 6, Week 16, n=198 | 7.5 International units per liter | Standard Deviation 21.41 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 6, Week 24, n=190 | 7.5 International units per liter | Standard Deviation 22.41 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 6, Week 32, n=193 | 14.0 International units per liter | Standard Deviation 67.61 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 6, Week 40, n=185 | 10.2 International units per liter | Standard Deviation 24.43 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 6, Week 48, n=186 | 9.1 International units per liter | Standard Deviation 22.93 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 7, Week 16, n=179 | 9.6 International units per liter | Standard Deviation 25.7 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 7, Week 24, n=173 | 9.9 International units per liter | Standard Deviation 25.38 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 7, Week 32, n=180 | 11.5 International units per liter | Standard Deviation 27.02 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 7, Week 40, n=175 | 9.6 International units per liter | Standard Deviation 25.13 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 7, Week 48, n=175 | 11.1 International units per liter | Standard Deviation 24.96 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 8, Week 16, n=170 | 10.1 International units per liter | Standard Deviation 27.16 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 8, Week 24, n=168 | 10.4 International units per liter | Standard Deviation 26.44 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 8, Week 32, n=168 | 12.9 International units per liter | Standard Deviation 27.45 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 8, Week 40, n=162 | 11.1 International units per liter | Standard Deviation 25.66 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 8, Week 48, n=159 | 11.5 International units per liter | Standard Deviation 30.97 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 9, Week 8, n=164 | 12.0 International units per liter | Standard Deviation 25.38 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 9, Week 16, n=162 | 10.9 International units per liter | Standard Deviation 25.48 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 9, Week 24, n=161 | 10.5 International units per liter | Standard Deviation 22.81 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 9, Week 32, n=163 | 10.4 International units per liter | Standard Deviation 24.05 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 9, Week 40, n=156 | 9.5 International units per liter | Standard Deviation 24.43 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 9, Week 48, n=151 | 10.2 International units per liter | Standard Deviation 22.77 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 10, Week 8, n=152 | 10.6 International units per liter | Standard Deviation 24.51 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 10, Week 16, n=143 | 11.9 International units per liter | Standard Deviation 29.31 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 10, Week 24, n=145 | 13.0 International units per liter | Standard Deviation 22.92 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 10, Week 32, n=142 | 14.4 International units per liter | Standard Deviation 24.55 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 10, Week 40, n=138 | 13.7 International units per liter | Standard Deviation 23.2 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 10, Week 48, n=135 | 12.5 International units per liter | Standard Deviation 23.89 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 11, Week 8, n=138 | 13.3 International units per liter | Standard Deviation 26.11 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 11, Week 16, n=128 | 14.2 International units per liter | Standard Deviation 26.05 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 11, Week 24, n=130 | 12.9 International units per liter | Standard Deviation 23.22 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 11, Week 32, n=125 | 13.3 International units per liter | Standard Deviation 23.74 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 11, Week 40, n=124 | 13.3 International units per liter | Standard Deviation 23.05 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 11, Week 48, n=108 | 11.9 International units per liter | Standard Deviation 25.59 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 12, Week 8, n=110 | 12.3 International units per liter | Standard Deviation 25.69 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 12, Week 16, n=97 | 10.2 International units per liter | Standard Deviation 22.48 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 12, Week 32, n=84 | 10.7 International units per liter | Standard Deviation 19.91 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 12, Week 40, n=82 | 10.8 International units per liter | Standard Deviation 21.35 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 12, Week 48, n=72 | 11.6 International units per liter | Standard Deviation 21.77 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 13, Week 8, n=53 | 12.2 International units per liter | Standard Deviation 19.25 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 13, Week 16, n=42 | 16.9 International units per liter | Standard Deviation 37.69 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 13, Week 24, n=20 | 20.7 International units per liter | Standard Deviation 23.57 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 13, Week 32, n=7 | 18.1 International units per liter | Standard Deviation 21.47 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Year 13, Week 40, n=1 | 15.0 International units per liter | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, Exit, n=248 | 8.3 International units per liter | Standard Deviation 26.49 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, 8-Week Follow-up, n=220 | 10.3 International units per liter | Standard Deviation 42.15 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AP, 24-Week Follow-up , n=200 | 10.7 International units per liter | Standard Deviation 32.86 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 1, Week 8, n=281 | -0.3 International units per liter | Standard Deviation 8.68 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 1, Week 16, n=283 | 2.0 International units per liter | Standard Deviation 22.78 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 1, Week 24, n=287 | 2.3 International units per liter | Standard Deviation 26.94 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 1, Week 32, n=283 | 0.5 International units per liter | Standard Deviation 12.19 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 1, Week 40, n=282 | -0.1 International units per liter | Standard Deviation 9.63 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 1, Week 48, n=284 | -1.2 International units per liter | Standard Deviation 6.98 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 2, Week 8, n=288 | -0.8 International units per liter | Standard Deviation 9.15 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 2, Week 24, n=269 | -0.3 International units per liter | Standard Deviation 9.04 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 2, Week 48, n=267 | 0.7 International units per liter | Standard Deviation 10.95 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 3, Week 8, n=262 | 0.3 International units per liter | Standard Deviation 10.81 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 3, Week 24, n=241 | 0.4 International units per liter | Standard Deviation 10.36 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 3, Week 32, n=245 | 1.3 International units per liter | Standard Deviation 11.19 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 3, Week 40, n=242 | 0.2 International units per liter | Standard Deviation 10.99 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 3, Week 48, n=239 | 0.6 International units per liter | Standard Deviation 10.6 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 4, Week 8, n=237 | 0.5 International units per liter | Standard Deviation 7.73 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 4, Week 16, n=235 | -0.2 International units per liter | Standard Deviation 12.78 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 4, Week 24, n=226 | 0.4 International units per liter | Standard Deviation 11.45 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 4, Week 32, n=230 | 0.8 International units per liter | Standard Deviation 9.26 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 4, Week 40, n=218 | -0.3 International units per liter | Standard Deviation 9.44 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 4, Week 48, n=214 | -0.2 International units per liter | Standard Deviation 9.48 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 5, Week 8, n=217 | 0.3 International units per liter | Standard Deviation 12.79 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 5, Week 16, n=213 | 0.8 International units per liter | Standard Deviation 15.76 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 5, Week 24, n=206 | -0.5 International units per liter | Standard Deviation 11.36 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 5, Week 32, n=211 | -0.8 International units per liter | Standard Deviation 10.64 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 6, Week 8, n=205 | -0.4 International units per liter | Standard Deviation 9.04 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 6, Week 16, n=198 | -0.7 International units per liter | Standard Deviation 9.83 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 6, Week 24, n=189 | -0.9 International units per liter | Standard Deviation 11.35 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 6, Week 32, n=192 | -0.6 International units per liter | Standard Deviation 11.04 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 6, Week 48, n=186 | 0.1 International units per liter | Standard Deviation 12.21 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 7, Week 8, n=177 | -0.2 International units per liter | Standard Deviation 10.76 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 7, Week 16, n=178 | 1.0 International units per liter | Standard Deviation 12.91 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 7, Week 24, n=171 | 1.5 International units per liter | Standard Deviation 14.44 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 7, Week 32, n=179 | 0.5 International units per liter | Standard Deviation 10.56 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 7, Week 40, n=172 | 0.4 International units per liter | Standard Deviation 14.51 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 7, Week 48, n=175 | 0.2 International units per liter | Standard Deviation 11.15 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 8, Week 8, n=170 | 1.0 International units per liter | Standard Deviation 16.78 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 8, Week 16, n=169 | 1.0 International units per liter | Standard Deviation 21.12 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 8, Week 24, n=167 | 0.5 International units per liter | Standard Deviation 13.61 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 8, Week 32, n=166 | 0.7 International units per liter | Standard Deviation 14.74 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 8, Week 40, n=161 | 1.4 International units per liter | Standard Deviation 16.28 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 8, Week 48, n=159 | 0.2 International units per liter | Standard Deviation 11 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 9, Week 8, n=163 | 1.6 International units per liter | Standard Deviation 16.09 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 9, Week 16, n=160 | 0.8 International units per liter | Standard Deviation 13.55 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 9, Week 24, n=160 | 0.3 International units per liter | Standard Deviation 12.6 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 9, Week 32, n=162 | 1.3 International units per liter | Standard Deviation 17.39 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 9, Week 40, n=156 | 1.0 International units per liter | Standard Deviation 14.17 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 9, Week 48, n=150 | 1.5 International units per liter | Standard Deviation 15.79 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 10, Week 8, n=151 | 0.0 International units per liter | Standard Deviation 11.05 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 10, Week 16, n=143 | 0.1 International units per liter | Standard Deviation 13.75 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 10, Week 24, n=145 | 0.1 International units per liter | Standard Deviation 13.8 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 10, Week 32, n=140 | 0.5 International units per liter | Standard Deviation 13.9 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 10, Week 40, n=137 | -0.4 International units per liter | Standard Deviation 13.3 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 10, Week 48, n=135 | 0.9 International units per liter | Standard Deviation 14.71 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 11, Week 8, n=138 | -0.2 International units per liter | Standard Deviation 12.04 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 11, Week 16, n=128 | -0.1 International units per liter | Standard Deviation 12.72 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 11, Week 24, n=129 | -0.3 International units per liter | Standard Deviation 12.69 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 11, Week 32, n=124 | -1.0 International units per liter | Standard Deviation 10.03 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 11, Week 40, n=124 | 0.1 International units per liter | Standard Deviation 14.28 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 11, Week 48, n=107 | 1.3 International units per liter | Standard Deviation 17.7 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 12, Week 8, n=109 | 0.1 International units per liter | Standard Deviation 16.11 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 12, Week 16, n=97 | -0.5 International units per liter | Standard Deviation 7.74 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 12, Week 32, n=84 | 0.5 International units per liter | Standard Deviation 11.11 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 12, Week 40, n=82 | 0.2 International units per liter | Standard Deviation 11.6 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 12, Week 48, n=72 | -1.0 International units per liter | Standard Deviation 12.48 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 13, Week 8, n=53 | -2.5 International units per liter | Standard Deviation 10 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 13, Week 16, n=42 | -3.4 International units per liter | Standard Deviation 14.32 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 13, Week 24, n=20 | 0.1 International units per liter | Standard Deviation 7.94 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 13, Week 32, n=7 | 0.3 International units per liter | Standard Deviation 4.96 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Year 13, Week 40, n=1 | 1.0 International units per liter | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, Exit, n=248 | -0.9 International units per liter | Standard Deviation 10.19 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | AST, 8-Week Follow-up, n=220 | -0.3 International units per liter | Standard Deviation 11.02 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 1, Week 16, n=286 | 5.0 International units per liter | Standard Deviation 32.94 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 1, Week 24, n=292 | 6.3 International units per liter | Standard Deviation 48.1 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 1, Week 40, n=284 | 6.7 International units per liter | Standard Deviation 55.51 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 1, Week 48, n=287 | 5.2 International units per liter | Standard Deviation 58.66 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 2, Week 8, n=288 | 4.6 International units per liter | Standard Deviation 50.82 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 2, Week 16, n=278 | 2.9 International units per liter | Standard Deviation 37.57 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 2, Week 24, n=273 | 4.5 International units per liter | Standard Deviation 42.01 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 2, Week 32, n=284 | 3.8 International units per liter | Standard Deviation 38.55 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 2, Week 40, n=264 | 4.2 International units per liter | Standard Deviation 41.34 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 2, Week 48, n=269 | 5.7 International units per liter | Standard Deviation 48.48 |
| Belimumab 10 mg/kg IV | Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points | GGT, Year 3, Week 8, n=265 | 3.9 International units per liter | Standard Deviation 33.83 |
Primary
Change From Baseline in Albumin and Protein at the Indicated Time Points
Clinical chemistry parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in albumin and protein is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.
Time frame: Baseline and approximately up to 13 years
Population: MITT Population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 1, Week 8, n=284 | 0.1 grams/liter | Standard Deviation 2.36 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 1, Week 16, n=286 | -0.2 grams/liter | Standard Deviation 2.68 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 1, Week 24, n=292 | 0.2 grams/liter | Standard Deviation 2.74 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 1, Week 32, n=287 | 0.1 grams/liter | Standard Deviation 2.91 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 1, Week 40, n=284 | 0.2 grams/liter | Standard Deviation 3.06 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 1, Week 48, n=287 | 0.3 grams/liter | Standard Deviation 3.21 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 2, Week 8, n=288 | 0.4 grams/liter | Standard Deviation 2.84 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 2, Week 16, n=278 | 0.4 grams/liter | Standard Deviation 2.95 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 2, Week 24, n=273 | 0.1 grams/liter | Standard Deviation 3.17 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 2, Week 32, n=284 | 0.7 grams/liter | Standard Deviation 3.08 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 2, Week 40, n=264 | 0.8 grams/liter | Standard Deviation 2.92 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 2, Week 48, n=269 | 1.1 grams/liter | Standard Deviation 3.25 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 3, Week 8, n=265 | 0.7 grams/liter | Standard Deviation 3.39 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 3, Week 16, n=260 | 1.0 grams/liter | Standard Deviation 3.05 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 3, Week 24, n=244 | 1.2 grams/liter | Standard Deviation 3.23 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 3, Week 32, n=249 | 1.3 grams/liter | Standard Deviation 3.13 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 3, Week 40, n=245 | 1.4 grams/liter | Standard Deviation 3.11 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 3, Week 48, n=244 | 1.5 grams/liter | Standard Deviation 3.12 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 4, Week 8, n=239 | 1.4 grams/liter | Standard Deviation 3.36 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 4, Week 16, n=238 | 1.3 grams/liter | Standard Deviation 3.21 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 4, Week 24, n=227 | 1.2 grams/liter | Standard Deviation 3.15 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 4, Week 32, n=233 | 1.3 grams/liter | Standard Deviation 3.31 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 4, Week 40, n=220 | 1.2 grams/liter | Standard Deviation 3.29 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 4, Week 48, n=218 | 1.6 grams/liter | Standard Deviation 3.57 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 5, Week 8, n=218 | 1.6 grams/liter | Standard Deviation 3.37 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 5, Week 16, n=214 | 1.5 grams/liter | Standard Deviation 3.07 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 5, Week 24, n=211 | 1.5 grams/liter | Standard Deviation 3.36 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 5, Week 32, n=211 | 1.9 grams/liter | Standard Deviation 3.34 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 5, Week 40, n=198 | 1.8 grams/liter | Standard Deviation 3.4 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 5, Week 48, n=207 | 1.7 grams/liter | Standard Deviation 3.41 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 6, Week 8, n=206 | 1.8 grams/liter | Standard Deviation 3.27 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 6, Week 16, n=198 | 1.5 grams/liter | Standard Deviation 3.72 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 6, Week 24, n=190 | 1.6 grams/liter | Standard Deviation 3.32 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 6, Week 32, n=193 | 2.0 grams/liter | Standard Deviation 3.71 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 6, Week 40, n=185 | 1.9 grams/liter | Standard Deviation 3.52 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 6, Week 48, n=186 | 1.9 grams/liter | Standard Deviation 3.64 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 7, Week 8, n=179 | 1.9 grams/liter | Standard Deviation 3.36 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 7, Week 16, n=179 | 1.7 grams/liter | Standard Deviation 3.57 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 7, Week 24, n=173 | 1.7 grams/liter | Standard Deviation 3.88 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 7, Week 32, n=180 | 1.9 grams/liter | Standard Deviation 3.53 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 7, Week 40, n=175 | 1.6 grams/liter | Standard Deviation 3.41 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 7, Week 48, n=175 | 1.6 grams/liter | Standard Deviation 3.6 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 8, Week 8, n=171 | 1.7 grams/liter | Standard Deviation 3.61 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 8, Week 16, n=170 | 1.5 grams/liter | Standard Deviation 3.31 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 8, Week 24, n=168 | 1.6 grams/liter | Standard Deviation 3.47 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 8, Week 32, n=168 | 1.7 grams/liter | Standard Deviation 3.25 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 8, Week 40, n=162 | 1.3 grams/liter | Standard Deviation 3.46 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 8, Week 48, n=159 | 1.7 grams/liter | Standard Deviation 3.56 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 9, Week 8, n=164 | 2.0 grams/liter | Standard Deviation 3.97 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 9, Week 16, n=162 | 1.9 grams/liter | Standard Deviation 3.58 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 9, Week 24, n=161 | 1.6 grams/liter | Standard Deviation 3.38 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 9, Week 32, n=163 | 1.9 grams/liter | Standard Deviation 3.27 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 9, Week 40, n=156 | 1.6 grams/liter | Standard Deviation 3.54 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 9, Week 48, n=151 | 1.9 grams/liter | Standard Deviation 3.55 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 10, Week 8, n=152 | 1.9 grams/liter | Standard Deviation 3.64 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 10, Week 16, n=143 | 2.1 grams/liter | Standard Deviation 3.55 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 10, Week 24, n=145 | 2.0 grams/liter | Standard Deviation 3.85 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 10, Week 32, n=142 | 2.1 grams/liter | Standard Deviation 4.05 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 10, Week 40, n=138 | 1.8 grams/liter | Standard Deviation 3.78 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 10, Week 48, n=135 | 2.0 grams/liter | Standard Deviation 3.52 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 11, Week 8, n=138 | 2.0 grams/liter | Standard Deviation 3.74 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 11, Week 16, n=128 | 2.2 grams/liter | Standard Deviation 3.58 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 11, Week 24, n=130 | 2.1 grams/liter | Standard Deviation 3.87 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 11, Week 32, n=125 | 1.8 grams/liter | Standard Deviation 3.89 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 11, Week 40, n=124 | 1.7 grams/liter | Standard Deviation 3.69 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 11, Week 48, n=108 | 1.8 grams/liter | Standard Deviation 3.91 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 12, Week 8, n=110 | 1.8 grams/liter | Standard Deviation 3.43 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 12, Week 16, n=97 | 1.9 grams/liter | Standard Deviation 3.68 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 12, Week 24, n=87 | 2.5 grams/liter | Standard Deviation 4.01 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 12, Week 32, n=84 | 1.9 grams/liter | Standard Deviation 4.01 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 12, Week 40, n=82 | 1.7 grams/liter | Standard Deviation 3.76 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 12, Week 48, n=72 | 2.1 grams/liter | Standard Deviation 3.67 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 13, Week 8, n=53 | 2.8 grams/liter | Standard Deviation 3.68 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 13, Week 16, n=42 | 2.3 grams/liter | Standard Deviation 3.61 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 13, Week 24, n=20 | 2.5 grams/liter | Standard Deviation 3.3 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 13, Week 32, n=7 | 1.1 grams/liter | Standard Deviation 2.67 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Year 13, Week 40, n=1 | 5.0 grams/liter | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, Exit, n=248 | 2.0 grams/liter | Standard Deviation 4.02 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, 8-Week Follow-up, n=220 | 1.6 grams/liter | Standard Deviation 3.92 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Albumin, 24-Week Follow-up , n=200 | 2.2 grams/liter | Standard Deviation 4.24 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 1, Week 8, n=284 | -1.3 grams/liter | Standard Deviation 4.31 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 1, Week 16, n=286 | -1.8 grams/liter | Standard Deviation 4.63 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 1, Week 24, n=292 | -1.5 grams/liter | Standard Deviation 4.76 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 1, Week 32, n=287 | -1.7 grams/liter | Standard Deviation 4.69 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 1, Week 40, n=284 | -1.6 grams/liter | Standard Deviation 5 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 1, Week 48, n=287 | -2.0 grams/liter | Standard Deviation 5.01 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 2, Week 8, n=288 | -2.1 grams/liter | Standard Deviation 4.74 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 2, Week 16, n=278 | -2.5 grams/liter | Standard Deviation 4.66 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 2, Week 24, n=273 | -2.9 grams/liter | Standard Deviation 5.07 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 2, Week 32, n=284 | -2.4 grams/liter | Standard Deviation 5.13 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 2, Week 40, n=264 | -2.4 grams/liter | Standard Deviation 4.87 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 2, Week 48, n=269 | -1.5 grams/liter | Standard Deviation 5.18 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 3, Week 8, n=265 | -2.2 grams/liter | Standard Deviation 5.49 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 3, Week 16, n=260 | -2.0 grams/liter | Standard Deviation 5.19 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 3, Week 24, n=244 | -1.9 grams/liter | Standard Deviation 5.63 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 3, Week 32, n=249 | -1.8 grams/liter | Standard Deviation 5.19 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 3, Week 40, n=245 | -1.6 grams/liter | Standard Deviation 5.34 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 3, Week 48, n=244 | -1.8 grams/liter | Standard Deviation 5.16 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 4, Week 8, n=239 | -2.1 grams/liter | Standard Deviation 5.27 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 4, Week 16, n=238 | -1.8 grams/liter | Standard Deviation 4.93 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 4, Week 24, n=227 | -2.5 grams/liter | Standard Deviation 5.06 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 4, Week 32, n=233 | -2.3 grams/liter | Standard Deviation 5.02 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 4, Week 40, n=220 | -2.8 grams/liter | Standard Deviation 4.97 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 4, Week 48, n=218 | -2.2 grams/liter | Standard Deviation 5.44 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 5, Week 8, n=218 | -2.5 grams/liter | Standard Deviation 5.34 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 5, Week 16, n=214 | -2.6 grams/liter | Standard Deviation 5.09 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 5, Week 24, n=211 | -3.2 grams/liter | Standard Deviation 5.22 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 5, Week 32, n=211 | -2.5 grams/liter | Standard Deviation 5.05 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 5, Week 40, n=198 | -2.9 grams/liter | Standard Deviation 5.47 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 5, Week 48, n=207 | -2.8 grams/liter | Standard Deviation 5.67 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 6, Week 8, n=206 | -3.1 grams/liter | Standard Deviation 5.39 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 6, Week 16, n=198 | -3.4 grams/liter | Standard Deviation 5.75 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 6, Week 24, n=190 | -3.5 grams/liter | Standard Deviation 5.6 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 6, Week 32, n=193 | -3.0 grams/liter | Standard Deviation 5.77 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 6, Week 40, n=185 | -3.4 grams/liter | Standard Deviation 5.84 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 6, Week 48, n=186 | -3.5 grams/liter | Standard Deviation 6 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 7, Week 8, n=179 | -3.6 grams/liter | Standard Deviation 5.52 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 7, Week 16, n=179 | -4.1 grams/liter | Standard Deviation 5.87 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 7, Week 24, n=173 | -3.9 grams/liter | Standard Deviation 5.96 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 7, Week 32, n=180 | -3.7 grams/liter | Standard Deviation 5.68 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 7, Week 40, n=175 | -4.2 grams/liter | Standard Deviation 5.39 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 7, Week 48, n=175 | -4.5 grams/liter | Standard Deviation 5.6 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 8, Week 8, n=171 | -4.6 grams/liter | Standard Deviation 5.75 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 8, Week 16, n=170 | -4.7 grams/liter | Standard Deviation 5.37 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 8, Week 24, n=168 | -4.7 grams/liter | Standard Deviation 5.54 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 8, Week 32, n=168 | -4.5 grams/liter | Standard Deviation 5.46 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 8, Week 40, n=162 | -5.2 grams/liter | Standard Deviation 5.36 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 8, Week 48, n=159 | -4.5 grams/liter | Standard Deviation 5.3 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 9, Week 8, n=164 | -4.5 grams/liter | Standard Deviation 5.75 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 9, Week 16, n=162 | -4.8 grams/liter | Standard Deviation 5.34 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 9, Week 24, n=161 | -5.0 grams/liter | Standard Deviation 5.32 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 9, Week 32, n=163 | -4.8 grams/liter | Standard Deviation 5.18 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 9, Week 40, n=156 | -5.4 grams/liter | Standard Deviation 5.51 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 9, Week 48, n=151 | -5.1 grams/liter | Standard Deviation 5.6 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 10, Week 8, n=152 | -5.2 grams/liter | Standard Deviation 5.86 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 10, Week 16, n=143 | -5.0 grams/liter | Standard Deviation 5.79 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 10, Week 24, n=145 | -5.2 grams/liter | Standard Deviation 5.88 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 10, Week 32, n=142 | -5.1 grams/liter | Standard Deviation 5.98 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 10, Week 40, n=138 | -5.4 grams/liter | Standard Deviation 5.98 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 10, Week 48, n=135 | -5.4 grams/liter | Standard Deviation 5.62 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 11, Week 8, n=138 | -5.4 grams/liter | Standard Deviation 6.15 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 11, Week 16, n=128 | -5.1 grams/liter | Standard Deviation 5.51 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 11, Week 24, n=130 | -5.1 grams/liter | Standard Deviation 6.15 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 11, Week 32, n=125 | -5.6 grams/liter | Standard Deviation 6.12 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 11, Week 40, n=124 | -5.6 grams/liter | Standard Deviation 5.81 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 11, Week 48, n=108 | -5.4 grams/liter | Standard Deviation 6.42 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 12, Week 8, n=110 | -5.0 grams/liter | Standard Deviation 5.65 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 12, Week 16, n=97 | -5.1 grams/liter | Standard Deviation 5.86 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 12, Week 24, n=87 | -4.6 grams/liter | Standard Deviation 6.26 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 12, Week 32, n=84 | -5.1 grams/liter | Standard Deviation 5.82 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 12, Week 40, n=82 | -5.7 grams/liter | Standard Deviation 5.35 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 12, Week 48, n=72 | -5.0 grams/liter | Standard Deviation 5.86 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 13, Week 8, n=53 | -4.8 grams/liter | Standard Deviation 6 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 13, Week 16, n=42 | -5.6 grams/liter | Standard Deviation 6.04 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 13, Week 24, n=20 | -4.4 grams/liter | Standard Deviation 6.3 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 13, Week 32, n=7 | -8.9 grams/liter | Standard Deviation 5.08 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Year 13, Week 40, n=1 | 1.0 grams/liter | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, Exit, n=248 | -3.2 grams/liter | Standard Deviation 6.12 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, 8-Week Follow-up, n=220 | -3.7 grams/liter | Standard Deviation 6.39 |
| Belimumab 10 mg/kg IV | Change From Baseline in Albumin and Protein at the Indicated Time Points | Protein, 24-Week Follow-up , n=200 | -2.6 grams/liter | Standard Deviation 6.72 |
Primary
Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points
Hematology parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in basophils, eosinophils, lymphocytes, monocytes, neutrophils segmented and platelets is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.
Time frame: Baseline and approximately up to 13 years
Population: MITT Population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 9, Week 48, n=151 | -0.018 10^9 per liter | Standard Deviation 0.1307 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 13, Week 8, n=53 | -0.001 10^9 per liter | Standard Deviation 0.1436 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 1, Week 8, n=287 | 0.001 10^9 per liter | Standard Deviation 0.0163 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 1, Week 16, n=288 | 0.000 10^9 per liter | Standard Deviation 0.0181 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 1, Week 24, n=293 | 0.000 10^9 per liter | Standard Deviation 0.0171 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 1, Week 32, n=290 | 0.002 10^9 per liter | Standard Deviation 0.0166 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 1, Week 40, n=287 | 0.001 10^9 per liter | Standard Deviation 0.0159 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 1, Week 48, n=287 | 0.001 10^9 per liter | Standard Deviation 0.0178 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 2, Week 8, n=288 | 0.001 10^9 per liter | Standard Deviation 0.0164 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 2, Week 16, n=279 | 0.002 10^9 per liter | Standard Deviation 0.0172 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 2, Week 24, n=276 | 0.001 10^9 per liter | Standard Deviation 0.0168 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 2, Week 32, n=281 | 0.003 10^9 per liter | Standard Deviation 0.0179 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 2, Week 40, n=262 | 0.002 10^9 per liter | Standard Deviation 0.0162 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 2, Week 48, n=260 | 0.003 10^9 per liter | Standard Deviation 0.0174 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 3, Week 8, n=260 | 0.003 10^9 per liter | Standard Deviation 0.0167 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 3, Week 16, n=258 | 0.004 10^9 per liter | Standard Deviation 0.0177 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 3, Week 24, n=242 | 0.002 10^9 per liter | Standard Deviation 0.016 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 3, Week 32, n=248 | 0.004 10^9 per liter | Standard Deviation 0.0204 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 3, Week 40, n=242 | 0.004 10^9 per liter | Standard Deviation 0.0178 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 3, Week 48, n=240 | 0.002 10^9 per liter | Standard Deviation 0.0172 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 4, Week 8, n=234 | 0.001 10^9 per liter | Standard Deviation 0.0189 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 4, Week 16, n=238 | 0.003 10^9 per liter | Standard Deviation 0.0183 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 4, Week 24, n=227 | 0.003 10^9 per liter | Standard Deviation 0.016 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 4, Week 32, n=229 | 0.003 10^9 per liter | Standard Deviation 0.0174 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 4, Week 40, n=216 | 0.004 10^9 per liter | Standard Deviation 0.0174 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 4, Week 48, n=220 | 0.002 10^9 per liter | Standard Deviation 0.0181 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 5, Week 8, n=215 | 0.004 10^9 per liter | Standard Deviation 0.0173 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 5, Week 16, n=214 | 0.003 10^9 per liter | Standard Deviation 0.0182 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 5, Week 24, n=207 | 0.003 10^9 per liter | Standard Deviation 0.0174 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 5, Week 32, n=207 | 0.002 10^9 per liter | Standard Deviation 0.0159 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 5, Week 40, n=196 | 0.003 10^9 per liter | Standard Deviation 0.0184 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 5, Week 48, n=209 | 0.004 10^9 per liter | Standard Deviation 0.0177 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 6, Week 8, n=206 | 0.004 10^9 per liter | Standard Deviation 0.0183 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 6, Week 16, n=195 | 0.004 10^9 per liter | Standard Deviation 0.0203 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 6, Week 24, n=192 | 0.003 10^9 per liter | Standard Deviation 0.0212 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 6, Week 32, n=197 | 0.004 10^9 per liter | Standard Deviation 0.0177 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 6, Week 40, n=183 | 0.003 10^9 per liter | Standard Deviation 0.0157 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 6, Week 48, n=188 | 0.002 10^9 per liter | Standard Deviation 0.0174 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 7, Week 8, n=180 | 0.002 10^9 per liter | Standard Deviation 0.0194 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 7, Week 16, n=181 | 0.001 10^9 per liter | Standard Deviation 0.0186 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 7, Week 24, n=176 | 0.003 10^9 per liter | Standard Deviation 0.0178 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 7, Week 32, n=179 | 0.004 10^9 per liter | Standard Deviation 0.0173 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 7, Week 40, n=177 | 0.004 10^9 per liter | Standard Deviation 0.0172 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 7, Week 48, n=173 | 0.004 10^9 per liter | Standard Deviation 0.0171 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 8, Week 8, n=172 | 0.003 10^9 per liter | Standard Deviation 0.0184 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 8, Week 16, n=173 | 0.005 10^9 per liter | Standard Deviation 0.0167 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 8, Week 24, n=170 | 0.005 10^9 per liter | Standard Deviation 0.016 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 8, Week 32, n=169 | 0.003 10^9 per liter | Standard Deviation 0.0165 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 8, Week 40, n=162 | 0.005 10^9 per liter | Standard Deviation 0.0177 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 8, Week 48, n=161 | 0.004 10^9 per liter | Standard Deviation 0.0187 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 9, Week 8, n=164 | 0.006 10^9 per liter | Standard Deviation 0.0227 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 9, Week 16, n=161 | 0.005 10^9 per liter | Standard Deviation 0.0194 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 9, Week 24, n=163 | 0.004 10^9 per liter | Standard Deviation 0.017 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 9, Week 32, n=159 | 0.004 10^9 per liter | Standard Deviation 0.0167 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 9, Week 40, n=156 | 0.004 10^9 per liter | Standard Deviation 0.018 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 9, Week 48, n=151 | 0.003 10^9 per liter | Standard Deviation 0.0153 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 10, Week 8, n=149 | 0.002 10^9 per liter | Standard Deviation 0.0183 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 10, Week 16, n=145 | 0.006 10^9 per liter | Standard Deviation 0.0205 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 10, Week 24, n=147 | 0.003 10^9 per liter | Standard Deviation 0.0186 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 10, Week 32, n=142 | 0.005 10^9 per liter | Standard Deviation 0.0214 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 10, Week 40, n=137 | 0.004 10^9 per liter | Standard Deviation 0.0192 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 10, Week 48, n=137 | 0.006 10^9 per liter | Standard Deviation 0.0185 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 11, Week 8, n=137 | 0.004 10^9 per liter | Standard Deviation 0.02 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 11, Week 16, n=130 | 0.004 10^9 per liter | Standard Deviation 0.0188 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 11, Week 24, n=130 | 0.005 10^9 per liter | Standard Deviation 0.0176 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 11, Week 32, n=128 | 0.006 10^9 per liter | Standard Deviation 0.0187 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 11, Week 40, n=122 | 0.006 10^9 per liter | Standard Deviation 0.0232 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 11, Week 48, n=106 | 0.005 10^9 per liter | Standard Deviation 0.0189 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 12, Week 8, n=109 | 0.007 10^9 per liter | Standard Deviation 0.0209 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 12, Week 16, n=97 | 0.004 10^9 per liter | Standard Deviation 0.0197 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 12, Week 24, n=86 | 0.007 10^9 per liter | Standard Deviation 0.0204 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 12, Week 32, n=88 | 0.004 10^9 per liter | Standard Deviation 0.0213 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 12, Week 40, n=83 | 0.007 10^9 per liter | Standard Deviation 0.0201 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 12, Week 48, n=72 | 0.006 10^9 per liter | Standard Deviation 0.0172 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 13, Week 8, n=53 | 0.005 10^9 per liter | Standard Deviation 0.0173 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 13, Week 16, n=42 | 0.006 10^9 per liter | Standard Deviation 0.0178 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 13, Week 24, n=20 | 0.008 10^9 per liter | Standard Deviation 0.017 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 13, Week 32, n=7 | 0.014 10^9 per liter | Standard Deviation 0.0151 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 5, Week 40, n=196 | 0.019 10^9 per liter | Standard Deviation 0.1224 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 5, Week 48, n=209 | 0.022 10^9 per liter | Standard Deviation 0.1224 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 6, Week 8, n=206 | 0.020 10^9 per liter | Standard Deviation 0.1288 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 6, Week 16, n=195 | 0.021 10^9 per liter | Standard Deviation 0.1103 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 6, Week 24, n=192 | 0.034 10^9 per liter | Standard Deviation 0.1335 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 6, Week 32, n=197 | 0.026 10^9 per liter | Standard Deviation 0.1171 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 6, Week 40, n=183 | 0.044 10^9 per liter | Standard Deviation 0.158 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 6, Week 48, n=188 | 0.026 10^9 per liter | Standard Deviation 0.1299 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 7, Week 8, n=180 | 0.021 10^9 per liter | Standard Deviation 0.1317 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 7, Week 16, n=181 | 0.015 10^9 per liter | Standard Deviation 0.117 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 7, Week 24, n=176 | 0.014 10^9 per liter | Standard Deviation 0.1239 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 7, Week 32, n=179 | 0.010 10^9 per liter | Standard Deviation 0.1149 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 7, Week 40, n=177 | 0.009 10^9 per liter | Standard Deviation 0.1167 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 7, Week 48, n=173 | -0.008 10^9 per liter | Standard Deviation 0.1176 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 8, Week 8, n=172 | -0.003 10^9 per liter | Standard Deviation 0.1389 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 8, Week 16, n=173 | -0.009 10^9 per liter | Standard Deviation 0.1234 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 8, Week 24, n=170 | -0.007 10^9 per liter | Standard Deviation 0.1309 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 8, Week 32, n=169 | -0.023 10^9 per liter | Standard Deviation 0.1136 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 8, Week 40, n=162 | -0.009 10^9 per liter | Standard Deviation 0.1263 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 8, Week 48, n=161 | -0.011 10^9 per liter | Standard Deviation 0.1341 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 9, Week 8, n=164 | -0.004 10^9 per liter | Standard Deviation 0.1373 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 9, Week 16, n=161 | -0.020 10^9 per liter | Standard Deviation 0.1204 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 9, Week 24, n=163 | -0.020 10^9 per liter | Standard Deviation 0.1134 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 9, Week 32, n=159 | -0.012 10^9 per liter | Standard Deviation 0.1154 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 9, Week 40, n=156 | -0.029 10^9 per liter | Standard Deviation 0.12 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 10, Week 8, n=149 | -0.020 10^9 per liter | Standard Deviation 0.1343 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 10, Week 16, n=145 | -0.010 10^9 per liter | Standard Deviation 0.1438 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 10, Week 24, n=147 | -0.019 10^9 per liter | Standard Deviation 0.1237 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 10, Week 32, n=142 | -0.002 10^9 per liter | Standard Deviation 0.1332 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 10, Week 40, n=137 | -0.021 10^9 per liter | Standard Deviation 0.1184 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 10, Week 48, n=137 | -0.021 10^9 per liter | Standard Deviation 0.1274 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 11, Week 8, n=137 | -0.018 10^9 per liter | Standard Deviation 0.1167 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 11, Week 16, n=130 | -0.004 10^9 per liter | Standard Deviation 0.1336 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 11, Week 24, n=130 | 0.004 10^9 per liter | Standard Deviation 0.1445 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 11, Week 32, n=128 | 0.003 10^9 per liter | Standard Deviation 0.136 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 11, Week 40, n=122 | -0.013 10^9 per liter | Standard Deviation 0.1298 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 11, Week 48, n=106 | -0.021 10^9 per liter | Standard Deviation 0.1435 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 12, Week 8, n=109 | -0.021 10^9 per liter | Standard Deviation 0.1242 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 12, Week 16, n=97 | -0.020 10^9 per liter | Standard Deviation 0.1349 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 12, Week 24, n=86 | -0.000 10^9 per liter | Standard Deviation 0.1535 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 12, Week 32, n=88 | -0.008 10^9 per liter | Standard Deviation 0.1356 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 12, Week 40, n=83 | -0.020 10^9 per liter | Standard Deviation 0.1242 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 12, Week 48, n=72 | -0.016 10^9 per liter | Standard Deviation 0.1319 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 13, Week 16, n=42 | -0.009 10^9 per liter | Standard Deviation 0.1244 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 13, Week 24, n=20 | 0.035 10^9 per liter | Standard Deviation 0.181 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 13, Week 32, n=7 | 0.081 10^9 per liter | Standard Deviation 0.0722 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 13, Week 40, n=1 | 0.080 10^9 per liter | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Exit, n=241 | 0.006 10^9 per liter | Standard Deviation 0.143 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, 8-Week Follow-up, n=219 | -0.002 10^9 per liter | Standard Deviation 0.1436 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, 24-Week Follow-up, n=198 | 0.013 10^9 per liter | Standard Deviation 0.2255 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 1, Week 8, n=287 | 0.006 10^9 per liter | Standard Deviation 0.4143 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 1, Week 16, n=288 | -0.046 10^9 per liter | Standard Deviation 0.4612 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 1, Week 24, n=293 | -0.035 10^9 per liter | Standard Deviation 0.4725 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 1, Week 32, n=290 | -0.057 10^9 per liter | Standard Deviation 0.4425 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 1, Week 40, n=287 | -0.074 10^9 per liter | Standard Deviation 0.5084 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 1, Week 48, n=287 | -0.075 10^9 per liter | Standard Deviation 0.4832 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 2, Week 8, n=288 | -0.049 10^9 per liter | Standard Deviation 0.4324 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 2, Week 16, n=279 | -0.025 10^9 per liter | Standard Deviation 0.4774 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 2, Week 24, n=276 | -0.053 10^9 per liter | Standard Deviation 0.4949 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 2, Week 32, n=281 | -0.038 10^9 per liter | Standard Deviation 0.508 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 2, Week 40, n=262 | -0.025 10^9 per liter | Standard Deviation 0.5046 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 2, Week 48, n=260 | 0.006 10^9 per liter | Standard Deviation 0.4874 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 3, Week 8, n=260 | -0.037 10^9 per liter | Standard Deviation 0.5202 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 3, Week 16, n=258 | -0.019 10^9 per liter | Standard Deviation 0.5004 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 3, Week 24, n=242 | -0.045 10^9 per liter | Standard Deviation 0.5131 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 3, Week 32, n=248 | -0.008 10^9 per liter | Standard Deviation 0.4702 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 3, Week 40, n=242 | -0.015 10^9 per liter | Standard Deviation 0.5407 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 3, Week 48, n=240 | -0.016 10^9 per liter | Standard Deviation 0.5858 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 4, Week 8, n=234 | -0.041 10^9 per liter | Standard Deviation 0.4933 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 4, Week 16, n=238 | -0.012 10^9 per liter | Standard Deviation 0.4974 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Year 13, Week 40, n=1 | 0.020 10^9 per liter | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, Exit, n=241 | 0.005 10^9 per liter | Standard Deviation 0.0171 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, 8-Week Follow-up, n=219 | 0.006 10^9 per liter | Standard Deviation 0.0205 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Basophils, 24-Week Follow-up, n=198 | 0.006 10^9 per liter | Standard Deviation 0.0213 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 1, Week 8, n=287 | 0.003 10^9 per liter | Standard Deviation 0.0999 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 1, Week 16, n=288 | 0.007 10^9 per liter | Standard Deviation 0.1213 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 1, Week 24, n=293 | 0.008 10^9 per liter | Standard Deviation 0.1222 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 1, Week 32, n=290 | 0.011 10^9 per liter | Standard Deviation 0.1219 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 1, Week 40, n=287 | 0.007 10^9 per liter | Standard Deviation 0.107 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 1, Week 48, n=287 | 0.006 10^9 per liter | Standard Deviation 0.113 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 2, Week 8, n=288 | 0.003 10^9 per liter | Standard Deviation 0.1135 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 2, Week 16, n=279 | 0.034 10^9 per liter | Standard Deviation 0.1312 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 2, Week 24, n=276 | 0.023 10^9 per liter | Standard Deviation 0.1375 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 2, Week 32, n=281 | 0.028 10^9 per liter | Standard Deviation 0.1423 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 2, Week 40, n=262 | 0.028 10^9 per liter | Standard Deviation 0.128 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 2, Week 48, n=260 | 0.042 10^9 per liter | Standard Deviation 0.1635 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 3, Week 8, n=260 | 0.033 10^9 per liter | Standard Deviation 0.1353 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 3, Week 16, n=258 | 0.038 10^9 per liter | Standard Deviation 0.1391 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 3, Week 24, n=242 | 0.038 10^9 per liter | Standard Deviation 0.161 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 3, Week 32, n=248 | 0.029 10^9 per liter | Standard Deviation 0.1427 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 3, Week 40, n=242 | 0.035 10^9 per liter | Standard Deviation 0.1539 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 5, Week 40, n=196 | 0.057 10^9 per liter | Standard Deviation 0.5482 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 5, Week 48, n=209 | 0.031 10^9 per liter | Standard Deviation 0.5125 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 6, Week 8, n=206 | 0.059 10^9 per liter | Standard Deviation 0.5734 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 3, Week 48, n=240 | 0.033 10^9 per liter | Standard Deviation 0.1369 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 6, Week 16, n=195 | 0.045 10^9 per liter | Standard Deviation 0.5931 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 6, Week 24, n=192 | 0.087 10^9 per liter | Standard Deviation 0.5757 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 6, Week 32, n=197 | 0.066 10^9 per liter | Standard Deviation 0.597 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 6, Week 40, n=183 | 0.075 10^9 per liter | Standard Deviation 0.5984 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 4, Week 8, n=234 | 0.035 10^9 per liter | Standard Deviation 0.1331 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 6, Week 48, n=188 | 0.043 10^9 per liter | Standard Deviation 0.5839 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 7, Week 8, n=180 | 0.110 10^9 per liter | Standard Deviation 0.6114 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 7, Week 16, n=181 | 0.077 10^9 per liter | Standard Deviation 0.6114 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 7, Week 24, n=176 | 0.091 10^9 per liter | Standard Deviation 0.5944 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 7, Week 32, n=179 | 0.104 10^9 per liter | Standard Deviation 0.5944 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 7, Week 40, n=177 | 0.075 10^9 per liter | Standard Deviation 0.5385 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 7, Week 48, n=173 | 0.060 10^9 per liter | Standard Deviation 0.6039 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 8, Week 8, n=172 | 0.036 10^9 per liter | Standard Deviation 0.5942 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 8, Week 16, n=173 | -0.005 10^9 per liter | Standard Deviation 0.548 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 8, Week 24, n=170 | 0.030 10^9 per liter | Standard Deviation 0.6126 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 8, Week 32, n=169 | -0.020 10^9 per liter | Standard Deviation 0.5269 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 8, Week 40, n=162 | 0.065 10^9 per liter | Standard Deviation 0.626 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 8, Week 48, n=161 | 0.087 10^9 per liter | Standard Deviation 0.7204 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 9, Week 8, n=164 | 0.090 10^9 per liter | Standard Deviation 0.6612 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 9, Week 16, n=161 | 0.022 10^9 per liter | Standard Deviation 0.5664 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 9, Week 24, n=163 | 0.062 10^9 per liter | Standard Deviation 0.5704 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 9, Week 32, n=159 | 0.017 10^9 per liter | Standard Deviation 0.5326 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 9, Week 40, n=156 | 0.069 10^9 per liter | Standard Deviation 0.641 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 9, Week 48, n=151 | 0.064 10^9 per liter | Standard Deviation 0.5979 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 10, Week 8, n=149 | 0.046 10^9 per liter | Standard Deviation 0.5547 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 10, Week 16, n=145 | 0.089 10^9 per liter | Standard Deviation 0.6336 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 10, Week 24, n=147 | 0.033 10^9 per liter | Standard Deviation 0.5811 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 4, Week 16, n=238 | 0.034 10^9 per liter | Standard Deviation 0.1273 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 10, Week 32, n=142 | 0.076 10^9 per liter | Standard Deviation 0.5914 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 10, Week 40, n=137 | 0.071 10^9 per liter | Standard Deviation 0.5621 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 4, Week 24, n=227 | 0.033 10^9 per liter | Standard Deviation 0.1384 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 10, Week 48, n=137 | 0.073 10^9 per liter | Standard Deviation 0.5807 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 11, Week 8, n=137 | 0.112 10^9 per liter | Standard Deviation 0.5764 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 11, Week 16, n=130 | 0.112 10^9 per liter | Standard Deviation 0.6926 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 11, Week 24, n=130 | 0.129 10^9 per liter | Standard Deviation 0.7026 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 11, Week 32, n=128 | 0.139 10^9 per liter | Standard Deviation 0.6249 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 11, Week 40, n=122 | 0.143 10^9 per liter | Standard Deviation 0.6927 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 11, Week 48, n=106 | 0.133 10^9 per liter | Standard Deviation 0.5942 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 12, Week 8, n=109 | 0.145 10^9 per liter | Standard Deviation 0.5976 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 12, Week 16, n=97 | 0.179 10^9 per liter | Standard Deviation 0.5839 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 12, Week 24, n=86 | 0.150 10^9 per liter | Standard Deviation 0.5857 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 12, Week 32, n=88 | 0.135 10^9 per liter | Standard Deviation 0.6319 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 12, Week 40, n=83 | 0.150 10^9 per liter | Standard Deviation 0.6512 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 12, Week 48, n=72 | 0.106 10^9 per liter | Standard Deviation 0.5855 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 13, Week 8, n=53 | 0.133 10^9 per liter | Standard Deviation 0.6269 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 13, Week 16, n=42 | 0.078 10^9 per liter | Standard Deviation 0.6783 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 13, Week 24, n=20 | 0.131 10^9 per liter | Standard Deviation 0.676 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 4, Week 24, n=227 | 0.034 10^9 per liter | Standard Deviation 0.5406 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 4, Week 32, n=229 | 0.017 10^9 per liter | Standard Deviation 0.527 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 4, Week 40, n=216 | 0.003 10^9 per liter | Standard Deviation 0.4347 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 4, Week 32, n=229 | 0.039 10^9 per liter | Standard Deviation 0.1381 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 4, Week 48, n=220 | 0.017 10^9 per liter | Standard Deviation 0.4826 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 5, Week 8, n=215 | 0.012 10^9 per liter | Standard Deviation 0.4654 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 5, Week 16, n=214 | 0.050 10^9 per liter | Standard Deviation 0.5205 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 5, Week 24, n=207 | 0.052 10^9 per liter | Standard Deviation 0.5355 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 5, Week 32, n=207 | 0.031 10^9 per liter | Standard Deviation 0.5323 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 13, Week 32, n=7 | 0.293 10^9 per liter | Standard Deviation 0.8019 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Year 13, Week 40, n=1 | 0.160 10^9 per liter | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, Exit, n=241 | 0.088 10^9 per liter | Standard Deviation 0.6208 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 4, Week 40, n=216 | 0.038 10^9 per liter | Standard Deviation 0.1284 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, 8-Week Follow-up, n=219 | 0.119 10^9 per liter | Standard Deviation 0.6554 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Lymphocytes, 24-Week Follow-up, n=198 | 0.054 10^9 per liter | Standard Deviation 0.6847 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 1, Week 8, n=287 | 0.014 10^9 per liter | Standard Deviation 0.1795 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 1, Week 16, n=288 | 0.018 10^9 per liter | Standard Deviation 0.1903 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 1, Week 24, n=293 | 0.007 10^9 per liter | Standard Deviation 0.1834 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 1, Week 32, n=290 | 0.016 10^9 per liter | Standard Deviation 0.1666 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 1, Week 40, n=287 | 0.020 10^9 per liter | Standard Deviation 0.175 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 1, Week 48, n=287 | 0.018 10^9 per liter | Standard Deviation 0.1739 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 2, Week 8, n=288 | 0.009 10^9 per liter | Standard Deviation 0.1718 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 2, Week 16, n=279 | 0.016 10^9 per liter | Standard Deviation 0.1783 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 2, Week 24, n=276 | 0.029 10^9 per liter | Standard Deviation 0.1764 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 2, Week 32, n=281 | 0.018 10^9 per liter | Standard Deviation 0.1842 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 2, Week 40, n=262 | 0.014 10^9 per liter | Standard Deviation 0.1848 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 4, Week 48, n=220 | 0.030 10^9 per liter | Standard Deviation 0.1261 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 5, Week 8, n=215 | 0.035 10^9 per liter | Standard Deviation 0.1242 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 5, Week 16, n=214 | 0.019 10^9 per liter | Standard Deviation 0.1294 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 5, Week 24, n=207 | 0.023 10^9 per liter | Standard Deviation 0.1078 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Eosinophils, Year 5, Week 32, n=207 | 0.027 10^9 per liter | Standard Deviation 0.1201 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 2, Week 48, n=260 | 0.030 10^9 per liter | Standard Deviation 0.1594 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 3, Week 8, n=260 | 0.024 10^9 per liter | Standard Deviation 0.1677 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 3, Week 16, n=258 | 0.038 10^9 per liter | Standard Deviation 0.1705 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 3, Week 24, n=242 | 0.034 10^9 per liter | Standard Deviation 0.1632 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 3, Week 32, n=248 | 0.022 10^9 per liter | Standard Deviation 0.1776 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 3, Week 40, n=242 | 0.044 10^9 per liter | Standard Deviation 0.165 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 3, Week 48, n=240 | 0.039 10^9 per liter | Standard Deviation 0.1855 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 4, Week 8, n=234 | 0.035 10^9 per liter | Standard Deviation 0.1687 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 4, Week 16, n=238 | 0.039 10^9 per liter | Standard Deviation 0.1665 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 4, Week 24, n=227 | 0.032 10^9 per liter | Standard Deviation 0.1667 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 4, Week 32, n=229 | 0.027 10^9 per liter | Standard Deviation 0.1566 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 4, Week 40, n=216 | 0.035 10^9 per liter | Standard Deviation 0.1688 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 4, Week 48, n=220 | 0.015 10^9 per liter | Standard Deviation 0.1771 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 5, Week 8, n=215 | 0.018 10^9 per liter | Standard Deviation 0.1824 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 5, Week 16, n=214 | 0.036 10^9 per liter | Standard Deviation 0.1527 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 5, Week 24, n=207 | 0.041 10^9 per liter | Standard Deviation 0.1632 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 5, Week 32, n=207 | 0.039 10^9 per liter | Standard Deviation 0.1625 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 5, Week 40, n=196 | 0.049 10^9 per liter | Standard Deviation 0.151 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 5, Week 48, n=209 | 0.050 10^9 per liter | Standard Deviation 0.1628 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 6, Week 8, n=206 | 0.045 10^9 per liter | Standard Deviation 0.167 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 6, Week 16, n=195 | 0.033 10^9 per liter | Standard Deviation 0.17 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 6, Week 24, n=192 | 0.030 10^9 per liter | Standard Deviation 0.1556 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 6, Week 32, n=197 | 0.048 10^9 per liter | Standard Deviation 0.1635 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 6, Week 40, n=183 | 0.051 10^9 per liter | Standard Deviation 0.1342 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 6, Week 48, n=188 | 0.038 10^9 per liter | Standard Deviation 0.1665 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 7, Week 8, n=180 | 0.028 10^9 per liter | Standard Deviation 0.1507 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 7, Week 16, n=181 | 0.030 10^9 per liter | Standard Deviation 0.1482 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 7, Week 24, n=176 | 0.033 10^9 per liter | Standard Deviation 0.1583 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 7, Week 32, n=179 | 0.039 10^9 per liter | Standard Deviation 0.1534 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 7, Week 40, n=177 | 0.047 10^9 per liter | Standard Deviation 0.1391 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 7, Week 48, n=173 | 0.055 10^9 per liter | Standard Deviation 0.1508 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 8, Week 8, n=172 | 0.071 10^9 per liter | Standard Deviation 0.1536 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 8, Week 16, n=173 | 0.072 10^9 per liter | Standard Deviation 0.1464 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 8, Week 24, n=170 | 0.075 10^9 per liter | Standard Deviation 0.1545 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 8, Week 32, n=169 | 0.049 10^9 per liter | Standard Deviation 0.1414 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 8, Week 40, n=162 | 0.070 10^9 per liter | Standard Deviation 0.148 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 8, Week 48, n=161 | 0.072 10^9 per liter | Standard Deviation 0.1744 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 9, Week 8, n=164 | 0.069 10^9 per liter | Standard Deviation 0.1513 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 9, Week 16, n=161 | 0.063 10^9 per liter | Standard Deviation 0.1462 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 9, Week 24, n=163 | 0.077 10^9 per liter | Standard Deviation 0.1603 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 9, Week 32, n=159 | 0.074 10^9 per liter | Standard Deviation 0.1393 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 9, Week 40, n=156 | 0.075 10^9 per liter | Standard Deviation 0.144 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 9, Week 48, n=151 | 0.063 10^9 per liter | Standard Deviation 0.1576 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 10, Week 8, n=149 | 0.084 10^9 per liter | Standard Deviation 0.1511 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 10, Week 16, n=145 | 0.083 10^9 per liter | Standard Deviation 0.1439 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 10, Week 24, n=147 | 0.087 10^9 per liter | Standard Deviation 0.1874 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 10, Week 32, n=142 | 0.077 10^9 per liter | Standard Deviation 0.1517 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 10, Week 40, n=137 | 0.064 10^9 per liter | Standard Deviation 0.1522 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 10, Week 48, n=137 | 0.070 10^9 per liter | Standard Deviation 0.1454 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 11, Week 8, n=137 | 0.077 10^9 per liter | Standard Deviation 0.1622 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 11, Week 16, n=130 | 0.077 10^9 per liter | Standard Deviation 0.1484 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 11, Week 24, n=130 | 0.079 10^9 per liter | Standard Deviation 0.1775 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 11, Week 32, n=128 | 0.080 10^9 per liter | Standard Deviation 0.1849 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 11, Week 40, n=122 | 0.075 10^9 per liter | Standard Deviation 0.1435 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 11, Week 48, n=106 | 0.075 10^9 per liter | Standard Deviation 0.1854 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 12, Week 8, n=109 | 0.088 10^9 per liter | Standard Deviation 0.2166 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 12, Week 16, n=97 | 0.104 10^9 per liter | Standard Deviation 0.1829 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 12, Week 24, n=86 | 0.073 10^9 per liter | Standard Deviation 0.1616 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 12, Week 32, n=88 | 0.065 10^9 per liter | Standard Deviation 0.1682 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 12, Week 40, n=83 | 0.078 10^9 per liter | Standard Deviation 0.1734 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 12, Week 48, n=72 | 0.060 10^9 per liter | Standard Deviation 0.1635 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 13, Week 8, n=53 | 0.013 10^9 per liter | Standard Deviation 0.1453 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 13, Week 16, n=42 | 0.061 10^9 per liter | Standard Deviation 0.1882 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 13, Week 24, n=20 | 0.074 10^9 per liter | Standard Deviation 0.1471 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 13, Week 32, n=7 | 0.097 10^9 per liter | Standard Deviation 0.1452 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Year 13, Week 40, n=1 | 0.120 10^9 per liter | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, Exit, n=241 | 0.062 10^9 per liter | Standard Deviation 0.1813 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, 8-Week Follow-up, n=219 | 0.061 10^9 per liter | Standard Deviation 0.2153 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Monocytes, 24-Week Follow-up , n=198 | 0.049 10^9 per liter | Standard Deviation 0.2118 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 1, Week 8, n=287 | 0.003 10^9 per liter | Standard Deviation 1.7881 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 1, Week 16, n=288 | -0.107 10^9 per liter | Standard Deviation 1.7909 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 1, Week 24, n=293 | -0.166 10^9 per liter | Standard Deviation 1.9241 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 1, Week 32, n=290 | -0.129 10^9 per liter | Standard Deviation 2.0814 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 1, Week 40, n=287 | -0.140 10^9 per liter | Standard Deviation 1.7884 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 1, Week 48, n=287 | -0.223 10^9 per liter | Standard Deviation 1.7187 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 2, Week 8, n=288 | -0.301 10^9 per liter | Standard Deviation 2.0434 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 2, Week 16, n=279 | -0.392 10^9 per liter | Standard Deviation 2.0076 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 2, Week 24, n=276 | -0.250 10^9 per liter | Standard Deviation 2.2163 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 2, Week 32, n=281 | -0.129 10^9 per liter | Standard Deviation 2.1622 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 2, Week 40, n=262 | -0.236 10^9 per liter | Standard Deviation 2.1413 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 2, Week 48, n=260 | -0.148 10^9 per liter | Standard Deviation 2.1176 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 3, Week 8, n=260 | -0.333 10^9 per liter | Standard Deviation 2.1308 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 3, Week 16, n=258 | -0.308 10^9 per liter | Standard Deviation 2.2022 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 3, Week 24, n=242 | -0.129 10^9 per liter | Standard Deviation 1.9829 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 3, Week 32, n=248 | -0.211 10^9 per liter | Standard Deviation 2.2333 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 3, Week 40, n=242 | -0.161 10^9 per liter | Standard Deviation 1.9939 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 3, Week 48, n=240 | -0.159 10^9 per liter | Standard Deviation 2.1315 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 4, Week 8, n=234 | -0.119 10^9 per liter | Standard Deviation 2.0635 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 4, Week 16, n=238 | -0.177 10^9 per liter | Standard Deviation 2.1063 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 4, Week 24, n=227 | -0.136 10^9 per liter | Standard Deviation 1.9402 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 4, Week 32, n=229 | -0.123 10^9 per liter | Standard Deviation 2.2231 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 4, Week 40, n=216 | -0.119 10^9 per liter | Standard Deviation 1.9639 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 4, Week 48, n=220 | -0.024 10^9 per liter | Standard Deviation 2.2228 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 5, Week 8, n=215 | -0.169 10^9 per liter | Standard Deviation 2.2107 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 5, Week 16, n=214 | -0.189 10^9 per liter | Standard Deviation 2.0362 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 5, Week 24, n=207 | -0.120 10^9 per liter | Standard Deviation 2.0997 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 5, Week 32, n=207 | -0.088 10^9 per liter | Standard Deviation 2.1895 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 5, Week 40, n=196 | -0.064 10^9 per liter | Standard Deviation 2.1536 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 5, Week 48, n=209 | 0.014 10^9 per liter | Standard Deviation 2.0473 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 6, Week 8, n=206 | -0.097 10^9 per liter | Standard Deviation 1.9542 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 6, Week 16, n=195 | -0.218 10^9 per liter | Standard Deviation 2.2682 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 6, Week 24, n=192 | -0.226 10^9 per liter | Standard Deviation 2.1749 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 6, Week 32, n=197 | -0.144 10^9 per liter | Standard Deviation 2.0689 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 6, Week 40, n=183 | -0.359 10^9 per liter | Standard Deviation 2.2241 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 6, Week 48, n=188 | -0.306 10^9 per liter | Standard Deviation 2.1609 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 7, Week 8, n=180 | -0.371 10^9 per liter | Standard Deviation 2.1016 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 7, Week 16, n=181 | -0.410 10^9 per liter | Standard Deviation 2.0287 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 7, Week 24, n=176 | -0.363 10^9 per liter | Standard Deviation 2.2018 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 7, Week 32, n=179 | -0.214 10^9 per liter | Standard Deviation 2.2148 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 7, Week 40, n=177 | -0.360 10^9 per liter | Standard Deviation 2.2393 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 7, Week 48, n=173 | -0.423 10^9 per liter | Standard Deviation 2.1389 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 8, Week 8, n=172 | -0.387 10^9 per liter | Standard Deviation 2.1621 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 8, Week 16, n=173 | -0.310 10^9 per liter | Standard Deviation 2.1373 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 8, Week 24, n=170 | -0.152 10^9 per liter | Standard Deviation 2.3134 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 8, Week 32, n=169 | -0.218 10^9 per liter | Standard Deviation 2.1233 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 8, Week 40, n=162 | -0.281 10^9 per liter | Standard Deviation 2.2042 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 8, Week 48, n=161 | -0.407 10^9 per liter | Standard Deviation 2.2558 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 9, Week 8, n=164 | -0.161 10^9 per liter | Standard Deviation 2.1968 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 9, Week 16, n=161 | -0.332 10^9 per liter | Standard Deviation 2.0436 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 9, Week 24, n=163 | -0.240 10^9 per liter | Standard Deviation 2.1439 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 9, Week 32, n=159 | -0.114 10^9 per liter | Standard Deviation 2.3286 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 9, Week 40, n=156 | -0.252 10^9 per liter | Standard Deviation 2.2301 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 9, Week 48, n=151 | -0.268 10^9 per liter | Standard Deviation 2.4153 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 10, Week 8, n=149 | 0.049 10^9 per liter | Standard Deviation 2.4409 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 10, Week 16, n=145 | 0.008 10^9 per liter | Standard Deviation 2.7611 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 10, Week 24, n=147 | -0.166 10^9 per liter | Standard Deviation 2.297 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 10, Week 32, n=142 | -0.299 10^9 per liter | Standard Deviation 2.1597 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 10, Week 40, n=137 | -0.051 10^9 per liter | Standard Deviation 2.1023 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 10, Week 48, n=137 | -0.176 10^9 per liter | Standard Deviation 2.0628 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 11, Week 8, n=137 | -0.077 10^9 per liter | Standard Deviation 2.4456 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 11, Week 16, n=130 | -0.035 10^9 per liter | Standard Deviation 2.3922 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 11, Week 24, n=130 | -0.031 10^9 per liter | Standard Deviation 2.2826 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 11, Week 32, n=128 | 0.145 10^9 per liter | Standard Deviation 2.4689 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 11, Week 40, n=122 | -0.043 10^9 per liter | Standard Deviation 2.2994 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 11, Week 48, n=106 | -0.004 10^9 per liter | Standard Deviation 2.5913 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 12, Week 8, n=109 | -0.011 10^9 per liter | Standard Deviation 2.5216 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 12, Week 16, n=97 | -0.032 10^9 per liter | Standard Deviation 2.675 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 12, Week 24, n=86 | -0.126 10^9 per liter | Standard Deviation 2.2583 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 12, Week 32, n=88 | -0.081 10^9 per liter | Standard Deviation 2.5744 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 12, Week 40, n=83 | -0.293 10^9 per liter | Standard Deviation 2.2448 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 12, Week 48, n=72 | -0.126 10^9 per liter | Standard Deviation 2.9212 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 13, Week 8, n=53 | -0.747 10^9 per liter | Standard Deviation 2.7599 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 13, Week 16, n=42 | 0.169 10^9 per liter | Standard Deviation 2.5731 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 13, Week 24, n=20 | -0.121 10^9 per liter | Standard Deviation 2.8499 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 13, Week 32, n=7 | -0.927 10^9 per liter | Standard Deviation 2.9565 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Year 13, Week 40, n=1 | -0.680 10^9 per liter | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, Exit, n=241 | 0.436 10^9 per liter | Standard Deviation 2.6133 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, 8-Week Follow-up, n=219 | 0.514 10^9 per liter | Standard Deviation 3.6918 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Neutrophils segmented, 24-Week Follow-up, n=198 | 0.369 10^9 per liter | Standard Deviation 2.6988 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 1, Week ,8 n=279 | 3.7 10^9 per liter | Standard Deviation 34.73 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 1, Week 16, n=279 | 4.5 10^9 per liter | Standard Deviation 34.48 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 1, Week 24, n=286 | 7.9 10^9 per liter | Standard Deviation 36.76 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 1, Week 32, n=285 | 10.3 10^9 per liter | Standard Deviation 41.03 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 1, Week 40, n=283 | 13.1 10^9 per liter | Standard Deviation 39.75 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 1, Week 48, n=282 | 13.2 10^9 per liter | Standard Deviation 46.13 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 2, Week 8, n=280 | 18.1 10^9 per liter | Standard Deviation 48.14 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 2, Week 16, n=276 | 15.4 10^9 per liter | Standard Deviation 45.99 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 2, Week 24, n=273 | 16.7 10^9 per liter | Standard Deviation 49.67 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 2, Week 32, n=277 | 24.0 10^9 per liter | Standard Deviation 50.04 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 2, Week 40, n=259 | 21.9 10^9 per liter | Standard Deviation 46.95 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 2, Week 48, n=255 | 21.2 10^9 per liter | Standard Deviation 50.63 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 3, Week 8, n=256 | 22.0 10^9 per liter | Standard Deviation 53.16 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 3, Week 16, n=253 | 22.7 10^9 per liter | Standard Deviation 55.76 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 3, Week 24, n=239 | 18.4 10^9 per liter | Standard Deviation 50.97 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 3, Week 32, n=243 | 14.1 10^9 per liter | Standard Deviation 50.03 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 3, Week 40, n=240 | 14.3 10^9 per liter | Standard Deviation 55.47 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 3, Week 48, n=235 | 12.6 10^9 per liter | Standard Deviation 56.2 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 4, Week 8, n=230 | 11.5 10^9 per liter | Standard Deviation 48.78 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 4, Week 16, n=234 | 11.7 10^9 per liter | Standard Deviation 54.46 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 4, Week 24, n=226 | 11.7 10^9 per liter | Standard Deviation 51.12 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 4, Week 32, n=220 | 9.6 10^9 per liter | Standard Deviation 55.85 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 4, Week 40, n=214 | 5.6 10^9 per liter | Standard Deviation 54.44 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 4, Week 48, n=216 | 6.7 10^9 per liter | Standard Deviation 56.74 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 5, Week 8, n=211 | 4.6 10^9 per liter | Standard Deviation 62.04 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 5, Week 16, n=212 | -2.1 10^9 per liter | Standard Deviation 54.06 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 5, Week 24, n=206 | -3.0 10^9 per liter | Standard Deviation 52.05 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 5, Week 32, n=203 | -4.8 10^9 per liter | Standard Deviation 53.16 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 5, Week 40, n=194 | -7.7 10^9 per liter | Standard Deviation 51.97 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 5, Week 48, n=206 | -3.4 10^9 per liter | Standard Deviation 54.93 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 6, Week 8, n=203 | -10.8 10^9 per liter | Standard Deviation 56.67 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 6, Week 16, n=193 | -12.7 10^9 per liter | Standard Deviation 56.99 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 6, Week 24, n=190 | -15.6 10^9 per liter | Standard Deviation 51.76 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 6, Week 32, n=194 | -12.2 10^9 per liter | Standard Deviation 52.69 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 6, Week 40, n=182 | -15.8 10^9 per liter | Standard Deviation 56.24 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 6, Week 48, n=186 | -19.5 10^9 per liter | Standard Deviation 52.68 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 7, Week 8, n=179 | -17.3 10^9 per liter | Standard Deviation 53.81 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 7, Week 16, n=179 | -24.2 10^9 per liter | Standard Deviation 49.52 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 7, Week 24, n=175 | -22.0 10^9 per liter | Standard Deviation 52.19 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 7, Week 32, n=178 | -19.4 10^9 per liter | Standard Deviation 59.77 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 7, Week 40, n=176 | -16.6 10^9 per liter | Standard Deviation 63.5 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 7, Week 48, n=171 | -14.3 10^9 per liter | Standard Deviation 60.69 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 8, Week 8, n=168 | -11.5 10^9 per liter | Standard Deviation 54.16 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 8, Week 16, n=172 | -15.0 10^9 per liter | Standard Deviation 58.24 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 8, Week 24, n=169 | -11.0 10^9 per liter | Standard Deviation 56.12 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 8, Week 32, n=168 | -13.9 10^9 per liter | Standard Deviation 55.53 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 8, Week 40, n=161 | -12.0 10^9 per liter | Standard Deviation 62.73 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 8, Week 48, n=161 | -8.9 10^9 per liter | Standard Deviation 80.44 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 9, Week 8, n=162 | -8.4 10^9 per liter | Standard Deviation 64.02 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 9, Week 16, n=160 | -11.7 10^9 per liter | Standard Deviation 68.06 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 9, Week 24, n=162 | -13.6 10^9 per liter | Standard Deviation 60.2 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 9, Week 32, n=158 | -16.8 10^9 per liter | Standard Deviation 62.14 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 9, Week 40, n=156 | -13.4 10^9 per liter | Standard Deviation 63.09 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 9, Week 48, n=150 | -13.0 10^9 per liter | Standard Deviation 65.2 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 10, Week 8, n=149 | -10.9 10^9 per liter | Standard Deviation 60.24 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 10, Week 16, n=144 | -9.7 10^9 per liter | Standard Deviation 62.61 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 10, Week 24, n=146 | -9.7 10^9 per liter | Standard Deviation 60.67 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 10, Week 32, n=141 | -10.6 10^9 per liter | Standard Deviation 62.35 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 10, Week 40, n=136 | -9.5 10^9 per liter | Standard Deviation 61.8 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 10, Week 48, n=136 | -11.7 10^9 per liter | Standard Deviation 61.81 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 11, Week 8, n=136 | -8.4 10^9 per liter | Standard Deviation 69.58 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 11, Week 16, n=129 | -6.4 10^9 per liter | Standard Deviation 63.81 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 11, Week 24, n=129 | -6.7 10^9 per liter | Standard Deviation 61.75 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 11, Week 32, n=127 | -3.0 10^9 per liter | Standard Deviation 65.54 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 11, Week 40, n=121 | -5.8 10^9 per liter | Standard Deviation 68.01 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 11, Week 48, n=105 | -7.8 10^9 per liter | Standard Deviation 62.13 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 12, Week 8, n=108 | -4.1 10^9 per liter | Standard Deviation 73.02 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 12, Week 16, n=96 | -10.6 10^9 per liter | Standard Deviation 68.02 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 12, Week 24, n=84 | -11.5 10^9 per liter | Standard Deviation 60.94 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 12, Week 32, n=87 | -5.7 10^9 per liter | Standard Deviation 70.98 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 12, Week 40, n=82 | -10.7 10^9 per liter | Standard Deviation 67.51 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 12, Week 48, n=72 | -8.7 10^9 per liter | Standard Deviation 80.99 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 13, Week 8, n=53 | -8.6 10^9 per liter | Standard Deviation 70.53 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 13, Week 16, n=41 | -6.2 10^9 per liter | Standard Deviation 61.57 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 13, Week 24, n=20 | -7.1 10^9 per liter | Standard Deviation 47.37 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 13, Week 32, n=7 | -6.7 10^9 per liter | Standard Deviation 51.61 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Year 13, Week 40, n=1 | -29.0 10^9 per liter | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, Exit, n=236 | 8.4 10^9 per liter | Standard Deviation 77.24 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, 8-Week Follow-up, n=217 | 8.2 10^9 per liter | Standard Deviation 71.32 |
| Belimumab 10 mg/kg IV | Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points | Platelets, 24-Week Follow-up, n=194 | 4.0 10^9 per liter | Standard Deviation 67.29 |
Primary
Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points
Clinical chemistry parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in BUN, glucose, calcium, carbon dioxide, chloride, magnesium, phosphate, potassium and sodium is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.
Time frame: Baseline and approximately up to 13 years
Population: MITT Population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 8, Week 32, n=166 | -0.06 millimoles per liter | Standard Deviation 0.382 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 12, Week 48, n=72 | -0.06 millimoles per liter | Standard Deviation 0.527 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, 24-Week Follow-up , n=200 | 0.02 millimoles per liter | Standard Deviation 0.411 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 13, Week 32, n=7 | 1.1 millimoles per liter | Standard Deviation 3.13 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 13, Week 40, n=1 | 0.0 millimoles per liter | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Exit, n=248 | -0.8 millimoles per liter | Standard Deviation 3.38 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, 8-Week Follow-up, n=220 | -0.8 millimoles per liter | Standard Deviation 3.33 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, 24-Week Follow-up, n=200 | -0.8 millimoles per liter | Standard Deviation 3.52 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 1, Week 8, n=284 | -0.003 millimoles per liter | Standard Deviation 0.0646 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 1, Week 8, n=284 | 0.0189 millimoles per liter | Standard Deviation 1.4412 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 1, Week 16, n=286 | -0.0836 millimoles per liter | Standard Deviation 1.4928 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 1, Week 24, n=292 | -0.0281 millimoles per liter | Standard Deviation 1.5612 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 1, Week 32, n=287 | -0.0199 millimoles per liter | Standard Deviation 1.402 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 1, Week 40, n=284 | -0.1823 millimoles per liter | Standard Deviation 1.3626 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 1, Week 48, n=287 | 0.0224 millimoles per liter | Standard Deviation 1.6607 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 2, Week 8, n=288 | -0.0607 millimoles per liter | Standard Deviation 1.5714 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 2, Week 16, n=278 | -0.0796 millimoles per liter | Standard Deviation 1.622 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 2, Week 24, n=273 | -0.0850 millimoles per liter | Standard Deviation 1.69 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 1, Week 16, n=286 | -0.006 millimoles per liter | Standard Deviation 0.0707 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 1, Week 24, n=292 | -0.002 millimoles per liter | Standard Deviation 0.066 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 1, Week 32, n=287 | -0.007 millimoles per liter | Standard Deviation 0.068 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 1, Week 40, n=284 | -0.007 millimoles per liter | Standard Deviation 0.0657 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 1, Week 48, n=287 | -0.017 millimoles per liter | Standard Deviation 0.0724 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 2, Week 8, n=288 | -0.016 millimoles per liter | Standard Deviation 0.0694 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 2, Week 16, n=278 | -0.015 millimoles per liter | Standard Deviation 0.0723 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 2, Week 24, n=273 | -0.020 millimoles per liter | Standard Deviation 0.0704 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 2, Week 32, n=284 | -0.018 millimoles per liter | Standard Deviation 0.0642 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 2, Week 40, n=264 | -0.018 millimoles per liter | Standard Deviation 0.0699 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 2, Week 48, n=269 | -0.021 millimoles per liter | Standard Deviation 0.072 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 3, Week 8, n=265 | -0.029 millimoles per liter | Standard Deviation 0.0709 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 3, Week 16, n=260 | -0.027 millimoles per liter | Standard Deviation 0.0672 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 3, Week 24, n=244 | -0.040 millimoles per liter | Standard Deviation 0.0646 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 3, Week 32, n=249 | -0.042 millimoles per liter | Standard Deviation 0.0742 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 3, Week 40, n=245 | -0.054 millimoles per liter | Standard Deviation 0.0712 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 3, Week 48, n=244 | -0.051 millimoles per liter | Standard Deviation 0.0724 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 2, Week 32, n=284 | -0.0779 millimoles per liter | Standard Deviation 1.8263 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 2, Week 40, n=264 | -0.1136 millimoles per liter | Standard Deviation 1.7293 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 2, Week 48, n=269 | -0.0571 millimoles per liter | Standard Deviation 1.7035 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 3, Week 8, n=265 | -0.0620 millimoles per liter | Standard Deviation 1.658 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 3, Week 16, n=260 | -0.0357 millimoles per liter | Standard Deviation 1.7963 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 3, Week 24, n=244 | 0.0775 millimoles per liter | Standard Deviation 1.9949 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 3, Week 32, n=249 | 0.0129 millimoles per liter | Standard Deviation 1.8758 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 4, Week 8, n=239 | -0.052 millimoles per liter | Standard Deviation 0.0692 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 4, Week 16, n=238 | -0.049 millimoles per liter | Standard Deviation 0.0764 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 4, Week 24, n=227 | -0.046 millimoles per liter | Standard Deviation 0.072 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 4, Week 32, n=233 | -0.049 millimoles per liter | Standard Deviation 0.0709 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 4, Week 40, n=220 | -0.053 millimoles per liter | Standard Deviation 0.0702 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 4, Week 48, n=218 | -0.050 millimoles per liter | Standard Deviation 0.0757 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 5, Week 8, n=218 | -0.052 millimoles per liter | Standard Deviation 0.0676 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 5, Week 16, n=214 | -0.054 millimoles per liter | Standard Deviation 0.0633 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 5, Week 24, n=211 | -0.062 millimoles per liter | Standard Deviation 0.0648 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 5, Week 32, n=211 | -0.068 millimoles per liter | Standard Deviation 0.07 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 5, Week 40, n=198 | -0.063 millimoles per liter | Standard Deviation 0.0709 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 5, Week 48, n=207 | -0.067 millimoles per liter | Standard Deviation 0.0754 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 6, Week 8, n=206 | -0.059 millimoles per liter | Standard Deviation 0.0724 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 6, Week 16, n=198 | -0.067 millimoles per liter | Standard Deviation 0.0786 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 6, Week 24, n=190 | -0.065 millimoles per liter | Standard Deviation 0.0724 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 6, Week 32, n=193 | -0.063 millimoles per liter | Standard Deviation 0.0712 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 6, Week 40, n=185 | -0.060 millimoles per liter | Standard Deviation 0.075 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 6, Week 48, n=186 | -0.068 millimoles per liter | Standard Deviation 0.0721 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 7, Week 8, n=179 | -0.052 millimoles per liter | Standard Deviation 0.0746 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 7, Week 16, n=179 | -0.058 millimoles per liter | Standard Deviation 0.0711 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 7, Week 24, n=173 | -0.056 millimoles per liter | Standard Deviation 0.0712 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 7, Week 32, n=180 | -0.054 millimoles per liter | Standard Deviation 0.0747 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 7, Week 40, n=175 | -0.050 millimoles per liter | Standard Deviation 0.0826 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 7, Week 48, n=175 | -0.057 millimoles per liter | Standard Deviation 0.0772 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 8, Week 8, n=171 | -0.052 millimoles per liter | Standard Deviation 0.0761 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 8, Week 16, n=170 | -0.060 millimoles per liter | Standard Deviation 0.0748 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 8, Week 24, n=168 | -0.051 millimoles per liter | Standard Deviation 0.0739 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 8, Week 32, n=168 | -0.055 millimoles per liter | Standard Deviation 0.0777 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 8, Week 40, n=162 | -0.050 millimoles per liter | Standard Deviation 0.0737 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 3, Week 40, n=245 | 0.0903 millimoles per liter | Standard Deviation 1.9922 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 3, Week 48, n=244 | 0.1346 millimoles per liter | Standard Deviation 2.1131 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 4, Week 8, n=239 | 0.1658 millimoles per liter | Standard Deviation 1.9076 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 4, Week 16, n=238 | 0.0900 millimoles per liter | Standard Deviation 1.7799 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 4, Week 24, n=227 | 0.1258 millimoles per liter | Standard Deviation 2.0386 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 4, Week 32, n=233 | 0.0812 millimoles per liter | Standard Deviation 1.8611 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 4, Week 40, n=220 | 0.0325 millimoles per liter | Standard Deviation 2.0164 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 4, Week 48, n=218 | 0.2948 millimoles per liter | Standard Deviation 2.3008 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 5, Week 8, n=218 | 0.2047 millimoles per liter | Standard Deviation 2.0007 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 5, Week 16, n=214 | 0.2669 millimoles per liter | Standard Deviation 1.8316 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 5, Week 24, n=211 | 0.2064 millimoles per liter | Standard Deviation 2.0558 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 5, Week 32, n=211 | 0.0558 millimoles per liter | Standard Deviation 1.7962 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 5, Week 40, n=198 | 0.2632 millimoles per liter | Standard Deviation 2.0944 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 5, Week 48, n=207 | 0.1794 millimoles per liter | Standard Deviation 2.0505 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 6, Week 8, n=206 | 0.2773 millimoles per liter | Standard Deviation 1.8758 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 6, Week 16, n=198 | 0.2632 millimoles per liter | Standard Deviation 1.8983 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 6, Week 24, n=190 | 0.1447 millimoles per liter | Standard Deviation 2.0291 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 6, Week 32, n=193 | 0.2960 millimoles per liter | Standard Deviation 2.1213 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 6, Week 40, n=185 | 0.3184 millimoles per liter | Standard Deviation 2.1795 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 6, Week 48, n=186 | 0.3647 millimoles per liter | Standard Deviation 1.9359 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 7, Week 8, n=179 | 0.2852 millimoles per liter | Standard Deviation 2.1528 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 7, Week 16, n=179 | 0.3191 millimoles per liter | Standard Deviation 2.0398 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 7, Week 24, n=173 | 0.2683 millimoles per liter | Standard Deviation 2.5539 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 7, Week 32, n=180 | 0.1686 millimoles per liter | Standard Deviation 2.1547 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 7, Week 40, n=175 | 0.2285 millimoles per liter | Standard Deviation 1.9007 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 7, Week 48, n=175 | 0.2326 millimoles per liter | Standard Deviation 2.3098 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 8, Week 8, n=171 | 0.2234 millimoles per liter | Standard Deviation 2.333 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 8, Week 16, n=170 | 0.1932 millimoles per liter | Standard Deviation 2.1219 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 8, Week 24, n=168 | 0.2189 millimoles per liter | Standard Deviation 2.0413 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 8, Week 32, n=168 | 0.0680 millimoles per liter | Standard Deviation 2.0995 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 8, Week 40, n=162 | 0.1234 millimoles per liter | Standard Deviation 2.0504 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 8, Week 48, n=159 | 0.2560 millimoles per liter | Standard Deviation 1.8494 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 9, Week 8, n=164 | 0.1197 millimoles per liter | Standard Deviation 1.6667 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 9, Week 16, n=162 | 0.1719 millimoles per liter | Standard Deviation 1.8226 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 9, Week 24, n=161 | 0.1397 millimoles per liter | Standard Deviation 1.9255 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 9, Week 32, n=163 | 0.2979 millimoles per liter | Standard Deviation 1.902 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 9, Week 40, n=156 | 0.1304 millimoles per liter | Standard Deviation 1.8027 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 9, Week 48, n=151 | 0.0804 millimoles per liter | Standard Deviation 1.9432 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 10, Week 8, n=152 | 0.1973 millimoles per liter | Standard Deviation 2.1517 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 10, Week 16, n=143 | 0.1098 millimoles per liter | Standard Deviation 1.8916 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 10, Week 24, n=145 | 0.1847 millimoles per liter | Standard Deviation 1.833 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 10, Week 32, n=142 | 0.1911 millimoles per liter | Standard Deviation 1.8808 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 10, Week 40, n=138 | -0.0440 millimoles per liter | Standard Deviation 1.8103 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 10, Week 48, n=135 | 0.0926 millimoles per liter | Standard Deviation 1.8219 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 11, Week 8, n=138 | 0.1837 millimoles per liter | Standard Deviation 2.0925 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 11, Week 16, n=128 | 0.1060 millimoles per liter | Standard Deviation 1.9866 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 8, Week 48, n=159 | -0.047 millimoles per liter | Standard Deviation 0.0788 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 9, Week 8, n=164 | -0.049 millimoles per liter | Standard Deviation 0.0793 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 9, Week 16, n=162 | -0.047 millimoles per liter | Standard Deviation 0.0776 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 9, Week 24, n=161 | -0.052 millimoles per liter | Standard Deviation 0.0825 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 9, Week 32, n=163 | -0.052 millimoles per liter | Standard Deviation 0.0771 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 9, Week 40, n=156 | -0.048 millimoles per liter | Standard Deviation 0.084 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 9, Week 48, n=151 | -0.056 millimoles per liter | Standard Deviation 0.0771 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 10, Week 8, n=152 | -0.050 millimoles per liter | Standard Deviation 0.0795 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 10, Week 16, n=143 | -0.054 millimoles per liter | Standard Deviation 0.0772 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 10, Week 24, n=145 | -0.055 millimoles per liter | Standard Deviation 0.077 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 10, Week 32, n=142 | -0.050 millimoles per liter | Standard Deviation 0.075 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 10, Week 40, n=138 | -0.055 millimoles per liter | Standard Deviation 0.0798 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 10, Week 48, n=135 | -0.055 millimoles per liter | Standard Deviation 0.0825 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 11, Week 8, n=138 | -0.057 millimoles per liter | Standard Deviation 0.0823 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 11, Week 16, n=128 | -0.055 millimoles per liter | Standard Deviation 0.0809 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 11, Week 24, n=130 | -0.055 millimoles per liter | Standard Deviation 0.081 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 11, Week 32, n=125 | -0.055 millimoles per liter | Standard Deviation 0.0889 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 11, Week 40, n=124 | -0.044 millimoles per liter | Standard Deviation 0.0842 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 11, Week 48, n=108 | -0.057 millimoles per liter | Standard Deviation 0.08 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 12, Week 8, n=110 | -0.041 millimoles per liter | Standard Deviation 0.0855 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 12, Week 16, n=97 | -0.047 millimoles per liter | Standard Deviation 0.0797 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 12, Week 24, n=87 | -0.040 millimoles per liter | Standard Deviation 0.0846 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 12, Week 32, n=84 | -0.056 millimoles per liter | Standard Deviation 0.0808 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 12, Week 40, n=82 | -0.049 millimoles per liter | Standard Deviation 0.0909 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 12, Week 48, n=72 | -0.047 millimoles per liter | Standard Deviation 0.0809 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 13, Week 8, n=53 | -0.045 millimoles per liter | Standard Deviation 0.0834 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 13, Week 16, n=42 | -0.046 millimoles per liter | Standard Deviation 0.0752 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 13, Week 24, n=20 | -0.055 millimoles per liter | Standard Deviation 0.0776 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 13, Week 32, n=7 | -0.050 millimoles per liter | Standard Deviation 0.05 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Year 13, Week 40, n=1 | 0.050 millimoles per liter | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, Exit, n=248 | -0.037 millimoles per liter | Standard Deviation 0.0793 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, 8-Week Follow-up, n=220 | -0.037 millimoles per liter | Standard Deviation 0.0794 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Magnesium, 24-Week Follow-up , n=200 | -0.040 millimoles per liter | Standard Deviation 0.079 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 1, Week 8, n=284 | -0.0259 millimoles per liter | Standard Deviation 0.198 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 1, Week 16, n=286 | -0.0215 millimoles per liter | Standard Deviation 0.1849 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 1, Week 24, n=292 | -0.0001 millimoles per liter | Standard Deviation 0.2023 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 1, Week 32, n=287 | -0.0154 millimoles per liter | Standard Deviation 0.1983 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 1, Week 40, n=284 | -0.0024 millimoles per liter | Standard Deviation 0.1913 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 1, Week 48, n=287 | -0.0234 millimoles per liter | Standard Deviation 0.1926 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 2, Week 8, n=288 | -0.0185 millimoles per liter | Standard Deviation 0.1959 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 2, Week 16, n=278 | -0.0194 millimoles per liter | Standard Deviation 0.2003 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 2, Week 24, n=273 | -0.0209 millimoles per liter | Standard Deviation 0.1991 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 2, Week 32, n=284 | -0.0318 millimoles per liter | Standard Deviation 0.2122 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 2, Week 40, n=264 | -0.0297 millimoles per liter | Standard Deviation 0.2103 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 2, Week 48, n=269 | -0.0116 millimoles per liter | Standard Deviation 0.205 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 3, Week 8, n=265 | -0.04112 millimoles per liter | Standard Deviation 0.2073 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 3, Week 16, n=260 | -0.0451 millimoles per liter | Standard Deviation 0.2059 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 3, Week 24, n=244 | -0.0639 millimoles per liter | Standard Deviation 0.2068 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 3, Week 32, n=249 | -0.0484 millimoles per liter | Standard Deviation 0.2139 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 3, Week 40, n=245 | -0.0583 millimoles per liter | Standard Deviation 0.219 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 3, Week 48, n=244 | -0.0658 millimoles per liter | Standard Deviation 0.2179 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 4, Week 8, n=239 | -0.0621 millimoles per liter | Standard Deviation 0.2103 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 4, Week 16, n=238 | -0.0532 millimoles per liter | Standard Deviation 0.2217 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 4, Week 24, n=227 | -0.0700 millimoles per liter | Standard Deviation 0.2106 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 4, Week 32, n=233 | -0.0601 millimoles per liter | Standard Deviation 0.2034 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 4, Week 40, n=220 | -0.0710 millimoles per liter | Standard Deviation 0.2098 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 4, Week 48, n=218 | -0.0400 millimoles per liter | Standard Deviation 0.2213 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 5, Week 8, n=218 | -0.0529 millimoles per liter | Standard Deviation 0.2222 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 5, Week 16, n=214 | -0.0429 millimoles per liter | Standard Deviation 0.224 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 5, Week 24, n=211 | -0.0502 millimoles per liter | Standard Deviation 0.1996 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 5, Week 32, n=211 | -0.0435 millimoles per liter | Standard Deviation 0.2313 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 5, Week 40, n=198 | -0.0452 millimoles per liter | Standard Deviation 0.2147 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 5, Week 48, n=207 | -0.0323 millimoles per liter | Standard Deviation 0.2167 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 6, Week 8, n=206 | -0.0417 millimoles per liter | Standard Deviation 0.2246 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 6, Week 16, n=198 | -0.0354 millimoles per liter | Standard Deviation 0.2253 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 6, Week 24, n=190 | -0.0262 millimoles per liter | Standard Deviation 0.2326 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 6, Week 32, n=193 | -0.0341 millimoles per liter | Standard Deviation 0.2154 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 6, Week 40, n=185 | -0.0086 millimoles per liter | Standard Deviation 0.2179 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 6, Week 48, n=186 | -0.0085 millimoles per liter | Standard Deviation 0.2256 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 7, Week 8, n=179 | -0.0316 millimoles per liter | Standard Deviation 0.2254 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 7, Week 16, n=179 | -0.0372 millimoles per liter | Standard Deviation 0.1999 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 7, Week 24, n=173 | -0.0390 millimoles per liter | Standard Deviation 0.2099 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 7, Week 32, n=180 | -0.0321 millimoles per liter | Standard Deviation 0.2099 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 7, Week 40, n=175 | -0.0138 millimoles per liter | Standard Deviation 0.2146 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 7, Week 48, n=175 | -0.0400 millimoles per liter | Standard Deviation 0.2031 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 8, Week 8, n=171 | -0.0453 millimoles per liter | Standard Deviation 0.2135 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 8, Week 16, n=170 | -0.0319 millimoles per liter | Standard Deviation 0.2088 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 8, Week 24, n=168 | -0.0450 millimoles per liter | Standard Deviation 0.2136 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 8, Week 32, n=168 | -0.0530 millimoles per liter | Standard Deviation 0.2073 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 8, Week 40, n=162 | -0.0429 millimoles per liter | Standard Deviation 0.2341 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 8, Week 48, n=159 | -0.0266 millimoles per liter | Standard Deviation 0.2158 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 9, Week 8, n=164 | -0.0329 millimoles per liter | Standard Deviation 0.2133 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 9, Week 16, n=162 | -0.0255 millimoles per liter | Standard Deviation 0.214 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 9, Week 24, n=161 | -0.0327 millimoles per liter | Standard Deviation 0.2372 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 9, Week 32, n=163 | -0.0487 millimoles per liter | Standard Deviation 0.2039 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 9, Week 40, n=156 | -0.0230 millimoles per liter | Standard Deviation 0.2123 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 9, Week 48, n=151 | -0.0385 millimoles per liter | Standard Deviation 0.217 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 10, Week 8, n=152 | -0.0310 millimoles per liter | Standard Deviation 0.2136 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 10, Week 16, n=143 | -0.0458 millimoles per liter | Standard Deviation 0.2087 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 11, Week 24, n=130 | 0.1291 millimoles per liter | Standard Deviation 1.8654 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 10, Week 24, n=145 | -0.0307 millimoles per liter | Standard Deviation 0.213 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 10, Week 32, n=142 | -0.0241 millimoles per liter | Standard Deviation 0.2227 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 10, Week 40, n=138 | -0.0459 millimoles per liter | Standard Deviation 0.2184 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 11, Week 32, n=125 | 0.0029 millimoles per liter | Standard Deviation 1.7563 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 11, Week 40, n=124 | 0.0576 millimoles per liter | Standard Deviation 1.9364 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 11, Week 48, n=108 | -0.0926 millimoles per liter | Standard Deviation 1.8134 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 12, Week 8, n=110 | 0.1266 millimoles per liter | Standard Deviation 2.0325 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 12, Week 16, n=97 | 0.2687 millimoles per liter | Standard Deviation 1.9561 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 12, Week 24, n=87 | 0.0780 millimoles per liter | Standard Deviation 1.8996 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 12, Week 32, n=84 | -0.2167 millimoles per liter | Standard Deviation 1.6336 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 10, Week 48, n=135 | -0.0335 millimoles per liter | Standard Deviation 0.2158 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 11, Week 8, n=138 | -0.0314 millimoles per liter | Standard Deviation 0.2311 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 11, Week 16, n=128 | -0.0560 millimoles per liter | Standard Deviation 0.2327 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 11, Week 24, n=130 | -0.0365 millimoles per liter | Standard Deviation 0.2371 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 11, Week 32, n=125 | -0.0302 millimoles per liter | Standard Deviation 0.214 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 11, Week 40, n=124 | -0.0370 millimoles per liter | Standard Deviation 0.2215 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 11, Week 48, n=108 | -0.0287 millimoles per liter | Standard Deviation 0.2361 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 12, Week 8, n=110 | -0.0470 millimoles per liter | Standard Deviation 0.223 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 12, Week 16, n=97 | -0.0333 millimoles per liter | Standard Deviation 0.2264 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 12, Week 24, n=87 | -0.0238 millimoles per liter | Standard Deviation 0.2169 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 12, Week 32, n=84 | -0.0488 millimoles per liter | Standard Deviation 0.2235 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 12, Week 40, n=82 | -0.0555 millimoles per liter | Standard Deviation 0.2188 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 12, Week 48, n=72 | -0.0341 millimoles per liter | Standard Deviation 0.2213 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 13, Week 8, n=53 | -0.0804 millimoles per liter | Standard Deviation 0.2002 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 13, Week 16, n=42 | -0.0461 millimoles per liter | Standard Deviation 0.2669 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 13, Week 24, n=20 | 0.0533 millimoles per liter | Standard Deviation 0.1881 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 13, Week 32, n=7 | 0.0784 millimoles per liter | Standard Deviation 0.2075 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Year 13, Week 40, n=1 | -0.1615 millimoles per liter | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, Exit, n=248 | -0.0328 millimoles per liter | Standard Deviation 0.2385 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, 8-Week Follow-up, n=220 | -0.0631 millimoles per liter | Standard Deviation 0.2221 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Phosphate, 24-Week Follow-up , n=200 | -0.0375 millimoles per liter | Standard Deviation 0.2183 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 1, Week 8, n=281 | -0.01 millimoles per liter | Standard Deviation 0.354 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 1, Week 16, n=283 | 0.04 millimoles per liter | Standard Deviation 0.394 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 1, Week 24, n=287 | 0.04 millimoles per liter | Standard Deviation 0.406 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 1, Week 32, n=283 | 0.01 millimoles per liter | Standard Deviation 0.381 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 1, Week 40, n=282 | 0.03 millimoles per liter | Standard Deviation 0.378 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 1, Week 48, n=284 | 0.00 millimoles per liter | Standard Deviation 0.406 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 2, Week 8, n=288 | 0.00 millimoles per liter | Standard Deviation 0.37 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 2, Week 16, n=275 | 0.03 millimoles per liter | Standard Deviation 0.385 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 2, Week 24, n=269 | 0.02 millimoles per liter | Standard Deviation 0.398 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 2, Week 32, n=284 | 0.00 millimoles per liter | Standard Deviation 0.397 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 2, Week 40, n=261 | 0.04 millimoles per liter | Standard Deviation 0.378 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 2, Week 48, n=267 | 0.01 millimoles per liter | Standard Deviation 0.386 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 3, Week 8, n=262 | 0.00 millimoles per liter | Standard Deviation 0.415 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 3, Week 16, n=258 | 0.02 millimoles per liter | Standard Deviation 0.413 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 3, Week 24, n=241 | 0.02 millimoles per liter | Standard Deviation 0.407 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 3, Week 32, n=245 | -0.02 millimoles per liter | Standard Deviation 0.406 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 3, Week 40, n=242 | 0.02 millimoles per liter | Standard Deviation 0.428 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 3, Week 48, n=239 | 0.00 millimoles per liter | Standard Deviation 0.4 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 4, Week 8, n=237 | 0.03 millimoles per liter | Standard Deviation 0.414 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 4, Week 16, n=236 | 0.00 millimoles per liter | Standard Deviation 0.423 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 4, Week 24, n=225 | 0.03 millimoles per liter | Standard Deviation 0.4 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 4, Week 32, n=230 | 0.02 millimoles per liter | Standard Deviation 0.383 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 4, Week 40, n=218 | -0.02 millimoles per liter | Standard Deviation 0.396 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 4, Week 48, n=214 | 0.02 millimoles per liter | Standard Deviation 0.391 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 5, Week 8, n=217 | 0.01 millimoles per liter | Standard Deviation 0.413 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 5, Week 16, n=213 | 0.00 millimoles per liter | Standard Deviation 0.39 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 5, Week 24, n=206 | 0.03 millimoles per liter | Standard Deviation 0.42 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 5, Week 32, n=211 | -0.01 millimoles per liter | Standard Deviation 0.393 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 5, Week 40, n=196 | 0.03 millimoles per liter | Standard Deviation 0.416 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 5, Week 48, n=207 | -0.01 millimoles per liter | Standard Deviation 0.375 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 6, Week 8, n=205 | -0.02 millimoles per liter | Standard Deviation 0.424 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 6, Week 16, n=198 | -0.04 millimoles per liter | Standard Deviation 0.429 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 6, Week 24, n=189 | 0.00 millimoles per liter | Standard Deviation 0.411 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 6, Week 32, n=192 | -0.02 millimoles per liter | Standard Deviation 0.395 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 6, Week 40, n=181 | 0.03 millimoles per liter | Standard Deviation 0.435 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 6, Week 48, n=186 | -0.01 millimoles per liter | Standard Deviation 0.388 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium,Year 7, Week 8, n=177 | 0.00 millimoles per liter | Standard Deviation 0.424 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 7, Week 16, n=178 | -0.02 millimoles per liter | Standard Deviation 0.412 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 7, Week 24, n=171 | 0.03 millimoles per liter | Standard Deviation 0.388 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 7, Week 32, n=179 | 0.02 millimoles per liter | Standard Deviation 0.406 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 7, Week 40, n=172 | 0.03 millimoles per liter | Standard Deviation 0.453 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 12, Week 40, n=82 | -0.1741 millimoles per liter | Standard Deviation 1.8725 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 12, Week 48, n=72 | -0.0992 millimoles per liter | Standard Deviation 1.8146 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 13, Week 8, n=53 | 0.0808 millimoles per liter | Standard Deviation 1.7244 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 13, Week 16, n=42 | 0.5695 millimoles per liter | Standard Deviation 1.669 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 13, Week 24, n=20 | 0.1964 millimoles per liter | Standard Deviation 1.0708 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 13, Week 32, n=7 | -0.4590 millimoles per liter | Standard Deviation 1.6961 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Year 13, Week 40, n=1 | -1.7850 millimoles per liter | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, Exit, n=248 | 0.2519 millimoles per liter | Standard Deviation 2.3492 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, 8-Week Follow-up, n=220 | 0.0471 millimoles per liter | Standard Deviation 2.3709 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | BUN, 24-Week Follow-up , n=200 | -0.0268 millimoles per liter | Standard Deviation 2.1652 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 1, Week 8, n=284 | -0.0264 millimoles per liter | Standard Deviation 1.4683 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 1, Week 16, n=286 | 0.0314 millimoles per liter | Standard Deviation 1.5221 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 1, Week 24, n=292 | -0.0375 millimoles per liter | Standard Deviation 1.6213 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 1, Week 32, n=287 | -0.0265 millimoles per liter | Standard Deviation 1.6241 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 1, Week 40, n=284 | 0.0031 millimoles per liter | Standard Deviation 1.459 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 1, Week 48, n=287 | 0.0232 millimoles per liter | Standard Deviation 1.8176 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 2, Week 8, n=288 | 0.0168 millimoles per liter | Standard Deviation 1.6196 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 2, Week 16, n=278 | 0.0327 millimoles per liter | Standard Deviation 1.6027 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 2, Week 24, n=273 | 0.1194 millimoles per liter | Standard Deviation 1.645 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 2, Week 32, n=284 | 0.0510 millimoles per liter | Standard Deviation 1.4905 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 2, Week 40, n=264 | 0.0639 millimoles per liter | Standard Deviation 1.5995 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 2, Week 48, n=269 | 0.0017 millimoles per liter | Standard Deviation 1.6178 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 3, Week 8, n=265 | -0.0161 millimoles per liter | Standard Deviation 1.3878 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 3, Week 16, n=260 | -0.1223 millimoles per liter | Standard Deviation 1.5965 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 3, Week 24, n=244 | 0.0348 millimoles per liter | Standard Deviation 1.9713 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 3, Week 32, n=249 | -0.0887 millimoles per liter | Standard Deviation 1.7057 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 3, Week 40, n=245 | -0.0242 millimoles per liter | Standard Deviation 1.3532 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 3, Week 48, n=244 | -0.0271 millimoles per liter | Standard Deviation 2.1535 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 4, Week 8, n=239 | -0.0451 millimoles per liter | Standard Deviation 1.6912 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 4, Week 16, n=238 | -0.1199 millimoles per liter | Standard Deviation 1.7495 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 4, Week 24, n=227 | -0.1142 millimoles per liter | Standard Deviation 1.8087 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 4, Week 32, n=233 | 0.0741 millimoles per liter | Standard Deviation 1.7592 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 4, Week 40, n=220 | 0.1204 millimoles per liter | Standard Deviation 2.02 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 4, Week 48, n=218 | -0.0410 millimoles per liter | Standard Deviation 1.9212 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 5, Week 8, n=218 | 0.1350 millimoles per liter | Standard Deviation 1.8331 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 5, Week 16, n=214 | 0.0999 millimoles per liter | Standard Deviation 1.9373 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 5, Week 24, n=211 | 0.2402 millimoles per liter | Standard Deviation 1.7548 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 5, Week 32, n=211 | -0.0873 millimoles per liter | Standard Deviation 1.5258 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 5, Week 40, n=198 | 0.0535 millimoles per liter | Standard Deviation 1.7957 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 5, Week 48, n=207 | -0.0107 millimoles per liter | Standard Deviation 1.3758 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 6, Week 8, n=206 | 0.0385 millimoles per liter | Standard Deviation 2.0336 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 6, Week 16, n=198 | 0.0112 millimoles per liter | Standard Deviation 1.6676 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 6, Week 24, n=190 | 0.0894 millimoles per liter | Standard Deviation 2.1875 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 6, Week 32, n=193 | 0.0380 millimoles per liter | Standard Deviation 1.9025 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 6, Week 40, n=185 | 0.0939 millimoles per liter | Standard Deviation 1.9242 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 6, Week 48, n=186 | -0.0176 millimoles per liter | Standard Deviation 1.7507 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 7, Week 8, n=179 | 0.1098 millimoles per liter | Standard Deviation 1.9999 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 7, Week 16, n=179 | 0.0558 millimoles per liter | Standard Deviation 2.0164 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 7, Week 24, n=173 | 0.2118 millimoles per liter | Standard Deviation 2.3731 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 7, Week 32, n=180 | 0.1588 millimoles per liter | Standard Deviation 1.6939 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 7, Week 40, n=175 | 0.1380 millimoles per liter | Standard Deviation 2.1777 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 7, Week 48, n=175 | 0.0698 millimoles per liter | Standard Deviation 1.9178 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 8, Week 8, n=171 | 0.0217 millimoles per liter | Standard Deviation 2.0227 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 8, Week 16, n=170 | 0.0307 millimoles per liter | Standard Deviation 1.9951 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 8, Week 24, n=168 | 0.0430 millimoles per liter | Standard Deviation 1.567 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 8, Week 32, n=168 | 0.2029 millimoles per liter | Standard Deviation 2.1886 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 8, Week 40, n=162 | 0.3481 millimoles per liter | Standard Deviation 1.8895 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 8, Week 48, n=159 | 0.2821 millimoles per liter | Standard Deviation 2.3294 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 9, Week 8, n=164 | 0.2065 millimoles per liter | Standard Deviation 2.3063 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 9, Week 16, n=162 | 0.2457 millimoles per liter | Standard Deviation 2.2362 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 9, Week 24, n=161 | 0.2065 millimoles per liter | Standard Deviation 2.3096 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 9, Week 32, n=163 | 0.1437 millimoles per liter | Standard Deviation 1.7266 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 9, Week 40, n=156 | 0.2619 millimoles per liter | Standard Deviation 2.4664 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 9, Week 48, n=151 | 0.3110 millimoles per liter | Standard Deviation 1.7497 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 10, Week 8, n=152 | 0.2184 millimoles per liter | Standard Deviation 2.5367 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 10, Week 16, n=143 | 0.2713 millimoles per liter | Standard Deviation 2.2189 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 10, Week 24, n=145 | 0.2695 millimoles per liter | Standard Deviation 1.9119 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 10, Week 32, n=142 | 0.0192 millimoles per liter | Standard Deviation 2.0309 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 10, Week 40, n=138 | 0.2277 millimoles per liter | Standard Deviation 1.8718 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 10, Week 48, n=135 | 0.2919 millimoles per liter | Standard Deviation 2.242 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 11, Week 8, n=138 | 0.3524 millimoles per liter | Standard Deviation 2.4257 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 11, Week 16, n=128 | 0.1778 millimoles per liter | Standard Deviation 2.443 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 11, Week 24, n=130 | 0.2818 millimoles per liter | Standard Deviation 1.9155 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 7, Week 48, n=175 | -0.03 millimoles per liter | Standard Deviation 0.403 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 8, Week 8, n=170 | -0.05 millimoles per liter | Standard Deviation 0.426 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 8, Week 16, n=169 | -0.05 millimoles per liter | Standard Deviation 0.455 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 8, Week 24, n=167 | 0.00 millimoles per liter | Standard Deviation 0.386 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 11, Week 32, n=125 | 0.2203 millimoles per liter | Standard Deviation 2.2945 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 11, Week 40, n=124 | 0.0877 millimoles per liter | Standard Deviation 2.0564 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 11, Week 48, n=108 | 0.1778 millimoles per liter | Standard Deviation 2.2984 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 12, Week 8, n=110 | 0.2861 millimoles per liter | Standard Deviation 2.57 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 12, Week 16, n=97 | 0.0830 millimoles per liter | Standard Deviation 2.1347 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 12, Week 24, n=87 | 0.1448 millimoles per liter | Standard Deviation 1.8433 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 12, Week 32, n=84 | -0.0886 millimoles per liter | Standard Deviation 2.2813 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 12, Week 40, n=82 | 0.3209 millimoles per liter | Standard Deviation 1.4176 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 12, Week 48, n=72 | 0.3870 millimoles per liter | Standard Deviation 1.4519 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 13, Week 8, n=53 | 0.3561 millimoles per liter | Standard Deviation 1.1963 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 13, Week 16, n=42 | 0.2498 millimoles per liter | Standard Deviation 1.2196 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 13, Week 24, n=20 | 0.4663 millimoles per liter | Standard Deviation 1.6396 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 13, Week 32, n=7 | 0.3727 millimoles per liter | Standard Deviation 0.8144 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Year 13, Week 40, n=1 | -0.8326 millimoles per liter | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, Exit, n=248 | 0.1744 millimoles per liter | Standard Deviation 1.9656 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, 8-Week Follow-up, n=220 | 0.2707 millimoles per liter | Standard Deviation 1.5879 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Glucose, 24-Week Follow-up , n=200 | 0.3295 millimoles per liter | Standard Deviation 2.1561 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 1, Week 8, n=281 | -0.0033 millimoles per liter | Standard Deviation 0.1012 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 1, Week 16, n=283 | -0.0025 millimoles per liter | Standard Deviation 0.1175 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 1, Week 24, n=287 | 0.0156 millimoles per liter | Standard Deviation 0.1036 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 1, Week 32, n=283 | 0.0159 millimoles per liter | Standard Deviation 0.1067 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 1, Week 40, n=282 | 0.0203 millimoles per liter | Standard Deviation 0.1102 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 1, Week 48, n=284 | 0.0011 millimoles per liter | Standard Deviation 0.1193 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 2, Week 8, n=288 | 0.0010 millimoles per liter | Standard Deviation 0.1093 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 2, Week 16, n=276 | -0.0080 millimoles per liter | Standard Deviation 0.1104 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 2, Week 24, n=269 | -0.0180 millimoles per liter | Standard Deviation 0.1171 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 2, Week 32, n=284 | -0.0131 millimoles per liter | Standard Deviation 0.112 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 8, Week 40, n=161 | 0.00 millimoles per liter | Standard Deviation 0.401 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 8, Week 48, n=159 | -0.07 millimoles per liter | Standard Deviation 0.377 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 9, Week 8, n=163 | -0.02 millimoles per liter | Standard Deviation 0.448 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 9, Week 16, n=160 | -0.02 millimoles per liter | Standard Deviation 0.385 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 2, Week 40, n=261 | -0.0071 millimoles per liter | Standard Deviation 0.1091 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 2, Week 48, n=267 | -0.0081 millimoles per liter | Standard Deviation 0.1158 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 3, Week 8, n=262 | -0.0273 millimoles per liter | Standard Deviation 0.1291 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 3, Week 16, n=258 | -0.0189 millimoles per liter | Standard Deviation 0.1102 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 3, Week 24, n=241 | -0.0205 millimoles per liter | Standard Deviation 0.1165 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 3, Week 32, n=245 | -0.0205 millimoles per liter | Standard Deviation 0.1044 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 3, Week 40, n=242 | -0.0121 millimoles per liter | Standard Deviation 0.1122 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 3, Week 48, n=239 | -0.0156 millimoles per liter | Standard Deviation 0.1112 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 4, Week 8, n=237 | -0.0183 millimoles per liter | Standard Deviation 0.1147 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 4, Week 16, n=235 | -0.0264 millimoles per liter | Standard Deviation 0.1118 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 4, Week 24, n=225 | -0.0250 millimoles per liter | Standard Deviation 0.114 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 4, Week 32, n=230 | -0.0221 millimoles per liter | Standard Deviation 0.1074 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 4, Week 40, n=218 | -0.0220 millimoles per liter | Standard Deviation 0.1105 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 4, Week 48, n=214 | -0.0192 millimoles per liter | Standard Deviation 0.1162 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 5, Week 8, n=217 | -0.0297 millimoles per liter | Standard Deviation 0.1112 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 5, Week 16, n=213 | -0.0274 millimoles per liter | Standard Deviation 0.1149 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 5, Week 24, n=206 | -0.0292 millimoles per liter | Standard Deviation 0.1179 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 5, Week 32, n=211 | -0.0104 millimoles per liter | Standard Deviation 0.1132 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 5, Week 40, n=196 | -0.0140 millimoles per liter | Standard Deviation 0.1166 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 5, Week 48, n=207 | -0.0036 millimoles per liter | Standard Deviation 0.1133 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 6, Week 8, n=205 | -0.0127 millimoles per liter | Standard Deviation 0.1086 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 6, Week 16, n=198 | -0.0263 millimoles per liter | Standard Deviation 0.1269 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 6, Week 24, n=189 | -0.0037 millimoles per liter | Standard Deviation 0.1155 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 6, Week 32, n=192 | -0.0044 millimoles per liter | Standard Deviation 0.115 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 6, Week 40, n=181 | -0.0123 millimoles per liter | Standard Deviation 0.1068 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 6, Week 48, n=186 | -0.0025 millimoles per liter | Standard Deviation 0.1107 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 7, Week 8, n=177 | -0.0162 millimoles per liter | Standard Deviation 0.1076 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 7, Week 16, n=178 | -0.0175 millimoles per liter | Standard Deviation 0.1217 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 7, Week 24, n=171 | -0.0163 millimoles per liter | Standard Deviation 0.1169 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 7, Week 32, n=179 | -0.0114 millimoles per liter | Standard Deviation 0.1097 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 7, Week 40, n=172 | -0.0144 millimoles per liter | Standard Deviation 0.1111 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 7, Week 48, n=175 | -0.0234 millimoles per liter | Standard Deviation 0.1058 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 8, Week 8, n=170 | -0.0203 millimoles per liter | Standard Deviation 0.1144 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 8, Week 16, n=169 | -0.0176 millimoles per liter | Standard Deviation 0.1099 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 8, Week 24, n=167 | -0.0121 millimoles per liter | Standard Deviation 0.1047 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 8, Week 32, n=166 | -0.0153 millimoles per liter | Standard Deviation 0.1015 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 8, Week 40, n=161 | -0.0254 millimoles per liter | Standard Deviation 0.1111 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 8, Week 48, n=159 | -0.0210 millimoles per liter | Standard Deviation 0.1138 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 9, Week 8, n=163 | -0.0167 millimoles per liter | Standard Deviation 0.1283 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 9, Week 16, n=160 | -0.0198 millimoles per liter | Standard Deviation 0.1181 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 9, Week 24, n=160 | -0.0253 millimoles per liter | Standard Deviation 0.1231 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 9, Week 32, n=162 | -0.0205 millimoles per liter | Standard Deviation 0.115 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 9, Week 24, n=160 | -0.03 millimoles per liter | Standard Deviation 0.391 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 9, Week 32, n=162 | -0.05 millimoles per liter | Standard Deviation 0.391 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 9, Week 40, n=156 | -0.04 millimoles per liter | Standard Deviation 0.447 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 9, Week 48, n=150 | -0.04 millimoles per liter | Standard Deviation 0.432 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 10, Week 8, n=151 | -0.03 millimoles per liter | Standard Deviation 0.417 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 10, Week 16, n=143 | -0.05 millimoles per liter | Standard Deviation 0.415 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 10, Week 24, n=145 | 0.00 millimoles per liter | Standard Deviation 0.428 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 10, Week 32, n=140 | -0.03 millimoles per liter | Standard Deviation 0.452 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 10, Week 40, n=137 | -0.02 millimoles per liter | Standard Deviation 0.433 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 9, Week 40, n=156 | -0.0157 millimoles per liter | Standard Deviation 0.1246 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 9, Week 48, n=150 | -0.0075 millimoles per liter | Standard Deviation 0.1116 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 10, Week 8, n=151 | -0.0114 millimoles per liter | Standard Deviation 0.105 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 10, Week 16, n=143 | 0.0026 millimoles per liter | Standard Deviation 0.1015 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 10, Week 24, n=145 | -0.0067 millimoles per liter | Standard Deviation 0.1115 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 10, Week 32, n=140 | -0.0066 millimoles per liter | Standard Deviation 0.1109 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 10, Week 40, n=137 | -0.0067 millimoles per liter | Standard Deviation 0.1157 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 10, Week 48, n=135 | -0.0033 millimoles per liter | Standard Deviation 0.1268 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 11, Week 8, n=138 | -0.0043 millimoles per liter | Standard Deviation 0.1185 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 10, Week 48, n=135 | -0.02 millimoles per liter | Standard Deviation 0.442 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 11, Week 8, n=138 | -0.03 millimoles per liter | Standard Deviation 0.438 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 11, Week 16, n=128 | -0.04 millimoles per liter | Standard Deviation 0.395 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 11, Week 16, n=128 | -0.0033 millimoles per liter | Standard Deviation 0.1078 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 11, Week 24, n=129 | 0.02 millimoles per liter | Standard Deviation 0.433 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 11, Week 32, n=124 | -0.08 millimoles per liter | Standard Deviation 0.399 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 11, Week 24, n=129 | -0.0116 millimoles per liter | Standard Deviation 0.1304 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 11, Week 32, n=124 | -0.0131 millimoles per liter | Standard Deviation 0.1131 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 11, Week 40, n=124 | -0.01 millimoles per liter | Standard Deviation 0.383 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 11, Week 48, n=107 | 0.01 millimoles per liter | Standard Deviation 0.413 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 11, Week 40, n=124 | -0.0093 millimoles per liter | Standard Deviation 0.1157 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 12, Week 8, n=109 | 0.01 millimoles per liter | Standard Deviation 0.422 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 11, Week 48, n=107 | -0.0061 millimoles per liter | Standard Deviation 0.1238 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 12, Week 16, n=97 | -0.02 millimoles per liter | Standard Deviation 0.433 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 12, Week 8, n=109 | -0.0153 millimoles per liter | Standard Deviation 0.1214 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 12, Week 16, n=97 | -0.0005 millimoles per liter | Standard Deviation 0.1189 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 12, Week 24, n=85 | 0.0220 millimoles per liter | Standard Deviation 0.1251 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 12, Week 24, n=85 | 0.00 millimoles per liter | Standard Deviation 0.447 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 12, Week 32, n=84 | -0.06 millimoles per liter | Standard Deviation 0.443 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 12, Week 32, n=84 | 0.0009 millimoles per liter | Standard Deviation 0.1265 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 12, Week 40, n=82 | -0.0103 millimoles per liter | Standard Deviation 0.1247 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 12, Week 48, n=72 | -0.0028 millimoles per liter | Standard Deviation 0.1206 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 13, Week 8, n=53 | -0.0151 millimoles per liter | Standard Deviation 0.1402 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 12, Week 40, n=82 | -0.02 millimoles per liter | Standard Deviation 0.411 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 13, Week 16, n=42 | -0.0154 millimoles per liter | Standard Deviation 0.1595 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 13, Week 24, n=20 | 0.0037 millimoles per liter | Standard Deviation 0.1435 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 13, Week 8, n=53 | -0.14 millimoles per liter | Standard Deviation 0.401 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 13, Week 16, n=42 | -0.09 millimoles per liter | Standard Deviation 0.416 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 13, Week 24, n=20 | 0.01 millimoles per liter | Standard Deviation 0.525 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 13, Week 32, n=7 | -0.19 millimoles per liter | Standard Deviation 0.389 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Year 13, Week 40, n=1 | 0.60 millimoles per liter | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, Exit, n=248 | 0.03 millimoles per liter | Standard Deviation 0.409 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Potassium, 8-Week Follow-up, n=220 | 0.01 millimoles per liter | Standard Deviation 0.415 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 1, Week 8, n=284 | 0.1 millimoles per liter | Standard Deviation 2.76 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 1, Week 16, n=286 | 0.2 millimoles per liter | Standard Deviation 2.91 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, ,Year 1, Week 24, n=292 | 0.0 millimoles per liter | Standard Deviation 2.78 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 1, Week 32, n=287 | 0.0 millimoles per liter | Standard Deviation 2.83 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 1, Week 40, n=284 | -0.2 millimoles per liter | Standard Deviation 2.64 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 1, Week 48, n=287 | -0.1 millimoles per liter | Standard Deviation 2.75 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 2, Week 8, n=288 | 0.0 millimoles per liter | Standard Deviation 2.64 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 2, Week 16, n=278 | 0.1 millimoles per liter | Standard Deviation 2.74 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 2, Week 24, n=273 | 0.1 millimoles per liter | Standard Deviation 2.72 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 2, Week 32, n=284 | -0.3 millimoles per liter | Standard Deviation 2.79 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 2, Week 40, n=264 | -0.2 millimoles per liter | Standard Deviation 2.67 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 2, Week 48, n=269 | -0.1 millimoles per liter | Standard Deviation 2.86 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 3, Week 8, n=265 | -0.3 millimoles per liter | Standard Deviation 2.81 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 3, Week 16, n=260 | -0.3 millimoles per liter | Standard Deviation 2.9 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 3, Week 24, n=244 | -0.2 millimoles per liter | Standard Deviation 2.76 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 3, Week 32, n=249 | -0.2 millimoles per liter | Standard Deviation 2.74 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 3, Week 40, n=245 | -0.2 millimoles per liter | Standard Deviation 2.77 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 3, Week 48, n=244 | -0.3 millimoles per liter | Standard Deviation 2.91 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 4, Week 8, n=239 | -0.2 millimoles per liter | Standard Deviation 2.72 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 4, Week 16, n=238 | -0.2 millimoles per liter | Standard Deviation 2.71 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 4, Week 24, n=227 | -0.1 millimoles per liter | Standard Deviation 2.64 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 4, Week 32, n=233 | -0.2 millimoles per liter | Standard Deviation 2.57 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 4, Week 40, n=220 | -0.1 millimoles per liter | Standard Deviation 2.55 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 4, Week 48, n=218 | -0.1 millimoles per liter | Standard Deviation 2.64 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 5, Week 8, n=218 | -0.1 millimoles per liter | Standard Deviation 2.85 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 5, Week 16, n=214 | -0.1 millimoles per liter | Standard Deviation 2.6 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 5, Week 24, n=211 | 0.0 millimoles per liter | Standard Deviation 2.92 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 5, Week 32, n=211 | -0.1 millimoles per liter | Standard Deviation 2.74 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 5, Week 40, n=198 | 0.1 millimoles per liter | Standard Deviation 3.04 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 5, Week 48, n=207 | -0.3 millimoles per liter | Standard Deviation 2.9 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 6, Week 8, n=206 | -0.1 millimoles per liter | Standard Deviation 2.96 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 13, Week 32, n=7 | -0.0784 millimoles per liter | Standard Deviation 0.1234 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Year 13, Week 40, n=1 | 0.0000 millimoles per liter | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, Exit, n=248 | 0.0141 millimoles per liter | Standard Deviation 0.1239 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, 8-Week Follow-up, n=220 | 0.0082 millimoles per liter | Standard Deviation 0.1152 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Calcium, 24-Week Follow-up , n=200 | 0.0181 millimoles per liter | Standard Deviation 0.1211 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 1, Week 8, n=281 | 0.2 millimoles per liter | Standard Deviation 2.54 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 1, Week 16, n=283 | 0.7 millimoles per liter | Standard Deviation 2.73 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 1, Week 24, n=287 | 0.9 millimoles per liter | Standard Deviation 2.78 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 1, Week 32, n=283 | 1.0 millimoles per liter | Standard Deviation 2.51 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 1, Week 40, n=282 | 1.0 millimoles per liter | Standard Deviation 2.75 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 1, Week 48, n=284 | 1.3 millimoles per liter | Standard Deviation 2.71 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 2, Week 8, n=288 | 1.0 millimoles per liter | Standard Deviation 2.74 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 2, Week 16, n=275 | 1.2 millimoles per liter | Standard Deviation 2.74 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 2, Week 24, n=269 | 1.2 millimoles per liter | Standard Deviation 2.96 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 2, Week 32, n=284 | 1.3 millimoles per liter | Standard Deviation 2.77 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 2, Week 40, n=261 | 1.1 millimoles per liter | Standard Deviation 2.72 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 2, Week 48, n=267 | 1.7 millimoles per liter | Standard Deviation 3.02 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 3, Week 8, n=262 | 1.3 millimoles per liter | Standard Deviation 2.83 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 3, Week 16, n=258 | 1.5 millimoles per liter | Standard Deviation 2.95 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 3, Week 24, n=241 | 1.0 millimoles per liter | Standard Deviation 2.81 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 3, Week 32, n=245 | 1.1 millimoles per liter | Standard Deviation 2.96 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 3, Week 40, n=242 | 1.0 millimoles per liter | Standard Deviation 2.94 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 3, Week 48, n=239 | 1.3 millimoles per liter | Standard Deviation 3.29 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 4, Week 8, n=237 | 1.1 millimoles per liter | Standard Deviation 2.81 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 4, Week 16, n=235 | 1.3 millimoles per liter | Standard Deviation 3.04 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 4, Week 24, n=225 | 1.0 millimoles per liter | Standard Deviation 2.84 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 4, Week 32, n=230 | 1.1 millimoles per liter | Standard Deviation 2.9 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 4, Week 40, n=218 | 1.2 millimoles per liter | Standard Deviation 3.11 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 4, Week 48, n=214 | 1.6 millimoles per liter | Standard Deviation 3.17 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 5, Week 8, n=217 | 1.4 millimoles per liter | Standard Deviation 2.93 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 5, Week 16, n=213 | 1.7 millimoles per liter | Standard Deviation 2.93 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 5, Week 24, n=206 | 1.4 millimoles per liter | Standard Deviation 2.82 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 5, Week 32, n=211 | 1.5 millimoles per liter | Standard Deviation 2.98 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 5, Week 40, n=196 | 1.5 millimoles per liter | Standard Deviation 2.91 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 5, Week 48, n=207 | 1.7 millimoles per liter | Standard Deviation 2.82 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 6, Week 8, n=205 | 1.8 millimoles per liter | Standard Deviation 3.1 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 6, Week 16, n=198 | 1.8 millimoles per liter | Standard Deviation 2.94 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 6, Week 24, n=189 | 1.7 millimoles per liter | Standard Deviation 2.77 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 6, Week 32, n=192 | 1.7 millimoles per liter | Standard Deviation 2.82 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 6, Week 40, n=181 | 1.8 millimoles per liter | Standard Deviation 3.07 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 6, Week 48, n=186 | 1.9 millimoles per liter | Standard Deviation 2.97 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 7, Week 8, n=177 | 1.8 millimoles per liter | Standard Deviation 3.12 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 7, Week 16, n=178 | 1.6 millimoles per liter | Standard Deviation 3.11 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 7, Week 24, n=171 | 1.6 millimoles per liter | Standard Deviation 3.08 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 7, Week 32, n=179 | 1.6 millimoles per liter | Standard Deviation 3.1 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 7, Week 40, n=172 | 1.6 millimoles per liter | Standard Deviation 2.83 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 6, Week 16, n=198 | -0.3 millimoles per liter | Standard Deviation 2.85 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 6, Week 24, n=190 | -0.3 millimoles per liter | Standard Deviation 2.9 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 6, Week 32, n=193 | -0.3 millimoles per liter | Standard Deviation 2.9 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 7, Week 48, n=175 | 1.6 millimoles per liter | Standard Deviation 2.97 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 8, Week 8, n=170 | 1.5 millimoles per liter | Standard Deviation 3 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 8, Week 16, n=169 | 1.5 millimoles per liter | Standard Deviation 3.17 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 8, Week 24, n=167 | 1.5 millimoles per liter | Standard Deviation 3.08 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 8, Week 32, n=166 | 1.5 millimoles per liter | Standard Deviation 3.27 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 8, Week 40, n=161 | 1.6 millimoles per liter | Standard Deviation 3.32 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 8, Week 48, n=159 | 1.5 millimoles per liter | Standard Deviation 3.25 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 9, Week 8, n=163 | 1.1 millimoles per liter | Standard Deviation 3.26 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 6, Week 40, n=185 | -0.3 millimoles per liter | Standard Deviation 2.91 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 9, Week 16, n=160 | 1.4 millimoles per liter | Standard Deviation 3.08 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 9, Week 24, n=160 | 1.1 millimoles per liter | Standard Deviation 2.93 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 9, Week 32, n=162 | 1.4 millimoles per liter | Standard Deviation 3.13 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 9, Week 40, n=156 | 1.0 millimoles per liter | Standard Deviation 3.3 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 9, Week 48, n=150 | 1.0 millimoles per liter | Standard Deviation 3.16 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 10, Week 8, n=151 | 1.1 millimoles per liter | Standard Deviation 2.95 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 10, Week 16, n=143 | 1.2 millimoles per liter | Standard Deviation 3.14 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 10, Week 24, n=145 | 1.0 millimoles per liter | Standard Deviation 3.14 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 10, Week 32, n=140 | 1.5 millimoles per liter | Standard Deviation 3.12 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 10, Week 40, n=137 | 1.5 millimoles per liter | Standard Deviation 3.21 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 10, Week 48, n=135 | 1.3 millimoles per liter | Standard Deviation 3.03 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 11, Week 8, n=138 | 1.0 millimoles per liter | Standard Deviation 3.13 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 11, Week 16, n=128 | 1.5 millimoles per liter | Standard Deviation 3.04 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 11, Week 24, n=129 | 1.5 millimoles per liter | Standard Deviation 3.13 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 11, Week 32, n=124 | 1.6 millimoles per liter | Standard Deviation 2.99 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 11, Week 40, n=124 | 1.7 millimoles per liter | Standard Deviation 3.03 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 11, Week 48, n=107 | 1.7 millimoles per liter | Standard Deviation 3.1 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 12, Week 8, n=109 | 1.1 millimoles per liter | Standard Deviation 3.12 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 12, Week 16, n=97 | 2.1 millimoles per liter | Standard Deviation 3.05 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 12, Week 24, n=85 | 2.0 millimoles per liter | Standard Deviation 3.12 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 12, Week 32, n=84 | 2.3 millimoles per liter | Standard Deviation 3.58 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 12, Week 40, n=82 | 2.0 millimoles per liter | Standard Deviation 3.26 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 12, Week 48, n=72 | 1.7 millimoles per liter | Standard Deviation 3.39 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 13, Week 8, n=53 | 1.6 millimoles per liter | Standard Deviation 2.9 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 13, Week 16, n=42 | 2.0 millimoles per liter | Standard Deviation 2.76 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 13, Week 24, n=20 | 2.5 millimoles per liter | Standard Deviation 3.19 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 13, Week 32, n=7 | 1.3 millimoles per liter | Standard Deviation 3.59 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Year 13, Week 40, n=1 | 4.0 millimoles per liter | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, Exit, n=248 | 1.8 millimoles per liter | Standard Deviation 2.93 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, 8-Week Follow-up, n=220 | 1.8 millimoles per liter | Standard Deviation 3.26 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Carbon dioxide, 24-Week Follow-up , n=200 | 1.8 millimoles per liter | Standard Deviation 3.25 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 1, Week 8, n=284 | 0.1 millimoles per liter | Standard Deviation 2.52 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 1, Week 16, n=286 | 0.4 millimoles per liter | Standard Deviation 2.76 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 1, Week 24, n=292 | 0.0 millimoles per liter | Standard Deviation 2.64 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 1, Week 32, n=287 | 0.0 millimoles per liter | Standard Deviation 2.66 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 1, Week 40, n=284 | 0.0 millimoles per liter | Standard Deviation 2.74 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 1, Week 48, n=287 | 0.4 millimoles per liter | Standard Deviation 2.9 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 2, Week 8, n=288 | 0.2 millimoles per liter | Standard Deviation 2.77 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 2, Week 16, n=278 | 0.4 millimoles per liter | Standard Deviation 2.95 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 2, Week 24, n=273 | 0.6 millimoles per liter | Standard Deviation 2.82 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 2, Week 32, n=284 | 0.4 millimoles per liter | Standard Deviation 2.8 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 2, Week 40, n=264 | 0.3 millimoles per liter | Standard Deviation 3.05 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 2, Week 48, n=269 | 0.2 millimoles per liter | Standard Deviation 2.94 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 3, Week 8, n=265 | 0.3 millimoles per liter | Standard Deviation 3.07 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 3, Week 16, n=260 | 0.0 millimoles per liter | Standard Deviation 2.91 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 3, Week 24, n=244 | 0.1 millimoles per liter | Standard Deviation 2.93 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 3, Week 32, n=249 | -0.1 millimoles per liter | Standard Deviation 2.99 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 3, Week 40, n=245 | -0.2 millimoles per liter | Standard Deviation 2.87 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 3, Week 48, n=244 | -0.3 millimoles per liter | Standard Deviation 3.29 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 4, Week 8, n=239 | -0.2 millimoles per liter | Standard Deviation 2.93 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 4, Week 16, n=238 | -0.2 millimoles per liter | Standard Deviation 3.16 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 4, Week 24, n=227 | 0.1 millimoles per liter | Standard Deviation 2.85 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 4, Week 32, n=233 | -0.3 millimoles per liter | Standard Deviation 3.12 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 4, Week 40, n=220 | -0.4 millimoles per liter | Standard Deviation 2.94 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 4, Week 48, n=218 | -0.3 millimoles per liter | Standard Deviation 3.15 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 5, Week 8, n=218 | -0.1 millimoles per liter | Standard Deviation 3.2 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 5, Week 16, n=214 | 0.1 millimoles per liter | Standard Deviation 2.8 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 5, Week 24, n=211 | 0.2 millimoles per liter | Standard Deviation 3.05 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 5, Week 32, n=211 | -0.2 millimoles per liter | Standard Deviation 3.08 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 5, Week 40, n=198 | 0.1 millimoles per liter | Standard Deviation 2.97 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 5, Week 48, n=207 | -0.3 millimoles per liter | Standard Deviation 3 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 6, Week 48, n=186 | -0.4 millimoles per liter | Standard Deviation 2.77 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium,Year 7, Week 8, n=179 | -0.4 millimoles per liter | Standard Deviation 2.9 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 7, Week 16, n=179 | -0.5 millimoles per liter | Standard Deviation 2.86 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 7, Week 24, n=173 | -0.5 millimoles per liter | Standard Deviation 2.86 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 7, Week 32, n=180 | -0.4 millimoles per liter | Standard Deviation 4.24 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 7, Week 40, n=175 | -0.2 millimoles per liter | Standard Deviation 2.98 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 7, Week 48, n=175 | -0.5 millimoles per liter | Standard Deviation 3.01 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 8, Week 8, n=171 | -0.2 millimoles per liter | Standard Deviation 2.96 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 8, Week 16, n=170 | -0.3 millimoles per liter | Standard Deviation 3.22 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 8, Week 24, n=168 | -0.3 millimoles per liter | Standard Deviation 2.79 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 8, Week 32, n=168 | -0.5 millimoles per liter | Standard Deviation 3.01 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 8, Week 40, n=162 | -0.3 millimoles per liter | Standard Deviation 2.94 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 8, Week 48, n=159 | -0.3 millimoles per liter | Standard Deviation 2.88 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 9, Week 8, n=164 | -0.4 millimoles per liter | Standard Deviation 2.94 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 9, Week 16, n=162 | -0.4 millimoles per liter | Standard Deviation 3.14 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 9, Week 24, n=161 | -0.3 millimoles per liter | Standard Deviation 3.05 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 9, Week 32, n=163 | -0.7 millimoles per liter | Standard Deviation 2.94 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 9, Week 40, n=156 | -0.4 millimoles per liter | Standard Deviation 3.13 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 9, Week 48, n=151 | -0.6 millimoles per liter | Standard Deviation 3.22 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 10, Week 8, n=152 | -0.5 millimoles per liter | Standard Deviation 3.25 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 10, Week 16, n=143 | -0.3 millimoles per liter | Standard Deviation 3.31 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 10, Week 24, n=145 | -0.4 millimoles per liter | Standard Deviation 3.56 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 10, Week 32, n=142 | -0.2 millimoles per liter | Standard Deviation 3.15 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 10, Week 40, n=138 | -0.1 millimoles per liter | Standard Deviation 2.8 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 10, Week 48, n=135 | -0.4 millimoles per liter | Standard Deviation 3.26 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 11, Week 8, n=138 | -0.2 millimoles per liter | Standard Deviation 3.21 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 11, Week 16, n=128 | -0.5 millimoles per liter | Standard Deviation 3.3 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 11, Week 24, n=130 | -0.4 millimoles per liter | Standard Deviation 3.27 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 11, Week 32, n=125 | -0.6 millimoles per liter | Standard Deviation 3.19 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 11, Week 40, n=124 | -0.5 millimoles per liter | Standard Deviation 3.25 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 11, Week 48, n=108 | -0.7 millimoles per liter | Standard Deviation 3.16 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 12, Week 8, n=110 | -0.9 millimoles per liter | Standard Deviation 3.07 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 12, Week 16, n=97 | -0.7 millimoles per liter | Standard Deviation 3.12 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 12, Week 24, n=87 | -0.1 millimoles per liter | Standard Deviation 3.26 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 12, Week 32, n=84 | -0.3 millimoles per liter | Standard Deviation 2.91 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 12, Week 40, n=82 | -0.5 millimoles per liter | Standard Deviation 3.18 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 12, Week 48, n=72 | -1.1 millimoles per liter | Standard Deviation 2.98 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 13, Week 8, n=53 | -0.3 millimoles per liter | Standard Deviation 3.04 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 13, Week 16, n=42 | -0.3 millimoles per liter | Standard Deviation 2.68 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 13, Week 24, n=20 | 0.2 millimoles per liter | Standard Deviation 3.47 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 13, Week 32, n=7 | 0.0 millimoles per liter | Standard Deviation 3.21 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Year 13, Week 40, n=1 | 2.0 millimoles per liter | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, Exit, n=248 | -0.7 millimoles per liter | Standard Deviation 2.96 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, 8-Week Follow-up, n=220 | -0.5 millimoles per liter | Standard Deviation 3.06 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Sodium, 24-Week Follow-up , n=200 | -0.3 millimoles per liter | Standard Deviation 3.16 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 6, Week 8, n=206 | -0.2 millimoles per liter | Standard Deviation 3.11 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 6, Week 16, n=198 | -0.2 millimoles per liter | Standard Deviation 3.23 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 6, Week 24, n=190 | -0.2 millimoles per liter | Standard Deviation 3.11 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 6, Week 32, n=193 | -0.4 millimoles per liter | Standard Deviation 3.31 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 6, Week 40, n=185 | -0.3 millimoles per liter | Standard Deviation 3.25 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 6, Week 48, n=186 | -0.4 millimoles per liter | Standard Deviation 3.07 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 7, Week 8, n=179 | -0.3 millimoles per liter | Standard Deviation 2.95 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 7, Week 16, n=179 | -0.3 millimoles per liter | Standard Deviation 3.1 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 7, Week 24, n=173 | -0.2 millimoles per liter | Standard Deviation 3.18 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 7, Week 32, n=180 | -0.3 millimoles per liter | Standard Deviation 4.06 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 7, Week 40, n=175 | -0.4 millimoles per liter | Standard Deviation 3.32 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 7, Week 48, n=175 | -0.4 millimoles per liter | Standard Deviation 3.24 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 8, Week 8, n=171 | -0.3 millimoles per liter | Standard Deviation 3.46 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 8, Week 16, n=170 | -0.5 millimoles per liter | Standard Deviation 3.75 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 8, Week 24, n=168 | -0.5 millimoles per liter | Standard Deviation 3.37 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 8, Week 32, n=168 | -0.6 millimoles per liter | Standard Deviation 3.3 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 8, Week 40, n=162 | -0.4 millimoles per liter | Standard Deviation 3.26 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 8, Week 48, n=159 | -0.4 millimoles per liter | Standard Deviation 3.49 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 9, Week 8, n=164 | -0.7 millimoles per liter | Standard Deviation 3.36 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 9, Week 16, n=162 | -0.7 millimoles per liter | Standard Deviation 3.26 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 9, Week 24, n=161 | -0.3 millimoles per liter | Standard Deviation 3.21 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 9, Week 32, n=163 | -0.6 millimoles per liter | Standard Deviation 3.43 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 9, Week 40, n=156 | -0.3 millimoles per liter | Standard Deviation 3.72 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 9, Week 48, n=151 | -0.6 millimoles per liter | Standard Deviation 3.76 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 10, Week 8, n=152 | -0.6 millimoles per liter | Standard Deviation 3.61 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 10, Week 16, n=143 | -0.7 millimoles per liter | Standard Deviation 3.59 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 10, Week 24, n=145 | -0.3 millimoles per liter | Standard Deviation 3.87 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 10, Week 32, n=142 | -0.3 millimoles per liter | Standard Deviation 3.72 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 10, Week 40, n=138 | -0.2 millimoles per liter | Standard Deviation 3.18 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 10, Week 48, n=135 | -0.2 millimoles per liter | Standard Deviation 3.48 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 11, Week 8, n=138 | -0.1 millimoles per liter | Standard Deviation 3.28 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 11, Week 16, n=128 | -0.4 millimoles per liter | Standard Deviation 3.41 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 11, Week 24, n=130 | -0.5 millimoles per liter | Standard Deviation 3.39 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 11, Week 32, n=125 | -0.7 millimoles per liter | Standard Deviation 3.69 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 11, Week 40, n=124 | -0.4 millimoles per liter | Standard Deviation 3.22 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 11, Week 48, n=108 | -0.4 millimoles per liter | Standard Deviation 3.33 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 12, Week 8, n=110 | -0.3 millimoles per liter | Standard Deviation 3.51 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 12, Week 16, n=97 | -0.6 millimoles per liter | Standard Deviation 3.23 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 12, Week 24, n=87 | -0.3 millimoles per liter | Standard Deviation 3.18 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 12, Week 32, n=84 | -0.4 millimoles per liter | Standard Deviation 3.01 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 12, Week 40, n=82 | -0.4 millimoles per liter | Standard Deviation 3.32 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 12, Week 48, n=72 | -1.3 millimoles per liter | Standard Deviation 3.09 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 13, Week 8, n=53 | -0.8 millimoles per liter | Standard Deviation 3.31 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 13, Week 16, n=42 | -0.8 millimoles per liter | Standard Deviation 3 |
| Belimumab 10 mg/kg IV | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points | Chloride, Year 13, Week 24, n=20 | 0.0 millimoles per liter | Standard Deviation 3.03 |
Primary
Change From Baseline in BUN/Creatinine at the Indicated Time Points
Clinical chemistry parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in BUN/creatinine is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.
Time frame: Baseline and approximately up to 13 years
Population: MITT Population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 1, Week 8, n=284 | -0.1 Ratio | Standard Deviation 4.13 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 1, Week 16, n=286 | -0.4 Ratio | Standard Deviation 4.31 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 1, Week 24, n=292 | -0.4 Ratio | Standard Deviation 4.67 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 1, Week 32, n=287 | -0.4 Ratio | Standard Deviation 4.07 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 1, Week 40, n=284 | -0.8 Ratio | Standard Deviation 4.26 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 1, Week 48, n=287 | -0.3 Ratio | Standard Deviation 4.8 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 2, Week 8, n=288 | -0.4 Ratio | Standard Deviation 4.91 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 2, Week 16, n=278 | -0.6 Ratio | Standard Deviation 4.95 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 2, Week 24, n=273 | -0.6 Ratio | Standard Deviation 5 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 2, Week 32, n=284 | -0.4 Ratio | Standard Deviation 4.82 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 2, Week 40, n=264 | -0.8 Ratio | Standard Deviation 4.8 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 2, Week 48, n=269 | -0.5 Ratio | Standard Deviation 4.9 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 3, Week 8, n=265 | 0.2 Ratio | Standard Deviation 4.81 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 3, Week 16, n=260 | 0.2 Ratio | Standard Deviation 4.95 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 3, Week 24, n=244 | 0.6 Ratio | Standard Deviation 4.93 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 3, Week 32, n=249 | 0.5 Ratio | Standard Deviation 5.16 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 3, Week 40, n=245 | 0.9 Ratio | Standard Deviation 4.83 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 3, Week 48, n=244 | 0.8 Ratio | Standard Deviation 4.99 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 4, Week 8, n=239 | 1.1 Ratio | Standard Deviation 4.99 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 4, Week 16, n=238 | 0.8 Ratio | Standard Deviation 4.86 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 4, Week 24, n=227 | 0.9 Ratio | Standard Deviation 5.15 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 4, Week 32, n=233 | 0.5 Ratio | Standard Deviation 4.93 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 4, Week 40, n=220 | 0.3 Ratio | Standard Deviation 4.81 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 4, Week 48, n=218 | 1.1 Ratio | Standard Deviation 5.35 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 5, Week 8, n=218 | 0.8 Ratio | Standard Deviation 5.34 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 5, Week 16, n=214 | 1.2 Ratio | Standard Deviation 5.03 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 5, Week 24, n=211 | 0.8 Ratio | Standard Deviation 5.01 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 5, Week 32, n=211 | 0.3 Ratio | Standard Deviation 4.93 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 5, Week 40, n=198 | 1.2 Ratio | Standard Deviation 5.04 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 5, Week 48, n=207 | 0.9 Ratio | Standard Deviation 5.11 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 6, Week 8, n=206 | 1.4 Ratio | Standard Deviation 5.04 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 6, Week 16, n=198 | 1.3 Ratio | Standard Deviation 5.03 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 6, Week 24, n=190 | 1.2 Ratio | Standard Deviation 5.37 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 6, Week 32, n=193 | 1.6 Ratio | Standard Deviation 5.76 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 6, Week 40, n=185 | 1.5 Ratio | Standard Deviation 4.73 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 6, Week 48, n=186 | 1.8 Ratio | Standard Deviation 5.08 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 7, Week 8, n=179 | 1.6 Ratio | Standard Deviation 5.07 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 7, Week 16, n=179 | 2.1 Ratio | Standard Deviation 5.04 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 7, Week 24, n=173 | 2.1 Ratio | Standard Deviation 5.55 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 7, Week 32, n=180 | 2.3 Ratio | Standard Deviation 5.39 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 7, Week 40, n=175 | 2.6 Ratio | Standard Deviation 5.19 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 7, Week 48, n=175 | 2.6 Ratio | Standard Deviation 5.31 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 8, Week 8, n=171 | 2.7 Ratio | Standard Deviation 5.65 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 8, Week 16, n=170 | 2.5 Ratio | Standard Deviation 5.54 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 8, Week 24, n=168 | 2.6 Ratio | Standard Deviation 5.37 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 8, Week 32, n=168 | 2.2 Ratio | Standard Deviation 5.11 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 8, Week 40, n=162 | 2.3 Ratio | Standard Deviation 5.36 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 8, Week 48, n=159 | 2.9 Ratio | Standard Deviation 5.2 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 9, Week 8, n=164 | 2.4 Ratio | Standard Deviation 5.26 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 9, Week 16, n=162 | 2.5 Ratio | Standard Deviation 6.15 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 9, Week 24, n=161 | 2.4 Ratio | Standard Deviation 5.89 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 9, Week 32, n=163 | 2.7 Ratio | Standard Deviation 5.54 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 9, Week 40, n=156 | 2.4 Ratio | Standard Deviation 5.9 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 9, Week 48, n=151 | 2.2 Ratio | Standard Deviation 6.01 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 10, Week 8, n=152 | 2.6 Ratio | Standard Deviation 5.98 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 10, Week 16, n=143 | 2.6 Ratio | Standard Deviation 6.13 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 10, Week 24, n=145 | 2.5 Ratio | Standard Deviation 5.72 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 10, Week 32, n=142 | 2.8 Ratio | Standard Deviation 6.03 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 10, Week 40, n=138 | 2.0 Ratio | Standard Deviation 5.87 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 10, Week 48, n=135 | 2.4 Ratio | Standard Deviation 6.07 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 11, Week 8, n=138 | 2.7 Ratio | Standard Deviation 6.13 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 11, Week 16, n=128 | 2.6 Ratio | Standard Deviation 6.28 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 11, Week 24, n=130 | 2.8 Ratio | Standard Deviation 6.12 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 11, Week 32, n=125 | 2.2 Ratio | Standard Deviation 6.1 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 11, Week 40, n=124 | 2.3 Ratio | Standard Deviation 6.68 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 11, Week 48, n=108 | 1.7 Ratio | Standard Deviation 5.65 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 12, Week 8, n=110 | 2.4 Ratio | Standard Deviation 6.36 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 12, Week 16, n=97 | 2.4 Ratio | Standard Deviation 6.38 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 12, Week 24, n=87 | 2.2 Ratio | Standard Deviation 6.62 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 12, Week 32, n=84 | 1.5 Ratio | Standard Deviation 5.75 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 12, Week 40, n=82 | 1.4 Ratio | Standard Deviation 6.5 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 12, Week 48, n=72 | 1.6 Ratio | Standard Deviation 6.42 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 13, Week 8, n=53 | 2.1 Ratio | Standard Deviation 5.44 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 13, Week 16, n=42 | 3.5 Ratio | Standard Deviation 6.22 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 13, Week 24, n=20 | 3.6 Ratio | Standard Deviation 4.36 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 13, Week 32, n=7 | 0.3 Ratio | Standard Deviation 2.93 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Year 13, Week 40, n=1 | -6.0 Ratio | — |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, Exit, n=248 | 1.6 Ratio | Standard Deviation 5.66 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, 8-Week Follow-up, n=220 | 1.1 Ratio | Standard Deviation 5.88 |
| Belimumab 10 mg/kg IV | Change From Baseline in BUN/Creatinine at the Indicated Time Points | BUN/Creatinine, 24-Week Follow-up , n=200 | 1.3 Ratio | Standard Deviation 5.53 |
Primary
Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points
Clinical chemistry parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in creatinine, urate, and bilirubin is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value.
Time frame: Baseline and approximately up to 13 years
Population: MITT Population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 8, Week 8, n=171 | 0.020 micromoles per liter | Standard Deviation 2.9559 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 7, Week 16, n=179 | 0.143 micromoles per liter | Standard Deviation 2.6134 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 7, Week 24, n=173 | 0.287 micromoles per liter | Standard Deviation 2.6082 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 1, Week 8, n=284 | 0.436 micromoles per liter | Standard Deviation 11.3838 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 1, Week 16, n=286 | 0.464 micromoles per liter | Standard Deviation 12.482 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 1, Week 24, n=292 | 1.211 micromoles per liter | Standard Deviation 12.9503 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 7, Week 32, n=180 | 0.313 micromoles per liter | Standard Deviation 2.9727 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 7, Week 40, n=175 | 0.137 micromoles per liter | Standard Deviation 2.7527 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 7, Week 48, n=175 | 0.156 micromoles per liter | Standard Deviation 2.9747 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 8, Week 16, n=170 | -0.050 micromoles per liter | Standard Deviation 2.6856 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 8, Week 24, n=168 | 0.010 micromoles per liter | Standard Deviation 2.472 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 8, Week 32, n=168 | -0.336 micromoles per liter | Standard Deviation 2.5471 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 8, Week 40, n=162 | -0.032 micromoles per liter | Standard Deviation 2.8934 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 8, Week 48, n=159 | -0.097 micromoles per liter | Standard Deviation 3.255 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 9, Week 8, n=164 | -0.125 micromoles per liter | Standard Deviation 2.7616 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 9, Week 16, n=162 | -0.095 micromoles per liter | Standard Deviation 2.9603 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 9, Week 24, n=161 | -0.234 micromoles per liter | Standard Deviation 3.1385 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 9, Week 32, n=163 | -0.126 micromoles per liter | Standard Deviation 2.7175 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 9, Week 40, n=156 | -0.296 micromoles per liter | Standard Deviation 3.3709 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 9, Week 48, n=151 | 0.057 micromoles per liter | Standard Deviation 2.8231 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 10, Week 8, n=152 | -0.158 micromoles per liter | Standard Deviation 3.0763 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 10, Week 16, n=143 | -0.179 micromoles per liter | Standard Deviation 3.1616 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 10, Week 24, n=145 | -0.024 micromoles per liter | Standard Deviation 2.8853 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 10, Week 32, n=142 | 0.120 micromoles per liter | Standard Deviation 3.3068 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 10, Week 40, n=138 | -0.248 micromoles per liter | Standard Deviation 3.0684 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 10, Week 48, n=135 | 0.190 micromoles per liter | Standard Deviation 3.0751 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 11, Week 8, n=138 | 0.050 micromoles per liter | Standard Deviation 2.9936 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 11, Week 16, n=128 | 0.281 micromoles per liter | Standard Deviation 2.964 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 11, Week 24, n=130 | 0.026 micromoles per liter | Standard Deviation 2.8004 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 11, Week 32, n=125 | 0.192 micromoles per liter | Standard Deviation 2.516 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 11, Week 40, n=124 | 0.193 micromoles per liter | Standard Deviation 3.265 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 11, Week 48, n=108 | 0.538 micromoles per liter | Standard Deviation 2.9261 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 12, Week 8, n=110 | 0.311 micromoles per liter | Standard Deviation 2.8762 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 12, Week 16, n=97 | 0.776 micromoles per liter | Standard Deviation 3.0231 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 12, Week 24, n=87 | 0.511 micromoles per liter | Standard Deviation 3.4508 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 12, Week 32, n=84 | 1.282 micromoles per liter | Standard Deviation 3.3563 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 12, Week 40, n=82 | 0.542 micromoles per liter | Standard Deviation 3.2454 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 12, Week 48, n=72 | 0.570 micromoles per liter | Standard Deviation 3.8398 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 13, Week 8, n=53 | 0.129 micromoles per liter | Standard Deviation 2.8623 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 13, Week 16, n=42 | -0.244 micromoles per liter | Standard Deviation 3.1046 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 13, Week 24, n=20 | -0.513 micromoles per liter | Standard Deviation 2.008 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 13, Week 32, n=7 | -0.244 micromoles per liter | Standard Deviation 2.5032 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 13, Week 40, n=1 | 0.000 micromoles per liter | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Exit, n=248 | 0.510 micromoles per liter | Standard Deviation 3.0619 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, 8-Week Follow-up, n=220 | 0.389 micromoles per liter | Standard Deviation 2.7311 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, 24-Week Follow-up , n=200 | 0.650 micromoles per liter | Standard Deviation 3.3222 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 1, Week 32, n=287 | 1.047 micromoles per liter | Standard Deviation 12.5885 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 1, Week 40, n=284 | 0.965 micromoles per liter | Standard Deviation 12.0245 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 1, Week 48, n=287 | 0.955 micromoles per liter | Standard Deviation 12.476 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 2, Week 8, n=288 | 0.583 micromoles per liter | Standard Deviation 11.9874 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 2, Week 16, n=278 | 1.558 micromoles per liter | Standard Deviation 11.7857 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 2, Week 24, n=273 | 1.036 micromoles per liter | Standard Deviation 13.731 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 2, Week 32, n=284 | 0.716 micromoles per liter | Standard Deviation 14.1894 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 2, Week 40, n=264 | 1.976 micromoles per liter | Standard Deviation 15.759 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 2, Week 48, n=269 | 1.413 micromoles per liter | Standard Deviation 13.7896 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 3, Week 8, n=265 | -1.268 micromoles per liter | Standard Deviation 14.8256 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 3, Week 16, n=260 | -2.006 micromoles per liter | Standard Deviation 14.6735 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 3, Week 24, n=244 | -2.464 micromoles per liter | Standard Deviation 15.3328 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 3, Week 32, n=249 | -3.089 micromoles per liter | Standard Deviation 14.8793 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 3, Week 40, n=245 | -3.320 micromoles per liter | Standard Deviation 18.5589 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 3, Week 48, n=244 | -3.297 micromoles per liter | Standard Deviation 17.3222 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 4, Week 8, n=239 | -3.440 micromoles per liter | Standard Deviation 14.6181 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 4, Week 16, n=238 | -3.417 micromoles per liter | Standard Deviation 17.3832 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 4, Week 24, n=227 | -3.271 micromoles per liter | Standard Deviation 15.7446 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 4, Week 32, n=233 | -2.238 micromoles per liter | Standard Deviation 15.9372 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 4, Week 40, n=220 | -2.331 micromoles per liter | Standard Deviation 15.0967 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 4, Week 48, n=218 | -1.987 micromoles per liter | Standard Deviation 18.0028 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 5, Week 8, n=218 | -2.514 micromoles per liter | Standard Deviation 16.1511 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 5, Week 16, n=214 | -2.602 micromoles per liter | Standard Deviation 16.0764 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 5, Week 24, n=211 | -1.843 micromoles per liter | Standard Deviation 16.8703 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 5, Week 32, n=211 | -1.634 micromoles per liter | Standard Deviation 17.1 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 5, Week 40, n=198 | -2.456 micromoles per liter | Standard Deviation 17.8333 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 5, Week 48, n=207 | -3.203 micromoles per liter | Standard Deviation 17.3533 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 6, Week 8, n=206 | -3.562 micromoles per liter | Standard Deviation 16.8131 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 6, Week 16, n=198 | -2.634 micromoles per liter | Standard Deviation 26.0097 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 6, Week 24, n=190 | -4.373 micromoles per liter | Standard Deviation 15.1824 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 6, Week 32, n=193 | -3.527 micromoles per liter | Standard Deviation 18.6685 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 6, Week 40, n=185 | -3.488 micromoles per liter | Standard Deviation 19.8547 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 6, Week 48, n=186 | -3.565 micromoles per liter | Standard Deviation 18.7328 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 7, Week 8, n=179 | -4.198 micromoles per liter | Standard Deviation 19.0041 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 7, Week 16, n=179 | -5.185 micromoles per liter | Standard Deviation 20.4159 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 7, Week 24, n=173 | -6.438 micromoles per liter | Standard Deviation 20.9087 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 7, Week 32, n=180 | -7.907 micromoles per liter | Standard Deviation 19.4999 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 7, Week 40, n=175 | -8.486 micromoles per liter | Standard Deviation 15.0558 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 7, Week 48, n=175 | -8.789 micromoles per liter | Standard Deviation 17.9447 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 8, Week 8, n=171 | -9.202 micromoles per liter | Standard Deviation 17.7671 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 8, Week 16, n=170 | -8.008 micromoles per liter | Standard Deviation 19.5492 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 8, Week 24, n=168 | -8.630 micromoles per liter | Standard Deviation 19.0791 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 8, Week 32, n=168 | -8.682 micromoles per liter | Standard Deviation 19.2383 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 8, Week 40, n=162 | -8.349 micromoles per liter | Standard Deviation 21.3658 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 8, Week 48, n=159 | -8.228 micromoles per liter | Standard Deviation 18.9524 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 9, Week 8, n=164 | -8.517 micromoles per liter | Standard Deviation 14.5862 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 9, Week 16, n=162 | -7.585 micromoles per liter | Standard Deviation 20.0682 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 9, Week 24, n=161 | -8.291 micromoles per liter | Standard Deviation 21.4197 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 9, Week 32, n=163 | -7.593 micromoles per liter | Standard Deviation 18.2143 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 9, Week 40, n=156 | -7.763 micromoles per liter | Standard Deviation 18.4432 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 9, Week 48, n=151 | -8.430 micromoles per liter | Standard Deviation 15.7255 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 10, Week 8, n=152 | -8.258 micromoles per liter | Standard Deviation 19.3747 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 10, Week 16, n=143 | -9.273 micromoles per liter | Standard Deviation 14.3973 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 10, Week 24, n=145 | -7.986 micromoles per liter | Standard Deviation 17.3492 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 10, Week 32, n=142 | -8.217 micromoles per liter | Standard Deviation 17.1597 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 10, Week 40, n=138 | -9.417 micromoles per liter | Standard Deviation 16.4848 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 10, Week 48, n=135 | -8.120 micromoles per liter | Standard Deviation 15.7637 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 11, Week 8, n=138 | -8.584 micromoles per liter | Standard Deviation 16.5792 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 11, Week 16, n=128 | -9.254 micromoles per liter | Standard Deviation 16.0322 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 11, Week 24, n=130 | -8.500 micromoles per liter | Standard Deviation 16.4151 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 11, Week 32, n=125 | -8.699 micromoles per liter | Standard Deviation 15.1035 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 11, Week 40, n=124 | -7.058 micromoles per liter | Standard Deviation 19.1292 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 11, Week 48, n=108 | -7.858 micromoles per liter | Standard Deviation 15.6339 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 12, Week 8, n=110 | -7.715 micromoles per liter | Standard Deviation 14.5236 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 12, Week 16, n=97 | -6.744 micromoles per liter | Standard Deviation 13.1845 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 12, Week 24, n=87 | -7.316 micromoles per liter | Standard Deviation 13.4273 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 12, Week 32, n=84 | -7.998 micromoles per liter | Standard Deviation 14.5624 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 12, Week 40, n=82 | -7.331 micromoles per liter | Standard Deviation 14.9482 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 12, Week 48, n=72 | -8.103 micromoles per liter | Standard Deviation 14.0558 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 13, Week 8, n=53 | -7.672 micromoles per liter | Standard Deviation 12.1403 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 13, Week 16, n=42 | -6.104 micromoles per liter | Standard Deviation 9.857 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 13, Week 24, n=20 | -9.282 micromoles per liter | Standard Deviation 9.7155 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 13, Week 32, n=7 | -3.789 micromoles per liter | Standard Deviation 15.1893 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Year 13, Week 40, n=1 | -8.840 micromoles per liter | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, Exit, n=248 | -3.707 micromoles per liter | Standard Deviation 21.7147 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, 8-Week Follow-up, n=220 | -4.058 micromoles per liter | Standard Deviation 21.6587 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Creatinine, 24-Week Follow-up , n=200 | -5.216 micromoles per liter | Standard Deviation 19.0936 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 1, Week 8, n=284 | 1.8849 micromoles per liter | Standard Deviation 44.3384 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 1, Week 16, n=286 | -2.8076 micromoles per liter | Standard Deviation 47.4812 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 1, Week 24, n=292 | -2.6888 micromoles per liter | Standard Deviation 47.8723 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 1, Week 32, n=287 | -4.9739 micromoles per liter | Standard Deviation 51.9503 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 1, Week 40, n=284 | -10.2415 micromoles per liter | Standard Deviation 52.6846 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 1, Week 48, n=287 | -9.6785 micromoles per liter | Standard Deviation 52.9454 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 2, Week 8, n=288 | -5.8034 micromoles per liter | Standard Deviation 54.3409 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 2, Week 16, n=278 | -2.2679 micromoles per liter | Standard Deviation 55.1544 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 2, Week 24, n=273 | -2.5709 micromoles per liter | Standard Deviation 59.5925 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 2, Week 32, n=284 | -2.1153 micromoles per liter | Standard Deviation 62.2559 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 2, Week 40, n=264 | 0.8111 micromoles per liter | Standard Deviation 59.7227 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 2, Week 48, n=269 | 2.1448 micromoles per liter | Standard Deviation 60.1246 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 3, Week 8, n=265 | 2.1772 micromoles per liter | Standard Deviation 66.2923 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 3, Week 16, n=260 | 8.6246 micromoles per liter | Standard Deviation 60.1972 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 3, Week 24, n=244 | 17.1614 micromoles per liter | Standard Deviation 64.9072 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 3, Week 32, n=249 | 20.6627 micromoles per liter | Standard Deviation 69.7507 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 3, Week 40, n=245 | 15.5862 micromoles per liter | Standard Deviation 64.9204 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 3, Week 48, n=244 | 17.2346 micromoles per liter | Standard Deviation 69.9632 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 4, Week 8, n=239 | 18.8644 micromoles per liter | Standard Deviation 69.277 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 4, Week 16, n=238 | 17.0443 micromoles per liter | Standard Deviation 65.9764 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 4, Week 24, n=227 | 22.1150 micromoles per liter | Standard Deviation 73.0409 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 4, Week 32, n=233 | 27.1872 micromoles per liter | Standard Deviation 67.0773 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 4, Week 40, n=220 | 20.6017 micromoles per liter | Standard Deviation 77.3509 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 4, Week 48, n=218 | 27.3663 micromoles per liter | Standard Deviation 74.9898 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 5, Week 8, n=218 | 26.3294 micromoles per liter | Standard Deviation 73.0884 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 5, Week 16, n=214 | 26.4325 micromoles per liter | Standard Deviation 75.1583 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 5, Week 24, n=211 | 25.6525 micromoles per liter | Standard Deviation 73.5651 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 5, Week 32, n=211 | 32.0515 micromoles per liter | Standard Deviation 75.9635 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 5, Week 40, n=198 | 26.8862 micromoles per liter | Standard Deviation 77.2803 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 5, Week 48, n=207 | 24.9126 micromoles per liter | Standard Deviation 79.189 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 6, Week 8, n=206 | 26.3329 micromoles per liter | Standard Deviation 80.0258 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 6, Week 16, n=198 | 27.2166 micromoles per liter | Standard Deviation 79.2525 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 6, Week 24, n=190 | 32.5888 micromoles per liter | Standard Deviation 81.4485 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 6, Week 32, n=193 | 32.3904 micromoles per liter | Standard Deviation 81.455 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 6, Week 40, n=185 | 34.4019 micromoles per liter | Standard Deviation 75.0211 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 6, Week 48, n=186 | 39.1737 micromoles per liter | Standard Deviation 75.6743 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 7, Week 8, n=179 | 34.0930 micromoles per liter | Standard Deviation 75.0241 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 7, Week 16, n=179 | 35.0566 micromoles per liter | Standard Deviation 77.2918 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 7, Week 24, n=173 | 34.7941 micromoles per liter | Standard Deviation 80.7184 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 7, Week 32, n=180 | 32.8792 micromoles per liter | Standard Deviation 75.6337 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 7, Week 40, n=175 | 31.7453 micromoles per liter | Standard Deviation 81.9889 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 7, Week 48, n=175 | 31.9832 micromoles per liter | Standard Deviation 78.3131 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 8, Week 8, n=171 | 26.6790 micromoles per liter | Standard Deviation 79.7678 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 8, Week 16, n=170 | 30.7197 micromoles per liter | Standard Deviation 83.1681 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 8, Week 24, n=168 | 25.4560 micromoles per liter | Standard Deviation 83.0349 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 8, Week 32, n=168 | 30.0940 micromoles per liter | Standard Deviation 81.9997 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 8, Week 40, n=162 | 29.4096 micromoles per liter | Standard Deviation 76.1203 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 8, Week 48, n=159 | 29.9270 micromoles per liter | Standard Deviation 82.939 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 9, Week 8, n=164 | 37.6828 micromoles per liter | Standard Deviation 78.7998 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 9, Week 16, n=162 | 27.2066 micromoles per liter | Standard Deviation 79.3972 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 9, Week 24, n=161 | 25.9717 micromoles per liter | Standard Deviation 78.7793 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 9, Week 32, n=163 | 26.1639 micromoles per liter | Standard Deviation 78.0704 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 9, Week 40, n=156 | 24.7833 micromoles per liter | Standard Deviation 81.4956 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 9, Week 48, n=151 | 21.9012 micromoles per liter | Standard Deviation 82.0174 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 10, Week 8, n=152 | 24.8486 micromoles per liter | Standard Deviation 75.5325 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 10, Week 16, n=143 | 17.5528 micromoles per liter | Standard Deviation 82.4129 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 10, Week 24, n=145 | 17.6389 micromoles per liter | Standard Deviation 88.8154 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 10, Week 32, n=142 | 16.9644 micromoles per liter | Standard Deviation 84.0128 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 10, Week 40, n=138 | 16.0768 micromoles per liter | Standard Deviation 88.6943 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 10, Week 48, n=135 | 20.9722 micromoles per liter | Standard Deviation 92.24 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 11, Week 8, n=138 | 16.3354 micromoles per liter | Standard Deviation 88.737 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 11, Week 16, n=128 | 19.0057 micromoles per liter | Standard Deviation 80.9138 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 11, Week 24, n=129 | 13.8326 micromoles per liter | Standard Deviation 91.9844 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 11, Week 32, n=125 | 14.4180 micromoles per liter | Standard Deviation 81.6362 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 11, Week 40, n=124 | 17.8920 micromoles per liter | Standard Deviation 97.1467 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 11, Week 48, n=108 | 15.9164 micromoles per liter | Standard Deviation 86.7371 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 12, Week 8, n=110 | 18.3307 micromoles per liter | Standard Deviation 92.3013 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 12, Week 16, n=97 | 15.3912 micromoles per liter | Standard Deviation 85.1873 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 12, Week 24, n=87 | 15.3828 micromoles per liter | Standard Deviation 87.1985 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 12, Week 32, n=84 | 16.7817 micromoles per liter | Standard Deviation 89.8376 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 12, Week 40, n=82 | 12.2587 micromoles per liter | Standard Deviation 83.5304 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 12, Week 48, n=72 | 9.9133 micromoles per liter | Standard Deviation 85.1185 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 13, Week 8, n=53 | 32.4334 micromoles per liter | Standard Deviation 79.1035 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 13, Week 16, n=42 | 42.6273 micromoles per liter | Standard Deviation 74.2314 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 13, Week 24, n=20 | 25.5764 micromoles per liter | Standard Deviation 56.8583 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 13, Week 32, n=7 | 64.5783 micromoles per liter | Standard Deviation 59.0251 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Year 13, Week 40, n=1 | 53.5320 micromoles per liter | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, Exit, n=248 | 18.5635 micromoles per liter | Standard Deviation 89.428 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, 8-Week Follow-up, n=220 | 19.6014 micromoles per liter | Standard Deviation 89.9097 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Urate, 24-Week Follow-up , n=200 | 17.5763 micromoles per liter | Standard Deviation 82.142 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 1, Week 8, n=283 | 0.145 micromoles per liter | Standard Deviation 2.2995 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 1, Week 16, n=285 | 0.168 micromoles per liter | Standard Deviation 2.3476 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 1, Week 24, n=292 | 0.287 micromoles per liter | Standard Deviation 2.4529 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 1, Week 32, n=287 | 0.346 micromoles per liter | Standard Deviation 2.61 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 1, Week 40, n=283 | 0.236 micromoles per liter | Standard Deviation 2.3829 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 1, Week 48, n=286 | 0.293 micromoles per liter | Standard Deviation 2.5315 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 2, Week 8, n=288 | 0.243 micromoles per liter | Standard Deviation 2.6498 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 2, Week 16, n=277 | 0.019 micromoles per liter | Standard Deviation 2.5896 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 2, Week 24, n=272 | 0.176 micromoles per liter | Standard Deviation 2.5041 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 2, Week 32, n=284 | 0.331 micromoles per liter | Standard Deviation 2.6475 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 2, Week 40, n=262 | 0.398 micromoles per liter | Standard Deviation 2.9233 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 2, Week 48, n=269 | 0.464 micromoles per liter | Standard Deviation 2.5138 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 3, Week 8, n=264 | 0.343 micromoles per liter | Standard Deviation 2.6599 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 3, Week 16, n=258 | 0.252 micromoles per liter | Standard Deviation 2.8788 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 3, Week 24, n=243 | 0.274 micromoles per liter | Standard Deviation 3.0754 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 3, Week 32, n=249 | 0.494 micromoles per liter | Standard Deviation 2.586 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 3, Week 40, n=244 | 0.182 micromoles per liter | Standard Deviation 2.8589 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 3, Week 48, n=243 | 0.267 micromoles per liter | Standard Deviation 3.078 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 4, Week 8, n=239 | 0.336 micromoles per liter | Standard Deviation 2.7639 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 4, Week 16, n=238 | 0.481 micromoles per liter | Standard Deviation 2.8625 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 4, Week 24, n=227 | 0.309 micromoles per liter | Standard Deviation 2.8038 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 4, Week 32, n=231 | 0.326 micromoles per liter | Standard Deviation 2.9524 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 4, Week 40, n=220 | -0.023 micromoles per liter | Standard Deviation 2.5236 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 4, Week 48, n=218 | 0.157 micromoles per liter | Standard Deviation 2.8815 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 5, Week 8, n=218 | 0.329 micromoles per liter | Standard Deviation 2.4013 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 5, Week 16, n=214 | 0.304 micromoles per liter | Standard Deviation 2.618 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 5, Week 24, n=211 | 0.259 micromoles per liter | Standard Deviation 2.545 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 5, Week 32, n=211 | 0.575 micromoles per liter | Standard Deviation 2.652 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 5, Week 40, n=198 | 0.544 micromoles per liter | Standard Deviation 2.6496 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 5, Week 48, n=207 | 0.322 micromoles per liter | Standard Deviation 2.532 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 6, Week 8, n=206 | 0.282 micromoles per liter | Standard Deviation 2.5233 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 6, Week 16, n=198 | 0.138 micromoles per liter | Standard Deviation 2.6093 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 6, Week 24, n=190 | 0.099 micromoles per liter | Standard Deviation 2.76 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 6, Week 32, n=193 | 0.284 micromoles per liter | Standard Deviation 2.6431 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 6, Week 40, n=185 | 0.296 micromoles per liter | Standard Deviation 2.8314 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 6, Week 48, n=186 | 0.248 micromoles per liter | Standard Deviation 3.0097 |
| Belimumab 10 mg/kg IV | Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points | Bilirubin, Year 7, Week 8, n=179 | 0.258 micromoles per liter | Standard Deviation 2.6974 |
Primary
Change From Baseline in Erythrocytes at the Indicated Time Points
Hematology parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in erythrocytes is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.
Time frame: Baseline and approximately up to 13 years
Population: MITT Population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 1, Week 8, n=287 | 0.01 10^12 per liter | Standard Deviation 0.313 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 1, Week 16, n=288 | 0.04 10^12 per liter | Standard Deviation 0.361 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 1, Week 24, n=293 | 0.05 10^12 per liter | Standard Deviation 0.309 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 1, Week 32, n=291 | 0.07 10^12 per liter | Standard Deviation 0.301 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 1, Week 40, n=287 | 0.10 10^12 per liter | Standard Deviation 0.321 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 1, Week 48, n=287 | 0.11 10^12 per liter | Standard Deviation 0.338 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 2, Week 8, n=288 | 0.07 10^12 per liter | Standard Deviation 0.339 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 2, Week 16, n=280 | 0.09 10^12 per liter | Standard Deviation 0.32 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 2, Week 24, n=278 | 0.12 10^12 per liter | Standard Deviation 0.331 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 2, Week 32, n=281 | 0.15 10^12 per liter | Standard Deviation 0.331 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 2, Week 40, n=262 | 0.17 10^12 per liter | Standard Deviation 0.33 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 2, Week 48, n=260 | 0.19 10^12 per liter | Standard Deviation 0.336 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 3, Week 8, n=260 | 0.18 10^12 per liter | Standard Deviation 0.331 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 3, Week 16, n=258 | 0.19 10^12 per liter | Standard Deviation 0.347 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 3, Week 24, n=242 | 0.17 10^12 per liter | Standard Deviation 0.384 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 3, Week 32, n=248 | 0.16 10^12 per liter | Standard Deviation 0.356 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 3, Week 40, n=243 | 0.17 10^12 per liter | Standard Deviation 0.369 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 3, Week 48, n=240 | 0.15 10^12 per liter | Standard Deviation 0.368 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 4, Week 8, n=235 | 0.15 10^12 per liter | Standard Deviation 0.392 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 4, Week 16, n=238 | 0.15 10^12 per liter | Standard Deviation 0.367 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 4, Week 24, n=227 | 0.12 10^12 per liter | Standard Deviation 0.363 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 4, Week 32, n=229 | 0.14 10^12 per liter | Standard Deviation 0.394 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 4, Week 40, n=216 | 0.14 10^12 per liter | Standard Deviation 0.383 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 4, Week 48, n=220 | 0.14 10^12 per liter | Standard Deviation 0.42 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 5, Week 8, n=215 | 0.13 10^12 per liter | Standard Deviation 0.435 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 5, Week 16, n=214 | 0.15 10^12 per liter | Standard Deviation 0.432 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 5, Week 24, n=207 | 0.13 10^12 per liter | Standard Deviation 0.426 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 5, Week 32, n=207 | 0.12 10^12 per liter | Standard Deviation 0.43 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 5, Week 40, n=196 | 0.15 10^12 per liter | Standard Deviation 0.417 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 5, Week 48, n=209 | 0.15 10^12 per liter | Standard Deviation 0.42 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 6, Week 8, n=206 | 0.13 10^12 per liter | Standard Deviation 0.441 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 6, Week 16, n=195 | 0.10 10^12 per liter | Standard Deviation 0.448 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 6, Week 24, n=192 | 0.13 10^12 per liter | Standard Deviation 0.38 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 6, Week 32, n=197 | 0.14 10^12 per liter | Standard Deviation 0.42 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 6, Week 40, n=184 | 0.15 10^12 per liter | Standard Deviation 0.43 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 6, Week 48, n=188 | 0.13 10^12 per liter | Standard Deviation 0.401 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 7, Week 8, n=180 | 0.12 10^12 per liter | Standard Deviation 0.397 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 7, Week 16, n=181 | 0.09 10^12 per liter | Standard Deviation 0.407 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 7, Week 24, n=176 | 0.11 10^12 per liter | Standard Deviation 0.39 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 7, Week 32, n=179 | 0.14 10^12 per liter | Standard Deviation 0.395 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 7, Week 40, n=177 | 0.09 10^12 per liter | Standard Deviation 0.391 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 7, Week 48, n=173 | 0.09 10^12 per liter | Standard Deviation 0.394 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 8, Week 8, n=172 | 0.09 10^12 per liter | Standard Deviation 0.378 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 8, Week 16, n=173 | 0.08 10^12 per liter | Standard Deviation 0.368 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 8, Week 24, n=170 | 0.10 10^12 per liter | Standard Deviation 0.388 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 8, Week 32, n=169 | 0.11 10^12 per liter | Standard Deviation 0.373 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 8, Week 40, n=162 | 0.10 10^12 per liter | Standard Deviation 0.415 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 8, Week 48, n=161 | 0.12 10^12 per liter | Standard Deviation 0.411 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 9, Week 8, n=164 | 0.11 10^12 per liter | Standard Deviation 0.402 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 9, Week 16, n=161 | 0.09 10^12 per liter | Standard Deviation 0.396 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 9, Week 24, n=163 | 0.08 10^12 per liter | Standard Deviation 0.387 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 9, Week 32, n=160 | 0.11 10^12 per liter | Standard Deviation 0.409 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 9, Week 40, n=156 | 0.09 10^12 per liter | Standard Deviation 0.407 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 9, Week 48, n=151 | 0.11 10^12 per liter | Standard Deviation 0.431 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 10, Week 8, n=150 | 0.16 10^12 per liter | Standard Deviation 0.442 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 10, Week 16, n=145 | 0.17 10^12 per liter | Standard Deviation 0.411 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 10, Week 24, n=147 | 0.21 10^12 per liter | Standard Deviation 0.427 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 10, Week 32, n=142 | 0.18 10^12 per liter | Standard Deviation 0.419 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 10, Week 40, n=137 | 0.20 10^12 per liter | Standard Deviation 0.417 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 10, Week 48, n=137 | 0.19 10^12 per liter | Standard Deviation 0.429 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 11, Week 8, n=137 | 0.20 10^12 per liter | Standard Deviation 0.43 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 11, Week 16, n=130 | 0.24 10^12 per liter | Standard Deviation 0.422 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 11, Week 24, n=130 | 0.25 10^12 per liter | Standard Deviation 0.436 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 11, Week 32, n=128 | 0.27 10^12 per liter | Standard Deviation 0.41 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 11, Week 40, n=122 | 0.27 10^12 per liter | Standard Deviation 0.426 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 11, Week 48, n=106 | 0.25 10^12 per liter | Standard Deviation 0.426 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 12, Week 8, n=109 | 0.29 10^12 per liter | Standard Deviation 0.422 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 12, Week 16, n=97 | 0.28 10^12 per liter | Standard Deviation 0.435 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 12, Week 24, n=86 | 0.33 10^12 per liter | Standard Deviation 0.483 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 12, Week 32, n=88 | 0.26 10^12 per liter | Standard Deviation 0.512 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 12, Week 40, n=83 | 0.31 10^12 per liter | Standard Deviation 0.428 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 12, Week 48, n=72 | 0.32 10^12 per liter | Standard Deviation 0.467 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 13, Week 8, n=53 | 0.35 10^12 per liter | Standard Deviation 0.4 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 13, Week 16, n=42 | 0.34 10^12 per liter | Standard Deviation 0.387 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 13, Week 24, n=20 | 0.30 10^12 per liter | Standard Deviation 0.407 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 13, Week 32, n=7 | 0.20 10^12 per liter | Standard Deviation 0.379 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Year 13, Week 40, n=1 | 0.30 10^12 per liter | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, Exit, n=241 | 0.27 10^12 per liter | Standard Deviation 0.473 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, 8-Week Follow-up, n=220 | 0.28 10^12 per liter | Standard Deviation 0.478 |
| Belimumab 10 mg/kg IV | Change From Baseline in Erythrocytes at the Indicated Time Points | Erythrocytes, 24-Week Follow-up , n=198 | 0.33 10^12 per liter | Standard Deviation 0.539 |
Primary
Change From Baseline in Hematocrit at the Indicated Time Points
Hematology parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in hematocrit is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.
Time frame: Baseline and approximately up to 13 years
Population: MITT Population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 7, Week 24, n=176 | 1.88 Percentage of blood by volume | Standard Deviation 3.84 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 7, Week 32, n=179 | 2.25 Percentage of blood by volume | Standard Deviation 3.824 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 7, Week 40, n=177 | 2.07 Percentage of blood by volume | Standard Deviation 3.907 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 7, Week 48, n=173 | 1.97 Percentage of blood by volume | Standard Deviation 3.958 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 8, Week 8, n=172 | 1.89 Percentage of blood by volume | Standard Deviation 3.909 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 8, Week 16, n=173 | 1.87 Percentage of blood by volume | Standard Deviation 3.729 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 8, Week 24, n=170 | 2.12 Percentage of blood by volume | Standard Deviation 4.065 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 8, Week 32, n=169 | 2.20 Percentage of blood by volume | Standard Deviation 3.954 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 8, Week 40, n=162 | 2.10 Percentage of blood by volume | Standard Deviation 4.122 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 8, Week 48, n=161 | 2.18 Percentage of blood by volume | Standard Deviation 4.029 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 9, Week 8, n=164 | 1.99 Percentage of blood by volume | Standard Deviation 3.995 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 9, Week 16, n=161 | 1.76 Percentage of blood by volume | Standard Deviation 4.114 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 9, Week 24, n=163 | 1.70 Percentage of blood by volume | Standard Deviation 4.02 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 9, Week 32, n=160 | 1.95 Percentage of blood by volume | Standard Deviation 4.171 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 9, Week 40, n=156 | 1.88 Percentage of blood by volume | Standard Deviation 4.302 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 9, Week 48, n=151 | 2.32 Percentage of blood by volume | Standard Deviation 4.174 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 10, Week 8, n=150 | 2.87 Percentage of blood by volume | Standard Deviation 4.087 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 10, Week 16, n=145 | 2.80 Percentage of blood by volume | Standard Deviation 4.05 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 10, Week 24, n=147 | 2.94 Percentage of blood by volume | Standard Deviation 4.046 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 10, Week 32, n=142 | 2.78 Percentage of blood by volume | Standard Deviation 4.046 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 10, Week 40, n=137 | 2.95 Percentage of blood by volume | Standard Deviation 3.884 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 10, Week 48, n=137 | 3.00 Percentage of blood by volume | Standard Deviation 4.245 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 11, Week 8, n=137 | 3.04 Percentage of blood by volume | Standard Deviation 4.176 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 11, Week 16, n=130 | 3.20 Percentage of blood by volume | Standard Deviation 4.155 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 11, Week 24, n=130 | 2.93 Percentage of blood by volume | Standard Deviation 4.331 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 11, Week 32, n=128 | 3.06 Percentage of blood by volume | Standard Deviation 3.976 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 11, Week 40, n=122 | 3.15 Percentage of blood by volume | Standard Deviation 4.098 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 11, Week 48, n=106 | 2.93 Percentage of blood by volume | Standard Deviation 4.356 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 12, Week 8, n=109 | 3.12 Percentage of blood by volume | Standard Deviation 4.223 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 12, Week 16, n=97 | 3.43 Percentage of blood by volume | Standard Deviation 4.321 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 12, Week 24, n=86 | 3.74 Percentage of blood by volume | Standard Deviation 4.867 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 12, Week 32, n=88 | 2.99 Percentage of blood by volume | Standard Deviation 4.826 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 12, Week 40, n=83 | 3.57 Percentage of blood by volume | Standard Deviation 4.377 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 12, Week 48, n=72 | 3.88 Percentage of blood by volume | Standard Deviation 4.439 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 13, Week 8, n=53 | 4.20 Percentage of blood by volume | Standard Deviation 3.776 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 13, Week 16, n=42 | 4.26 Percentage of blood by volume | Standard Deviation 3.803 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 13, Week 24, n=20 | 3.81 Percentage of blood by volume | Standard Deviation 3.93 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 13, Week 32, n=7 | 3.26 Percentage of blood by volume | Standard Deviation 4.547 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 13, Week 40, n=1 | 2.20 Percentage of blood by volume | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Exit, n=241 | 3.35 Percentage of blood by volume | Standard Deviation 4.596 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, 8-Week Follow-up, n=220 | 3.46 Percentage of blood by volume | Standard Deviation 4.69 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, 24-Week Follow-up , n=198 | 3.51 Percentage of blood by volume | Standard Deviation 4.627 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 1, Week 8, n=287 | 0.11 Percentage of blood by volume | Standard Deviation 2.908 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 1, Week 16, n=288 | 0.23 Percentage of blood by volume | Standard Deviation 3.109 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 1, Week 24, n=293 | 0.28 Percentage of blood by volume | Standard Deviation 2.917 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 1, Week 32, n=291 | 0.44 Percentage of blood by volume | Standard Deviation 2.973 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 1, Week 40, n=287 | 0.60 Percentage of blood by volume | Standard Deviation 3.199 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 1, Week 48, n=287 | 0.84 Percentage of blood by volume | Standard Deviation 3.431 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 2, Week 8, n=288 | 0.67 Percentage of blood by volume | Standard Deviation 3.415 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 2, Week 16, n=280 | 0.93 Percentage of blood by volume | Standard Deviation 3.332 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 2, Week 24, n=278 | 0.96 Percentage of blood by volume | Standard Deviation 3.435 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 2, Week 32, n=281 | 1.34 Percentage of blood by volume | Standard Deviation 3.496 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 2, Week 40, n=262 | 1.43 Percentage of blood by volume | Standard Deviation 3.476 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 2, Week 48, n=260 | 1.65 Percentage of blood by volume | Standard Deviation 3.444 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 3, Week 8, n=260 | 1.54 Percentage of blood by volume | Standard Deviation 3.453 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 3, Week 16, n=258 | 1.76 Percentage of blood by volume | Standard Deviation 3.508 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 3, Week 24, n=242 | 1.68 Percentage of blood by volume | Standard Deviation 3.709 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 3, Week 32, n=248 | 1.55 Percentage of blood by volume | Standard Deviation 3.676 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 3, Week 40, n=243 | 1.55 Percentage of blood by volume | Standard Deviation 3.703 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 3, Week 48, n=240 | 1.26 Percentage of blood by volume | Standard Deviation 3.726 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 4, Week 8, n=235 | 1.33 Percentage of blood by volume | Standard Deviation 3.908 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 4, Week 16, n=238 | 1.37 Percentage of blood by volume | Standard Deviation 3.759 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 4, Week 24, n=227 | 1.27 Percentage of blood by volume | Standard Deviation 3.68 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 4, Week 32, n=229 | 1.34 Percentage of blood by volume | Standard Deviation 3.955 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 4, Week 40, n=216 | 1.39 Percentage of blood by volume | Standard Deviation 3.779 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 4, Week 48, n=220 | 1.37 Percentage of blood by volume | Standard Deviation 4.033 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 5, Week 8, n=215 | 1.27 Percentage of blood by volume | Standard Deviation 4.031 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 5, Week 16, n=214 | 1.58 Percentage of blood by volume | Standard Deviation 3.917 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 5, Week 24, n=207 | 1.45 Percentage of blood by volume | Standard Deviation 3.905 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 5, Week 32, n=207 | 1.39 Percentage of blood by volume | Standard Deviation 3.979 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 5, Week 40, n=196 | 1.59 Percentage of blood by volume | Standard Deviation 4.031 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 5, Week 48, n=209 | 1.35 Percentage of blood by volume | Standard Deviation 3.929 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 6, Week 8, n=206 | 1.24 Percentage of blood by volume | Standard Deviation 4.128 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 6, Week 16, n=195 | 1.07 Percentage of blood by volume | Standard Deviation 4.114 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 6, Week 24, n=192 | 1.43 Percentage of blood by volume | Standard Deviation 3.648 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 6, Week 32, n=197 | 1.77 Percentage of blood by volume | Standard Deviation 3.822 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 6, Week 40, n=184 | 2.07 Percentage of blood by volume | Standard Deviation 4.089 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 6, Week 48, n=188 | 2.02 Percentage of blood by volume | Standard Deviation 3.961 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 7, Week 8, n=180 | 1.80 Percentage of blood by volume | Standard Deviation 3.808 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hematocrit at the Indicated Time Points | Hematocrit, Year 7, Week 16, n=181 | 1.50 Percentage of blood by volume | Standard Deviation 3.883 |
Primary
Change From Baseline in Hemoglobin at the Indicated Time Points
Hematology parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in hemoglobin is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.
Time frame: Baseline and approximately up to 13 years
Population: MITT Population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 1, Week 8, n=287 | 0.1 grams per liter | Standard Deviation 9.42 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 1, Week 16, n=288 | 0.6 grams per liter | Standard Deviation 10.6 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 1, Week 24, n=293 | 1.5 grams per liter | Standard Deviation 9.86 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 1, Week 32, n=291 | 2.2 grams per liter | Standard Deviation 10.37 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 1, Week 40, n=287 | 2.8 grams per liter | Standard Deviation 10.84 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 1, Week 48, n=287 | 2.9 grams per liter | Standard Deviation 11.39 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 2, Week 8, n=288 | 2.2 grams per liter | Standard Deviation 11.62 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 2, Week 16, n=280 | 2.8 grams per liter | Standard Deviation 11.54 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 2, Week 24, n=278 | 3.2 grams per liter | Standard Deviation 12.2 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 2, Week 32, n=281 | 4.5 grams per liter | Standard Deviation 12.19 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 2, Week 40, n=262 | 4.9 grams per liter | Standard Deviation 12.15 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 2, Week 48, n=260 | 5.6 grams per liter | Standard Deviation 12.1 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 3, Week 8, n=260 | 4.8 grams per liter | Standard Deviation 12.01 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 3, Week 16, n=258 | 5.2 grams per liter | Standard Deviation 12.15 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 3, Week 24, n=242 | 5.4 grams per liter | Standard Deviation 12.47 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 3, Week 32, n=248 | 5.6 grams per liter | Standard Deviation 12.59 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 3, Week 40, n=243 | 5.9 grams per liter | Standard Deviation 12.9 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 3, Week 48, n=240 | 5.1 grams per liter | Standard Deviation 12.97 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 4, Week 8, n=235 | 5.2 grams per liter | Standard Deviation 13.49 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 4, Week 16, n=238 | 5.2 grams per liter | Standard Deviation 13.11 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 4, Week 24, n=227 | 4.1 grams per liter | Standard Deviation 13.05 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 4, Week 32, n=229 | 4.9 grams per liter | Standard Deviation 13.64 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 4, Week 40, n=216 | 4.9 grams per liter | Standard Deviation 13.25 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 4, Week 48, n=220 | 5.3 grams per liter | Standard Deviation 13.94 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 5, Week 8, n=215 | 5.1 grams per liter | Standard Deviation 14.2 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 5, Week 16, n=214 | 5.5 grams per liter | Standard Deviation 13.44 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 5, Week 24, n=207 | 4.4 grams per liter | Standard Deviation 13.73 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 5, Week 32, n=207 | 4.1 grams per liter | Standard Deviation 13.39 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 5, Week 40, n=196 | 5.2 grams per liter | Standard Deviation 14.31 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 5, Week 48, n=209 | 5.4 grams per liter | Standard Deviation 14.2 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 6, Week 8, n=206 | 5.5 grams per liter | Standard Deviation 14.72 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 6, Week 16, n=195 | 4.8 grams per liter | Standard Deviation 14.82 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 6, Week 24, n=192 | 5.6 grams per liter | Standard Deviation 12.8 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 6, Week 32, n=197 | 5.9 grams per liter | Standard Deviation 13.12 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 6, Week 40, n=184 | 6.6 grams per liter | Standard Deviation 13.96 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 6, Week 48, n=188 | 6.4 grams per liter | Standard Deviation 13.78 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 7, Week 8, n=180 | 6.3 grams per liter | Standard Deviation 13.58 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 7, Week 16, n=181 | 5.5 grams per liter | Standard Deviation 13.83 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 7, Week 24, n=176 | 6.0 grams per liter | Standard Deviation 13.51 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 7, Week 32, n=179 | 7.0 grams per liter | Standard Deviation 13.37 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 7, Week 40, n=177 | 6.4 grams per liter | Standard Deviation 13.61 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 7, Week 48, n=173 | 5.6 grams per liter | Standard Deviation 13.91 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 8, Week 8, n=172 | 5.7 grams per liter | Standard Deviation 13.69 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 8, Week 16, n=173 | 5.3 grams per liter | Standard Deviation 13.09 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 8, Week 24, n=170 | 6.1 grams per liter | Standard Deviation 14.13 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 8, Week 32, n=169 | 5.8 grams per liter | Standard Deviation 13.33 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 8, Week 40, n=162 | 4.9 grams per liter | Standard Deviation 13.93 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 8, Week 48, n=161 | 5.5 grams per liter | Standard Deviation 13.95 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 9, Week 8, n=164 | 5.5 grams per liter | Standard Deviation 13.79 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 9, Week 16, n=161 | 4.9 grams per liter | Standard Deviation 14.6 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 9, Week 24, n=163 | 4.6 grams per liter | Standard Deviation 14.32 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 9, Week 32, n=160 | 5.2 grams per liter | Standard Deviation 14.39 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 9, Week 40, n=156 | 3.9 grams per liter | Standard Deviation 15.2 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 9, Week 48, n=151 | 4.8 grams per liter | Standard Deviation 14.5 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 11, Week 8, n=137 | 5.9 grams per liter | Standard Deviation 14.4 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 10, Week 8, n=150 | 6.5 grams per liter | Standard Deviation 14.46 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 10, Week 16, n=145 | 6.5 grams per liter | Standard Deviation 14.05 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 10, Week 24, n=147 | 6.5 grams per liter | Standard Deviation 14.2 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 10, Week 32, n=142 | 5.9 grams per liter | Standard Deviation 14.02 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 10, Week 40, n=137 | 6.0 grams per liter | Standard Deviation 13.29 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 10, Week 48, n=137 | 5.7 grams per liter | Standard Deviation 14.86 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 11, Week 16, n=130 | 6.4 grams per liter | Standard Deviation 14.5 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 11, Week 24, n=130 | 5.9 grams per liter | Standard Deviation 15.02 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 11, Week 32, n=128 | 6.3 grams per liter | Standard Deviation 13.79 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 11, Week 40, n=122 | 6.7 grams per liter | Standard Deviation 14.03 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 11, Week 48, n=106 | 6.2 grams per liter | Standard Deviation 14.95 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 12, Week 8, n=109 | 6.8 grams per liter | Standard Deviation 14.55 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 12, Week 16, n=97 | 8.1 grams per liter | Standard Deviation 15.12 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 12, Week 24, n=86 | 8.9 grams per liter | Standard Deviation 16.83 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 12, Week 32, n=88 | 6.6 grams per liter | Standard Deviation 17.18 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 12, Week 40, n=83 | 7.0 grams per liter | Standard Deviation 15.41 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 12, Week 48, n=72 | 8.3 grams per liter | Standard Deviation 14.8 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 13, Week 8, n=53 | 8.4 grams per liter | Standard Deviation 12.37 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 13, Week 16, n=42 | 8.0 grams per liter | Standard Deviation 12.81 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 13, Week 24, n=20 | 6.3 grams per liter | Standard Deviation 12.01 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 13, Week 32, n=7 | 5.4 grams per liter | Standard Deviation 14.27 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Year 13, Week 40, n=1 | 3.0 grams per liter | — |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, Exit, n=241 | 7.4 grams per liter | Standard Deviation 15.11 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, 8-Week Follow-up, n=220 | 6.7 grams per liter | Standard Deviation 15.46 |
| Belimumab 10 mg/kg IV | Change From Baseline in Hemoglobin at the Indicated Time Points | Hemoglobin, 24-Week Follow-up , n=198 | 6.8 grams per liter | Standard Deviation 14.91 |
Primary
Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs)
An AE is defined as any unfavorable or unintended sign, symptom, or disease that is temporally associated with the use of a study agent but is not necessarily caused by the study agent. This includes worsening (example \[eg\], increase in frequency or severity) of pre-existing conditions. An SAE is defined as an AE resulting in any of the following outcomes: death, is life threatening (that is, an immediate threat to life), inpatient hospitalization, prolongation of an existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, and is medically important.
Time frame: Approximately up to 13 years
Population: MITT Population. Only those participants available at the specified time points (represented by n=X, in the category titles) were analyzed.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Belimumab 10 mg/kg IV | Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) | SAE, Year 11 plus, n=88 | 7 Participants |
| Belimumab 10 mg/kg IV | Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) | AE, Any time post baseline, n=296 | 294 Participants |
| Belimumab 10 mg/kg IV | Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) | AE, Year 0-1, n=296 | 291 Participants |
| Belimumab 10 mg/kg IV | Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) | AE, Year 1-2, n=294 | 283 Participants |
| Belimumab 10 mg/kg IV | Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) | AE, Year 2-3, n=276 | 260 Participants |
| Belimumab 10 mg/kg IV | Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) | AE, Year 3-4, n=250 | 239 Participants |
| Belimumab 10 mg/kg IV | Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) | AE, Year 4-5, n=223 | 203 Participants |
| Belimumab 10 mg/kg IV | Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) | AE, Year 5-6, n=209 | 190 Participants |
| Belimumab 10 mg/kg IV | Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) | AE, Year 6-7, n=192 | 182 Participants |
| Belimumab 10 mg/kg IV | Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) | AE, Year 7-8, n=178 | 162 Participants |
| Belimumab 10 mg/kg IV | Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) | AE, Year 8-9, n=169 | 157 Participants |
| Belimumab 10 mg/kg IV | Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) | AE, Year 9-10, n=152 | 137 Participants |
| Belimumab 10 mg/kg IV | Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) | AE, Year 10-11, n=131 | 105 Participants |
| Belimumab 10 mg/kg IV | Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) | AE, Year 11 plus, n=88 | 45 Participants |
| Belimumab 10 mg/kg IV | Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) | SAE, Any time post baseline, n=296 | 182 Participants |
| Belimumab 10 mg/kg IV | Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) | SAE, Year 0-1, n=296 | 41 Participants |
| Belimumab 10 mg/kg IV | Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) | SAE, Year 1-2, n=294 | 43 Participants |
| Belimumab 10 mg/kg IV | Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) | SAE, Year 2-3, n=276 | 50 Participants |
| Belimumab 10 mg/kg IV | Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) | SAE, Year 3-4, n=250 | 30 Participants |
| Belimumab 10 mg/kg IV | Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) | SAE, Year 4-5, n=223 | 40 Participants |
| Belimumab 10 mg/kg IV | Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) | SAE, Year 5-6, n=209 | 33 Participants |
| Belimumab 10 mg/kg IV | Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) | SAE, Year 6-7, n=192 | 35 Participants |
| Belimumab 10 mg/kg IV | Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) | SAE, Year 7-8, n=178 | 34 Participants |
| Belimumab 10 mg/kg IV | Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) | SAE, Year 8-9, n=169 | 28 Participants |
| Belimumab 10 mg/kg IV | Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) | SAE, Year 9-10, n=152 | 25 Participants |
| Belimumab 10 mg/kg IV | Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) | SAE, Year 10-11, n=131 | 14 Participants |
Primary
SAE Rates by System Organ Class (SOC) During the Study
SAE rates by SOC adjusting for participant-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatmentemergent SAEs are summarized. The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pretreatment value in the parent study for participants treated with belimumab in the parent study. The event rate of an SAE was calculated as the number of events per 100 participant years: Event Rate=100\* number of events divided by participant years. Participant years were calculated as sum across all participants (\[last visit of interval day minus first visit of interval day plus 1\] divided by 365).
Time frame: Approximately up to 13 years
Population: MITT population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Belimumab 10 mg/kg IV | SAE Rates by System Organ Class (SOC) During the Study | Infections and infestations | 69 Events per 100 participant years |
| Belimumab 10 mg/kg IV | SAE Rates by System Organ Class (SOC) During the Study | Musculoskeletal and connective tissue disorders | 44 Events per 100 participant years |
| Belimumab 10 mg/kg IV | SAE Rates by System Organ Class (SOC) During the Study | Gastrointestinal disorders | 38 Events per 100 participant years |
| Belimumab 10 mg/kg IV | SAE Rates by System Organ Class (SOC) During the Study | Nervous system disorders | 35 Events per 100 participant years |
| Belimumab 10 mg/kg IV | SAE Rates by System Organ Class (SOC) During the Study | General disorders, administration site conditions | 31 Events per 100 participant years |
| Belimumab 10 mg/kg IV | SAE Rates by System Organ Class (SOC) During the Study | Injury, poisoning and procedural complications | 29 Events per 100 participant years |
| Belimumab 10 mg/kg IV | SAE Rates by System Organ Class (SOC) During the Study | Respiratory, thoracic and mediastinal disorders | 25 Events per 100 participant years |
| Belimumab 10 mg/kg IV | SAE Rates by System Organ Class (SOC) During the Study | Cardiac disorders | 23 Events per 100 participant years |
| Belimumab 10 mg/kg IV | SAE Rates by System Organ Class (SOC) During the Study | Neoplasms benign, malignant and unspecified | 23 Events per 100 participant years |
| Belimumab 10 mg/kg IV | SAE Rates by System Organ Class (SOC) During the Study | Renal and urinary disorders | 20 Events per 100 participant years |
| Belimumab 10 mg/kg IV | SAE Rates by System Organ Class (SOC) During the Study | Vascular disorders | 19 Events per 100 participant years |
| Belimumab 10 mg/kg IV | SAE Rates by System Organ Class (SOC) During the Study | Reproductive system and breast disorders | 18 Events per 100 participant years |
| Belimumab 10 mg/kg IV | SAE Rates by System Organ Class (SOC) During the Study | Metabolism and nutrition disorders | 14 Events per 100 participant years |
| Belimumab 10 mg/kg IV | SAE Rates by System Organ Class (SOC) During the Study | Hepatobiliary disorders | 10 Events per 100 participant years |
| Belimumab 10 mg/kg IV | SAE Rates by System Organ Class (SOC) During the Study | Blood and lymphatic system disorders | 8 Events per 100 participant years |
| Belimumab 10 mg/kg IV | SAE Rates by System Organ Class (SOC) During the Study | Skin and subcutaneous tissue disorders | 8 Events per 100 participant years |
| Belimumab 10 mg/kg IV | SAE Rates by System Organ Class (SOC) During the Study | Investigations | 7 Events per 100 participant years |
| Belimumab 10 mg/kg IV | SAE Rates by System Organ Class (SOC) During the Study | Psychiatric disorders | 6 Events per 100 participant years |
| Belimumab 10 mg/kg IV | SAE Rates by System Organ Class (SOC) During the Study | Immune system disorders | 2 Events per 100 participant years |
| Belimumab 10 mg/kg IV | SAE Rates by System Organ Class (SOC) During the Study | Pregnancy, puerperium and perinatal conditions | 2 Events per 100 participant years |
| Belimumab 10 mg/kg IV | SAE Rates by System Organ Class (SOC) During the Study | Congenital, familial and genetic disorders | 1 Events per 100 participant years |
| Belimumab 10 mg/kg IV | SAE Rates by System Organ Class (SOC) During the Study | Eye disorders | 1 Events per 100 participant years |
| Belimumab 10 mg/kg IV | SAE Rates by System Organ Class (SOC) During the Study | Social circumstances | 1 Events per 100 participant years |
Secondary
Absolute Serum Immunoglobulin G Values at Indicated Time Points
Serum immunoglobulin G values were assessed at Baseline, Week 8, 16, 24, 32, 40, and 48 during Year 1 to 12 and Week 8, 16, 24, 32, and 40 during Year 13, Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study.
Time frame: Approximately up to 13 years
Population: MITT Population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 1, Week 8, n=288 | 12.10 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 1, Week 16, n=292 | 11.70 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 1, Week 24, n=293 | 11.60 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 1, Week 32, n=291 | 11.50 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 1, Week 40, n=288 | 11.40 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 3, Week 24, n=244 | 11.15 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 3, Week 48, n=244 | 11.70 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 4, Week 8, n=240 | 11.50 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 4, Week 16, n=240 | 11.60 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 4, Week 24, n=228 | 11.35 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 4, Week 32, n=233 | 11.20 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 5, Week 16, n=215 | 11.00 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 5, Week 24, n=212 | 10.80 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 5, Week 32, n=211 | 11.00 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 5, Week 40, n=199 | 11.10 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 6, Week 8, n=207 | 10.80 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 6, Week 16, n=199 | 10.30 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 8, Week 48, n=161 | 9.42 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 9, Week 16, n=163 | 9.24 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 9, Week 24, n=163 | 9.39 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 9, Week 32, n=164 | 9.25 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 9, Week 40, n=159 | 9.06 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 9, Week 48, n=151 | 9.01 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 10, Week 48, n=137 | 9.25 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 11, Week 32, n=128 | 9.46 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 11, Week 48, n=108 | 9.41 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 12, Week 8, n=111 | 8.92 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 12, Week 16, n=99 | 9.55 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 12, Week 24, n=87 | 9.33 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 13, Week 40, n=1 | 11.50 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Exit, n=248 | 9.62 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | 8-Week follow-up, n=222 | 9.88 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | 24-Week follow-up, n=200 | 9.89 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 2, Week 40, n=269 | 11.30 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 2, Week 48, n=269 | 11.30 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 1, Week 48, n=289 | 11.50 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 2, Week 8, n=286 | 11.20 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 2, Week 16, n=284 | 11.30 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 2, Week 24, n=288 | 11.55 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 2, Week 32, n=284 | 11.40 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 3, Week 8, n=265 | 11.40 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 3, Week 16, n=260 | 11.45 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 3, Week 32, n=250 | 11.40 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 3, Week 40, n=246 | 11.70 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 4, Week 40, n=220 | 11.40 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 4, Week 48, n=222 | 11.35 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 5, Week 8, n=218 | 11.45 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 5, Week 48, n=209 | 10.80 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 6, Week 24, n=192 | 10.20 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 6, Week 32, n=197 | 10.30 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 6, Week 40, n=186 | 10.30 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 6, Week 48, n=188 | 9.78 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 7, Week 8, n=183 | 10.10 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 7, Week 16, n=182 | 10.15 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 7, Week 24, n=176 | 10.10 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 7, Week 32, n=182 | 9.98 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 7, Week 40, n=177 | 9.85 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 7, Week 48, n=177 | 9.64 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 8, Week 8, n=173 | 9.64 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 8, Week 16, n=172 | 9.40 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 8, Week 24, n=169 | 9.67 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 8, Week 32, n=170 | 9.72 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 8, Week 40, n=163 | 9.41 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 9, Week 8, n=167 | 9.41 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 10, Week 8, n=153 | 9.02 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 10, Week 16, n=146 | 8.96 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 10, Week 24, n=146 | 8.98 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 10, Week 32, n=142 | 8.97 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 10, Week 40, n=138 | 9.09 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 11, Week 8, n=139 | 9.54 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 11, Week 16, n=129 | 9.36 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 11, Week 24, n=131 | 9.53 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 11, Week 40, n=124 | 9.68 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 12, Week 32, n=88 | 9.19 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 12, Week 40, n=84 | 8.79 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 12, Week 48, n=73 | 9.39 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 13, Week 8, n=53 | 9.62 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 13, Week 16, n=43 | 9.40 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 13, Week 24, n=20 | 9.77 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Year 13, Week 32, n=7 | 10.60 grams per liter |
| Belimumab 10 mg/kg IV | Absolute Serum Immunoglobulin G Values at Indicated Time Points | Baseline, n=293 | 12.90 grams per liter |
Secondary
Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points
Anti-double stranded DNA levels for participants positive at Baseline were assessed at Baseline, Week 16, 32, and 48 during Year 1 to 11, Week 16 and 32 during Year 13, Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study. Percent change from Baseline is defined as the percentage of the difference between the post-dose post-Baseline visit value and the Baseline value.
Time frame: Baseline and approximately up to 13 years
Population: MITT Population. Only those participants positive at Baseline and available at the specified time points (represented by n=X in the category titles) were analyzed.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 1 , Week 16, n=147 | -16.26 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 1 , Week 32, n=147 | -25.57 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 1 , Week 48, n=144 | -30.17 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 2 , Week 16, n=144 | -30.26 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 2, Week 32, n=143 | -31.25 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 2, Week 48, n=128 | -41.63 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 3, Week 16, n=134 | -41.10 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 3, Week 32, n=127 | -44.44 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 4, Week 16, n=124 | -47.33 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 4, Week 32, n=120 | -48.53 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 4, Week 48, n=116 | -48.45 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 5, Week 16, n=112 | -53.97 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 5, Week 32, n=111 | -47.27 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 5, Week 48, n=108 | -57.76 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 6, Week 16, n=105 | -60.00 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 6, Week 32, n=101 | -65.38 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 6, Week 48, n=99 | -66.42 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 7, Week 32, n=94 | -68.93 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 7, Week 48, n=89 | -68.63 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 8, Week 32, n=89 | -71.02 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 8, Week 48, n=80 | -76.62 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 9, Week 16, n=85 | -75.00 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 9, Week 32, n=83 | -80.13 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 9, Week 48, n=77 | -81.38 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 10, Week 16, n=77 | -81.25 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 10, Week 48, n=71 | -81.13 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 11, Week 16, n=67 | -82.86 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 11, Week 32, n=66 | -85.39 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 12, Week 16, n=54 | -85.39 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 12, Week 32, n=47 | -88.52 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 12, Week 48, n=39 | -87.76 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 13, Week 32, n=3 | -91.49 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Exit, n=124 | -75.68 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 3, Week 48, n=125 | -45.29 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 7, Week 16, n=89 | -64.14 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 8, Week 16, n=87 | -73.77 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 10, Week 32, n=75 | -78.11 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 11, Week 48, n=63 | -85.29 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points | Year 13, Week 16, n=20 | -86.87 Percent change |
Secondary
Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points
Complement C3 and C4 levels were assessed in participants low at Baseline at Baseline, Week 16, 32, and 48 during Year 1 to 12, Week 16 and 32 during Year 13, and Exit visit. The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study. Percent change from Baseline is defined as the percentage of the difference between the post-dose post-Baseline visit value and the Baseline value.
Time frame: Baseline and approximately up to 13 years
Population: MITT Population. Only those participants positive at Baseline and available at the specified time points (represented by n=X in the category titles) were analyzed.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 1, Week 16, n=86 | 8.87 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 2, Week 16, n=83 | 13.10 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 2, Week 32, n=83 | 13.21 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 2, Week 48, n=76 | 17.16 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 3, Week 16, n=75 | 15.48 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 3, Week 32, n=75 | 19.05 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 4, Week 16, n=74 | 22.51 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 5, Week 32, n=65 | 23.17 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 6, Week 16, n=61 | 29.41 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 6, Week 32, n=59 | 31.03 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 6, Week 48, n=57 | 28.24 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 7, Week 16, n=50 | 20.95 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 7, Week 48, n=52 | 39.88 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 8, Week 48, n=45 | 32.88 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 9, Week 16, n=49 | 36.99 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 9, Week 32, n=46 | 21.76 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 10, Week 48, n=44 | 26.90 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 12, Week 48, n=28 | 14.1 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 1, Week 16, n=112 | 25.00 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 2, Week 32, n=110 | 53.33 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 2, Week 48, n=103 | 53.85 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 3, Week 16, n=101 | 53.33 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 3, Week 32, n=100 | 63.39 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 5, Week 16, n=83 | 71.43 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 5, Week 32, n=81 | 66.67 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 6, Week 48, n=71 | 100.0 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 7, Week 16, n=66 | 79.29 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 7, Week 32, n=67 | 85.71 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 7, Week 48, n=65 | 100.0 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 8, Week 32, n=62 | 81.67 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 10, Week 16, n=54 | 81.82 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 10, Week 32, n=52 | 84.52 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 11, Week 16, n=50 | 75.71 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 11, Week 32, n=48 | 81.67 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 12, Week 16, n=41 | 75.0 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 12, Week 32, n=37 | 100.0 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 12, Week 48, n=31 | 80.0 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 13, Week 16, n=16 | 135.0 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 13, Week 32, n=3 | 190.0 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Exit, n=93 | 78.57 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 1, Week 32, n=88 | 8.43 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 1, Week 48, n=86 | 11.71 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 3, Week 48, n=73 | 16.46 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 4, Week 32, n=72 | 30.41 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 4, Week 48, n=67 | 26.58 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 5, Week 16, n=65 | 27.38 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 5, Week 48, n=65 | 35.96 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 7, Week 32, n=54 | 29.25 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 8, Week 16, n=46 | 28.35 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 8, Week 32, n=48 | 30.88 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 9, Week 48, n=47 | 23.29 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 10, Week 16, n=43 | 22.35 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 10, Week 32, n=45 | 23.81 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 11, Week 16, n=43 | 26.97 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 11, Week 32, n=42 | 30.36 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 11, Week 48, n=37 | 20.78 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 12, Week 16, n=31 | 15.58 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 12, Week 32, n=28 | 26.39 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 13, Week 16, n=12 | 35.33 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 13, Week 32, n=2 | 22.04 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Exit, n=74 | 29.19 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 1, Week 32, n=113 | 33.33 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 1, Week 48, n=112 | 34.52 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 2, Week 16, n=110 | 50.00 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 3, Week 48, n=97 | 53.33 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 4, Week 16, n=97 | 70.00 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 4, Week 32, n=93 | 69.23 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 4, Week 48, n=90 | 66.67 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 5, Week 48, n=81 | 80.00 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 6, Week 16, n=78 | 70.33 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 6, Week 32, n=74 | 85.71 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 8, Week 16, n=61 | 90.00 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 8, Week 48, n=56 | 76.36 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 9, Week 16, n=62 | 87.86 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 9, Week 32, n=59 | 72.73 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 9, Week 48, n=55 | 71.43 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 10, Week 48, n=51 | 73.33 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 11, Week 48, n=44 | 103.33 Percent change |
Secondary
Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points
Serum immunoglobulin G values were assessed at Baseline, Week 8, 16, 24, 32, 40, and 48 during Year 1 to 12 and Week 8, 16, 24, 32, and 40 during Year 13, Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study. Percent change from Baseline is defined as the percentage of the difference between the post-dose post-Baseline visit value and the Baseline value.
Time frame: Baseline and approximately up to 13 years
Population: MITT Population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 5, Week 24, n=210 | -14.61 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 2, Week 8, n=283 | -11.40 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 2, Week 16, n=281 | -10.76 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 2, Week 24, n=285 | -11.19 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 2, Week 40, n=266 | -10.29 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 2, Week 48, n=267 | -10.54 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 3, Week 8, n=263 | -10.28 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 3, Week 16, n=258 | -9.92 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 3, Week 24, n=242 | -9.77 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 3, Week 32, n=248 | -8.93 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 3, Week 40, n=244 | -8.04 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 3, Week 48, n=242 | -10.40 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 4, Week 8, n=238 | -10.70 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 4, Week 16, n=238 | -10.77 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 4, Week 24, n=226 | -11.73 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 4, Week 32, n=231 | -10.99 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 4, Week 40, n=218 | -10.47 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 4, Week 48, n=220 | -11.69 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 5, Week 16, n=213 | -14.62 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 5, Week 32, n=209 | -13.24 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 5, Week 40, n=197 | -15.97 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 5, Week 48, n=207 | -15.47 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 6, Week 8, n=205 | -17.13 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 6, Week 16, n=197 | -18.16 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 6, Week 24, n=190 | -18.67 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 6, Week 32, n=195 | -19.83 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 6, Week 40, n=184 | -19.84 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 6, Week 48, n=186 | -22.36 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 7, Week 8, n=181 | -21.26 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 7, Week 16, n=180 | -21.22 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 7, Week 24, n=175 | -21.39 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 7, Week 32, n=180 | -22.03 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 7, Week 48, n=175 | -22.20 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 8, Week 8, n=171 | -24.44 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 8, Week 16, n=170 | -25.51 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 8, Week 32, n=168 | -24.48 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 8, Week 40, n=161 | -25.50 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 8, Week 48, n=159 | -24.58 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 9, Week 8, n=165 | -25.41 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 9, Week 16, n=161 | -25.44 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 9, Week 24, n=161 | -27.23 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 9, Week 40, n=157 | -27.63 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 9, Week 48, n=149 | -26.48 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 10, Week 8, n=151 | -28.65 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 10, Week 16, n=144 | -28.45 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 10, Week 24, n=144 | -28.78 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 10, Week 32, n=140 | -27.98 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 10, Week 40, n=137 | -28.57 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 11, Week 8, n=138 | -28.91 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 11, Week 16, n=128 | -29.34 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 11, Week 24, n=130 | -29.64 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 11, Week 32, n=127 | -29.50 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 11, Week 40, n=123 | -27.58 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 11, Week 48, n=107 | -27.13 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 12, Week 8, n=110 | -29.27 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 12, Week 16, n=98 | -30.30 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 12, Week 24, n=86 | -30.25 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 12, Week 32, n=87 | -30.72 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 12, Week 40, n=83 | -32.96 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 12, Week 48, n=72 | -31.72 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 13, Week 8, n=52 | -32.23 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 13, Week 16, n=42 | -31.91 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 13, Week 24, n=20 | -28.18 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 13, Week 32, n=7 | -33.06 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 13, Week 40, n=1 | -12.9 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Exit, n=245 | -23.37 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | 8-Week follow-up, n=220 | -24.79 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | 24-Week follow-up, n=198 | -22.09 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 1, Week 8, n=285 | -6.09 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 1, Week 16, n=289 | -7.69 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 1, Week 24, n=290 | -8.78 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 1, Week 32, n=288 | -8.84 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 1, Week 40, n=285 | -10.32 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 1, Week 48, n=286 | -9.34 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 2, Week 32, n=281 | -11.40 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 5, Week 8, n=216 | -13.20 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 7, Week 40, n=175 | -22.31 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 8, Week 24, n=167 | -24.91 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 9, Week 32, n=162 | -26.92 Percent change |
| Belimumab 10 mg/kg IV | Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points | Year 10, Week 48, n=136 | -28.86 Percent change |
Secondary
Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points
Anti-double stranded DNA levels in participants positive at Baseline were assessed at Baseline, Week 16, 32, and 48 during Year 1 to 11, Week 16 and 32 during Year 13, Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study.
Time frame: Approximately up to 13 years
Population: MITT Population. Only those participants positive at Baseline and available at the specified time points (represented by n=X in the category titles) were analyzed.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 2, Week 48, n=128 | 83.50 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 3, Week 16, n=134 | 83.50 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 3, Week 32, n=127 | 76.00 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 3, Week 48, n=125 | 73.00 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 4, Week 16, n=124 | 80.00 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 4, Week 32, n=120 | 72.00 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 5, Week 16, n=112 | 54.00 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 5, Week 32, n=111 | 61.00 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 6, Week 16, n=105 | 41.00 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 6, Week 32, n=101 | 44.00 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 6, Week 48, n=99 | 36.00 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 7, Week 16, n=89 | 41.00 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 7, Week 32, n=94 | 36.50 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 7, Week 48, n=89 | 38.00 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 8, Week 16, n=87 | 30.00 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 8, Week 32, n=89 | 43.00 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 8, Week 48, n=80 | 27.50 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 9, Week 16, n=85 | 32.00 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 9, Week 32, n=83 | 20.00 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 9, Week 48, n=77 | 16.00 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 10, Week 16, n=77 | 18.00 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 10, Week 32, n=75 | 22.00 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 11, Week 16, n=67 | 17.00 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 11, Week 32, n=66 | 15.00 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 11, Week 48, n=63 | 11.00 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 12, Week 16, n=54 | 11.00 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 12, Week 32, n=47 | 8.00 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 12, Week 48, n=39 | 14.00 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 13, Week 16, n=20 | 13.50 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 13, Week 32, n=3 | 7.00 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Exit, n=124 | 31.00 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Baseline, n=149 | 147.00 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 1 , Week 16, n=147 | 114.00 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 1 , Week 32, n=147 | 113.00 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 1 , Week 48, n=144 | 106.50 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 2 , Week 16, n=144 | 93.50 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 2, Week 32, n=143 | 85.00 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 4, Week 48, n=116 | 66.50 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 5, Week 48, n=108 | 49.50 International units (IU)/milliliter (mL) |
| Belimumab 10 mg/kg IV | Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points | Year 10, Week 48, n=71 | 18.00 International units (IU)/milliliter (mL) |
Secondary
Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points
Complement C3 and C4 levels were assessed in participants low at Baseline at Baseline, Week 16, 32, and 48 during Year 1 to 12, Week 16 and 32 during Year 13, and Exit visit. The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study.
Time frame: Approximately up to 13 years
Population: MITT Population. Only those participants positive at Baseline and available at the specified time points (represented by n=X in the category titles) were analyzed.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Baseline, n=88 | 0.77 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 1, Week 16, n=86 | 0.81 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 1, Week 32, n=88 | 0.81 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 1, Week 48, n=86 | 0.82 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 2, Week 16, n=83 | 0.82 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 2, Week 32, n=83 | 0.84 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 3, Week 16, n=75 | 0.88 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 3, Week 32, n=75 | 0.90 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 3, Week 48, n=73 | 0.90 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 4, Week 16, n=74 | 0.93 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 4, Week 32, n=72 | 0.96 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 4, Week 48, n=67 | 0.93 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 5, Week 16, n=65 | 0.94 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 5, Week 32, n=65 | 0.97 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 5, Week 48, n=65 | 1.01 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 6, Week 32, n=59 | 1.03 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 6, Week 48, n=57 | 1.00 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 7, Week 16, n=50 | 0.94 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 7, Week 32, n=54 | 0.99 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 7, Week 48, n=52 | 0.98 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 8, Week 16, n=46 | 0.98 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 8, Week 32, n=48 | 1.01 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 9, Week 16, n=49 | 1.02 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 9, Week 32, n=46 | 0.95 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 9, Week 48, n=47 | 0.98 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 10, Week 16, n=43 | 0.91 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 10, Week 32, n=45 | 0.99 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 10, Week 48, n=44 | 0.90 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 11, Week 16, n=43 | 0.97 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 11, Week 32, n=42 | 0.99 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 11, Week 48, n=37 | 0.88 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 12, Week 32, n=28 | 0.94 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 12, Week 48, n=28 | 0.84 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 13, Week 16, n=12 | 0.95 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 13, Week 32, n=2 | 0.99 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Exit, n=74 | 0.98 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Baseline, n=116 | 0.10 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 1, Week 16, n=112 | 0.12 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 1, Week 32, n=113 | 0.13 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 1, Week 48, n=112 | 0.14 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 2, Week 16, n=110 | 0.15 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 2, Week 32, n=110 | 0.15 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 2, Week 48, n=103 | 0.17 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 3, Week 16, n=101 | 0.16 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 3, Week 32, n=100 | 0.17 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 3, Week 48, n=97 | 0.17 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 5, Week 16, n=83 | 0.18 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 5, Week 32, n=81 | 0.19 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 5, Week 48, n=81 | 0.19 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 6, Week 16, n=78 | 0.20 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 6, Week 32, n=74 | 0.19 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 6, Week 48, n=71 | 0.19 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 8, Week 32, n=62 | 0.20 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 8, Week 48, n=56 | 0.20 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 9, Week 16, n=62 | 0.20 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Exit, n=93 | 0.18 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 2, Week 48, n=76 | 0.88 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 6, Week 16, n=61 | 1.02 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 8, Week 48, n=45 | 1.01 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C3, Year 12, Week 16, n=31 | 0.92 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 4, Week 16, n=97 | 0.17 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 4, Week 32, n=93 | 0.17 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 4, Week 48, n=90 | 0.18 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 7, Week 16, n=66 | 0.19 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 7, Week 32, n=67 | 0.20 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 7, Week 48, n=65 | 0.20 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 8, Week 16, n=61 | 0.20 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 9, Week 32, n=59 | 0.19 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 9, Week 48, n=55 | 0.19 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 10, Week 16, n=54 | 0.2 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 10, Week 32, n=52 | 0.19 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 10, Week 48, n=51 | 0.18 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 11, Week 16, n=50 | 0.2 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 11, Week 32, n=48 | 0.20 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 11, Week 48, n=44 | 0.21 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 12, Week 16, n=41 | 0.18 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 12, Week 32, n=37 | 0.21 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 12, Week 48, n=31 | 0.18 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 13, Week 16, n=16 | 0.21 grams per liter |
| Belimumab 10 mg/kg IV | Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points | C4, Year 13, Week 32, n=3 | 0.29 grams per liter |
Secondary
Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points
SRI response was assessed at Week 16, 32, and 48 during Year 1 to 12 and Week 16 and 32 during Year 13. Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. SRI response is defined as:\>=4 point reduction from the Baseline in safety of estrogen in lupus national assessment (SELENA) SLE disease activity index (SLEDAI) score and no worsening (increase of \<0.30 points from the Baseline) in Physician's Global Assessment (PGA), and no new British Isles Lupus Assessment Group (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with the Baseline at the time of assessment.
Time frame: Approximately up to 13 years
Population: MITT Population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 2, Week 48, n=251 | 57.0 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 4, Week 16, n=225 | 56.9 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 6, Week 16, n=182 | 64.8 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 6, Week 32, n=181 | 65.7 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 8, Week 32, n=158 | 67.7 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 8, Week 48, n=149 | 62.4 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 9, Week 48, n=142 | 66.2 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 10, Week 48, n=126 | 65.1 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 11, Week 16, n=125 | 73.6 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 13, Week 32, n=7 | 57.1 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 1 , Week 16, n=268 | 32.8 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 1 , Week 32, n=269 | 41.6 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 1 , Week 48, n=266 | 47.0 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 2 , Week 16, n=266 | 50.8 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 2, Week 32, n=262 | 56.5 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 3, Week 16, n=245 | 59.2 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 3, Week 32, n=235 | 54.5 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 3, Week 48, n=225 | 57.8 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 4, Week 32, n=212 | 56.6 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 4, Week 48, n=206 | 59.7 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 5, Week 16, n=198 | 65.7 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 5, Week 32, n=194 | 64.4 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 5, Week 48, n=192 | 62.5 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 6, Week 48, n=176 | 63.6 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 7, Week 16, n=169 | 63.9 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 7, Week 32, n=173 | 69.4 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 7, Week 48, n=162 | 69.1 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 8, Week 16, n=161 | 68.3 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 9, Week 16, n=151 | 64.2 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 9, Week 32, n=148 | 66.2 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 10, Week 16, n=141 | 66.0 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 10, Week 32, n=135 | 66.7 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 11, Week 32, n=120 | 64.2 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 11, Week 48, n=109 | 65.1 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 12, Week 16, n=100 | 69.0 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 12, Week 32, n=90 | 75.6 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 12, Week 48, n=71 | 71.8 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points | Year 13, Week 16, n=42 | 73.8 Percentage of participants |
Secondary
Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points
Daily prednisone dose reduction was assessed at Baseline, Week 8, 16, 24, 32, 40, and 48 during Year 1 to 12 and Week 8, 16, 24, 32, and 40 during Year 13. Percentage of participants with daily prednisone dose reduced to \<=7.5 mg/day from \>7.5 mg/kg at the Baseline are summarized. Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.
Time frame: Approximately up to 13 years
Population: MITT Population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 1, Week 8, n=91 | 0 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 1, Week 16, n=90 | 5.6 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 1, Week 24, n=91 | 19.8 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 1, Week 32, n=91 | 19.8 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 1, Week 40, n=87 | 23.0 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 1, Week 48, n=88 | 27.3 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 2, Week 8, n=90 | 28.9 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 2, Week 16, n=89 | 31.5 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 2, Week 24, n=90 | 28.9 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 2, Week 32, n=88 | 34.1 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 2, Week 40, n=84 | 35.7 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 3, Week 16, n=81 | 34.6 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 3, Week 24, n=73 | 34.2 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 3, Week 48, n=75 | 30.7 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 4, Week 8, n=72 | 40.3 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 4, Week 16, n=74 | 41.9 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 4, Week 24, n=71 | 45.1 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 4, Week 32, n=69 | 37.7 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 4, Week 40, n=67 | 37.3 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 4, Week 48, n=68 | 38.2 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 5, Week 8, n=67 | 41.8 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 5, Week 16, n=63 | 42.9 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 5, Week 24, n=64 | 45.3 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 5, Week 40, n=58 | 48.3 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 5, Week 48, n=60 | 41.7 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 6, Week 8, n=61 | 44.3 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 6, Week 16, n=57 | 43.9 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 6, Week 48, n=55 | 38.2 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 7, Week 8, n=52 | 46.2 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 7, Week 16, n=51 | 39.2 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 7, Week 32, n=51 | 39.2 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 7, Week 40, n=51 | 39.2 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 7, Week 48, n=51 | 39.2 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 8, Week 40, n=49 | 38.8 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 9, Week 32, n=48 | 39.6 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 11, Week 24, n=40 | 32.5 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 11, Week 32, n=39 | 35.9 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 12, Week 24, n=29 | 34.5 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 12, Week 32, n=30 | 40.0 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 12, Week 40, n=30 | 46.7 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 12, Week 48, n=26 | 53.8 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 13, Week 8, n=19 | 47.4 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 13, Week 16, n=13 | 38.5 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 13, Week 24, n=6 | 50.0 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 13, Week 32, n=2 | 50.0 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 13, Week 40, n=1 | 0.0 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 2, Week 48, n=83 | 34.9 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 3, Week 8, n=81 | 35.8 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 3, Week 32, n=77 | 36.4 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 3, Week 40, n=78 | 33.3 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 5, Week 32, n=65 | 38.5 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 6, Week 24, n=58 | 48.3 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 6, Week 32, n=59 | 44.1 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 6, Week 40, n=55 | 41.8 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 7, Week 24, n=51 | 41.2 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 8, Week 8, n=50 | 40.0 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 8, Week 16, n=49 | 38.8 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 8, Week 24, n=50 | 38.0 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 8, Week 32, n=49 | 36.7 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 8, Week 48, n=48 | 41.7 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 9, Week 8, n=48 | 39.6 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 9, Week 16, n=49 | 38.8 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 9, Week 24, n=49 | 38.8 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 9, Week 40, n=48 | 35.4 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 9, Week 48, n=45 | 37.8 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 10, Week 8, n=46 | 37.0 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 10, Week 16, n=43 | 39.5 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 10, Week 24, n=44 | 31.8 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 10, Week 32, n=44 | 31.8 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 10, Week 40, n=43 | 34.9 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 10, Week 48, n=43 | 32.6 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 11, Week 8, n=44 | 36.4 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 11, Week 16, n=41 | 34.1 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 11, Week 40, n=40 | 40.0 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 11, Week 48, n=35 | 34.3 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 12, Week 8, n=35 | 34.3 Percentage of participants |
| Belimumab 10 mg/kg IV | Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points | Year 12, Week 16, n=32 | 31.3 Percentage of participants |